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2Abstract
Background: The human gene coding for apolipoprotein E is polymorphic, and the APOE 
s4 allele has been associated with less favourable outcome after acute brain injury 
including traumatic brain injury (TBI) and subarachnoid haemorrhage (SAH). 
Experimental studies identify key roles for apoE in the central nervous system such as the 
scavenging and recycling of lipids for cellular maintenance and repair and formation of 
cerebral amyloid aggregate. Human in-vivo evidence supporting the concept that apoE is 
involved in the response of the brain to acute injury is sparse. Objectives: This study tests 
the hypothesis that apoE is involved in the response of the human brain to injury, and this 
role is reflected by changes in cerebrospinal fluid (CSF) apoE concentration after brain 
injury which correlate with injury severity and outcome. In addition it was hypothesised 
that changes in apoE concentration would be paralleled by changes in the composition of 
CSF lipoprotein particles (Lps) of which apoE is a major component. Lastly, apoE is 
reported to chaperone amyloid-beta peptide (AP), therefore we hypothesised that alteration 
in CSF apoE after brain injury would parallel alterations in Ap. Methods: Enzyme linked 
immunosorbant assay (ELISA) was used to determine the concentration of apoE, Ap, 
S100B and Tau (as surrogate markers of brain injury) in CSF from TBI and SAH patients 
and a non-brain injured control group. Lipoprotein particles were isolated from CSF using 
size exclusion chromatography and characterised in relation to cholesterol, phospholipid, 
apolipoprotein E, and apolipoprotein AI composition. Injury severity was determined using 
the Glasgow Coma Score, and clinical outcome using the Glasgow Outcome Score. 
Results: Compared to controls there was a sustained decrease in the concentration of apoE 
in the CSF after TBI and SAH which was paralleled by a depletion of apoE containing 
lipoprotein particles. Furthermore, CSF Ap also decreased, and the decrease correlated 
with injury severity and clinical outcome. In contrast the levels of S100B and Tau in brain 
injury CSF was substantially elevated. Conclusion: Despite the likely leakage of plasma 
apolipoprotein E into the subarachnoid space at the time of brain injury, apoE in the form 
of LpE is cleared from the CSF within days of injury. In addition, indirect evidence 
suggesting apoE-Ap interactions in-vivo support the concept that apoE may form insoluble 
aggregates with Ap soon after brain injury. The finding that these alterations in the CSF 
correlate with injury severity and outcome provides novel indirect in-vivo evidence that 
apoE is important to the response of the human brain to injury.
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1 Introduction
Traumatic Brain Injury (TBI) and spontaneous Subarachnoid Haemorrhage (SAH) are two 
conditions commonly encountered in neurosurgical practice. There is considerable 
variation in clinical outcome for patients with these conditions even after accounting for 
injury severity, suggesting that other unidentified factors influence recovery. The 
possibility that genetic factors influence the recovery after TBI and SAH recently found 
preliminary support from studies associating possession of the APOE e4 allele with 
unfavourable outcome. (Niskakangas et al. 2001; Teasdale et al. 1997) Although, 
evidence from post mortem and experimental brain injury studies support the concept that 
apolipoproteinE (apoE indicates protein; APOE, gene) plays a key role in the response of 
the brain to injury, in-vivo evidence in humans is lacking. This thesis presents indirect in- 
vivo evidence from the analysis of cerebrospinal fluid (CSF) that apoE is involved in the 
response of the brain to injury. This chapter discusses TBI and SAH, the response of the 
brain to injury, apolipoprotein E, and the utility of CSF analysis for investigating acute 
brain injury.
1.1 Traumatic Brain Injury and Subarachnoid Haemorrhage
1.1.1 Definitions of TBI and SAH
1.1.1.1 TBI
TBI refers to brain injury resulting from trauma. Haemorrhage into the subarachnoid space 
may be a consequence of TBI, and is the commonest cause of secondary/non-spontaneous 
SAH. SAH secondary to TBI is often referred to as tSAH and is not to be confused with 
spontaneous SAH discussed below.
1.1.1.2 SAH
SAH, usually due to rupture of an intracranial aneurysm, is a spontaneous event, which 
results in haemorrhage into the subarachnoid space. Often the haemorrhage extends 
beyond the subarachnoid space into the ventricular system and brain parenchyma. 
Occasionally SAH is limited to the brain parenchyma with relatively little haemorrhage 
into the subarachnoid space.
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1.1.2 Epidemiology and aetiology of TBI and SAH
1.1.2.1 TBI
In the UK, there are estimated to be at least 1 million patients presenting to hospital each 
year following head injury, representing 10% of all patients attending Accident and 
Emergency (A&E) departments. Approximately 90% of these patients have minor 
(Glasgow Coma Score, GCS 15-see table 1) or "mild" (GCS 13-15) head injury, and 5% 
have moderate (GCS 9-12), and 5% severe (GCS 3-8) head injury. (Kay and Teasdale, 
2001) Approximately 20% require admission for observation, and less than 5% are 
transferred to neurosurgical care. It is estimated that 30-50% of trauma deaths are due to 
TBI accounting for 1-2% of all deaths of all causes. Importantly TBI accounts for 20% of 
deaths occurring between the ages of 5 and 45 years, in which group injury is the leading 
cause of death. Most head injuries result from a fall (40%) or an assault (20%) but most 
serious injuries follow a road traffic accident (RTA). These account for 58% of deaths and 
approximately one third of those transferred to neurosurgical care. (Teasdale, 1995) The 
population of patients in the regional neurosurgical unit tends to be a selected group with 
injuries at the more severe end of the spectrum, though differences exist due to variation in 
the criteria for transfer. In addition Geographical variations in aetiology exist within the 
United Kingdom (UK) and continental Europe, and between the European and American 
continents. A study of patients with severe head injury, admitted to four neurosurgical 
units in the UK, found that 22% of patients fell under the influence of alcohol in Glasgow 
compared to less than 10 % in Southampton, and that RTA accounted for less than 50% of 
the admissions to the Glasgow unit but nearly 70% in Southampton. (Kay and Teasdale, 
2001; Murray et al. 1999) In 1999 the European Brain Injury Consortium (EBIC) 
published the findings from a survey of more than one thousand severely and moderately 
head injured patients admitted to sixty seven neurosurgical units in twelve European 
countries. (Murray et al. 1999) This survey found that the proportions that were injured as 
a vehicle occupant ranged from 11% in the UK up to 48% in the Benelux countries. In 
Spain only 1% of patients admitted to the neurosurgical unit had fallen under the influence 
of alcohol compared to 33% in Scandinavia. Gunshot wound to the head is uncommon in 
the UK and Europe in contrast to the United States of America (USA). These differences in 
aetiology and severity of injury, and the patterns of transfer to neurosurgical care, must be 
borne in mind when considering the relevance of findings in one unit to other units. Many 
of these injuries are avoidable occurring in risk taking young males with impaired 
judgement due to excessive consumption of alcohol.
A D Kay 2003
1.1.2.2 SAH
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SAH, mostly from rupture of an intracranial saccular aneurysm, accounts for only 3% of 
strokes and 5% of stroke deaths, but 25% of life years lost through stroke. (Johnston et al. 
1998) The estimated overall incidence rate is 10.5 (95% Cl: 9.9-11.2) per 100,000 life 
years. (Linn et al. 1996) The reported incidence of SAH is higher in Finland (22/100,000 
patient years; 95% Cl: 20-23) and Japan (23/100,000; 95% Cl: 19-28). Women have a 1.6 
(95% Cl: 1.5-2.3) times higher risk than men, and black people have twice the risk of 
white people. (Broderick et al. 1992; Linn et al. 1996) The average age of patients with 
SAH is lower than for other types of stroke, peaking in the sixth decade, but higher than 
those with TBI. (Lanzino et al. 1996; Longstreth et al. 1993) Modifiable risk factors for 
SAH include smoking, hypertension, amphetamine/cocaine abuse and heavy alcohol 
consumption (Odds ratios of 2 - 3). (Teunissen et al. 1996) An important, but non- 
modifiable, risk factor is the familial predisposition to SAH such that 5-20% of patients 
with SAH have a positive family history. (Schievink, 1997) First degree relatives (parents, 
siblings, children) of patients with SAH have a three to seven fold increased risk, whilst 
second-degree relatives (grandparents, grandchildren, aunts, uncles, nieces, nephews) have 
a similar risk to the general population. (Bromberg et al. 1995; Gaist et al. 2000; 
Schievink, 1997) In addition, a small minority of patients with SAH have inherited 
connective tissue disorders. The commonest of these is Autosomal Dominant Polycystic 
Kidney Disease (ADPKD) and is found in 2% of all patients with SAH. (Schievink et al. 
1992) Other rare genetic disorders associated with SAH include Ehlers Danlos disease IV 
and Neurofibromatosis type I. (Schievink et al. 1990) Saccular aneurysm rupture accounts 
for 85% of spontaneous SAH. It is largely unknown why some adults develop aneurysms 
at points of arterial bifurcation and most do not. The idea that a tunica media defect allows 
the inner layers to bulge through has fallen from favour recently as these defects are 
equally as common in vessels without aneurysms and are strengthened by densely packed 
collagen fibrils. Furthermore they are found in the fundus of the aneurysm, not at the neck. 
(Finlay et al. 1998; Fujimoto, 1996; Stehbens, 1989) The current hypothesis is that risk 
factors such as smoking and hypertension result in acquired local thickening of the intimal 
layer (intimal pads) proximal and distal to the vessel branch point producing decreased 
elasticity, increasing the strain on more elastic portions of the vessel, (van Gijn J. and 
Rinkel, 2001). SAH not due to saccular aneurysm rupture is due to perimesencephalic or 
prepontine haemorrhage in 10% of cases and rare conditions (e.g. transmural arterial 
dissection, arterial-venous malformation, dural arterio-venous fistula, septic aneurysm, and 
pituitary apoplexy) in the remaining 5% of cases.
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1.1.3.1 TBI and the Glasgow Coma Scale
The Glasgow Coma Scale (GCS) is the internationally recognised measure of impaired 
consciousness. Prior to the development of this scale in 1974, impaired consciousness was 
described using terms such as comatose, stupor, obtunded, drowsy and delirium. 
Inconsistency in the definition and interpretation of these terms made assessment of 
recovery and deterioration for individual patients difficult and made meaningful 
comparisons of different patient cohorts difficult limiting their value for research purposes. 
In contrast the GCS is a simple robust method for describing the level of consciousness 
which can have a consistency as high as 97%. The Glasgow Coma Scale enables simple 
description of a patient's responsiveness in terms of best motor response, verbal response 
and eye opening. Each of these is then stratified according to increasing impairment. The 
GCS grades patients according to three scales, which are summed to give a total score 
ranging from three to fifteen. The Glasgow Coma Scale is an artificial index obtained by 
adding scores for the three responses. The GCS scoring system is summarised in table 1. 
This score can be used as a single figure summary for purposes of head injury 
classification, but contains less information than separate descriptions of the three 
responses. Hence the Scale, not the Score, should provide the basis for monitoring and 
exchange of information about individual patients. The motor scale awards six points for 
obeying commands, five for localising a painful stimulus, four for "normal" flexion, five 
for "abnormal" flexion, two for "extensor posturing" and one for no motor response. In the 
first description of the scale the motor response had only five options with no demarcation 
between "normal" and "abnormal flexion". The inclusion o f " abnormal flexion" to give a 
six point motor response, and a total score of fifteen, adds little to the monitoring of 
individual patients but is relevant to prognosis. The verbal scale awards five points to the 
patient who is orientated in time, place and person, four if speech is confused, three for 
inappropriate unsustained speech, two for incomprehensible sounds and one for no verbal 
response. Spontaneous eye opening is awarded four points, eye opening to speech three, 
eye opening to painful stimuli two, and no eye-opening one point. (Teasdale and Jennett, 
1974; Teasdale and Jennett, 1976; Teasdale et al. 1978)
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Table 1 The Glasgow Coma Score
Feature Scale Score
Spontaneous 4
Eye To Speech 3
Opening To Pain 2
None 1
Orientated 5
Confused 4
Verbal Words (inappropriate) 3
Response Sounds (incomprehensible) 2
None 1
Obeys Commands 6
Best Localises Pain 5
Motor Flexion Normal 4
Response Flexion Abnormal 3
Extends 2
None 1
Total Coma "Score" 3-15
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Despite extensive studies supporting the repeatability, validity, and other clinimetric 
properties of the GCS, as few as 30% of doctors making neurosurgical referrals may be 
fully conversant with its use. (Morris, 1993) The motor scale alone has almost as high 
predictive value as the total GCS, thus the GCS is still useful if eye-opening or verbal 
response cannot be assessed e.g. due to facial trauma. The timing of assessment of 
conscious level is important as this may be influenced by the presence of sedatives, 
intoxication, hypoxia and hypotension. The increased use of pre-hospital sedation and 
intubation complicates the early assessment of injury severity using the GCS. (Marion and 
Carlier, 1994) The GCS does not take account of other correlates with injury severity such 
as the reactivity of the pupils to light, the oculocephalic response, and physiological 
parameters.
1.1.3.2 The World Federation of Neurological Surgeons Severity Scale for SAH
Severity of brain injury after SAH is also based upon the assessment of consciousness level 
graded using the GCS. In addition the grading scale of the World Federation of 
Neurological Surgeons (WFNS) includes an assessment of the presence or absence of focal 
neurological deficits as summarised in table 2. (Teasdale et al. 1988) Though poor 
neurological condition after SAH may be due to global ischaemic damage secondary to 
raised intracranial pressure from the haemorrhage, potentially reversible factors such as 
hydrocephalus, intracerebral or subdural haematoma also contribute to the impairment of 
conscious level.
1.1.3.3 Radiological assessment of severity of TBI
The computerised tomography (CT) scan is currently the means by which the nature, 
distribution and severity of brain injury is assessed after trauma providing satisfactory 
imaging for immediate management decisions. The Marshall CT classification is often 
used to categorise the various radiological manifestations of TBI for the purposes of 
clinical research. This is summarised in table 3. Even after combining the CT scan 
appearance with clinical information such as age and motor score from the GCS, survival 
is correctly predicted in less than 40% of cases. Further limitations of CT classification of 
TBI relate to the dynamic nature of brain injury and the time elapsed between injury and 
investigation, coupled to the relatively poor resolution of the technique. Thus when the 
initial scan shows diffuse injury, without swelling or shift, approximately one in six 
patients will have evidence of a mass lesion on a later scan, and will have increased risk of 
unfavourable outcome. (Marshall et al. 1992; Servadei et al. 2000)
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Table 2 The World Federation of Neurological Surgeons Grading of SAH
WFNS grade of SAH Glasgow Coma Scale total Score
I 15
II 13-14 no focal deficit*
III 13-14 with focal deficit
IV 7-12
V 3-6
*Cranial nerve palsies are not considered a focal deficit 
WFNS: World federation of Neurological Surgeons 
SAH: Subarachnoid Haemorrhage
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Table 3 Radiological assessment of severity of TBI
Grade Classification CT findings
1 Diffuse injury Intracranial pathology not visible on CT scan
2 Diffuse injury
a) 1 only
b) 2 unilateral
c) Bilateral
Cisterns present with shift of 0-5 mm, 
lesion present, but no high or 
mixed density lesion >25 cc.
May include bone fragments 
and foreign bodies.
3 Diffuse injury + swelling Cisterns compressed or absent, 
shift of 0-5 mm, no high 
or mixed density lesion >25 cc
4 Diffuse injury + shift Shift of >5 mm ,
no high or mixed density lesion >25 cc
5 Evacuated mass lesion
a) Extradural
b) Subdural
c) Intracerebral
d) >/= 2 lesions
Any lesion surgically evacuated
6 Nonevacuated mass lesion
a) Extradural
b) Subdural
c) Intracerebral
d) > 2 lesions
High or mixed density
lesion >25 cc,
not surgically evacuated
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1.1.3.4 Radiological assessment of severity of SAH
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The Fisher grading system is often used to categorise radiologically the quantity of blood 
seen on the CT scan after SAH, for the purposes of clinical research and audit. The Fisher 
grading system for blood load on CT scan is summarised in table 4. The Fisher grade is 
reported to correlate with clinical outcome, and the development of vasospasm, but is 
renowned for poor inter-observer agreement. (Fisher et al. 1980)
Table 4 Fisher CT scan radiological grading system for SAH
Fisher group Blood on CT
1 No SAH detected
2 Diffuse or vertical layers <1 mm thick
3 Localised clot and/or vertical layers>lmm thick
4 Intracerebral or intraventricular clot with diffuse or no SAH
CT: computerised tomography 
SAH: Subarachnoid Haemorrhage
1.1.3.5 Classification of Clinical Outcome
Since it was described in 1975, the Glasgow Outcome Scale has become the most widely 
used method to summate the wide range of different sequelae of brain injury into a single 
overall method of classification of outcome. (Jennett and Bond, 1975) There are five 
grades to the scale: dead, persistent vegetative state, severe disability, moderate disability, 
and good recovery. The GOS is assessed six months after TBI. When assessment is 
performed three, six and twelve months after injury it is apparent that some patients 
(particularly those with severe disability at three months) improve supporting the concept 
of late recovery. From the European Brain Injury Consortium (EBIC) survey of 481 
patients not obeying commands after TBI, less than 50% had a favourable outcome six 
months after injury. (Murray et al. 1999) The GOS is often assessed three months after 
SAH. The average case fatality rate after SAH is approximately 50% ranging from 32 -
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67%. Approximately one third of survivors remain dependent and less than one third have 
no reduction in quality of life, (van Gijn J. and Rinkel, 2001) The GOS has proved 
acceptable in many parts of the world, in particular for describing the outcome in cohorts 
of patients, but there have been reservations about its reliability, sensitivity, validity, and 
relevance. These result in part from the original description having not provided explicit 
criteria for distinguishing between different outcome categories. As a consequence the 
outcome could be assigned variably, between observers. Moreover the problem could be 
compounded by inconsistencies in the method used to obtain information (e.g. face to face 
interview, telephone interview or postal questionnaire) and in the timing at which outcome 
is assessed. An extension of the original 5-category scale into an 8-category scale (GOSE) 
was described to improve discrimination but this was offset by less consistency in 
allocation. Recently, a structured interview based on a questionnaire has been developed to 
improve reliability of classification of outcome. Careful studies showed that the structured 
approach improved reliability and that a high level of consistency achieved by all methods 
of obtaining information. Furthermore, the classification produced by the structured 
assessment of the Glasgow Outcome Scale showed strong correlation with the results of a 
wide range of neuropsychological tests and with the findings of generic assessments of 
health and quality of life. As a consequence, the GOS remains a valuable ‘overall’ index, 
of particular use in classifying outcome in studies involving large cohorts of brain injured 
patients. Much experience supports the use of the GOS in studies of outcome after a severe 
TBI. (Pettigrew et al. 1998; Teasdale et al. 1998; Wilson et al. 1998; Wilson et al. 2000) 
More recently application of the GOS to survivors of so called mild TBI has challenged the 
assumption that most survivors are free of sequelae. A recent study of 3,000 adults with a 
head injury in Glasgow, confirmed that 90% had a GCS of 13-15 when they arrived at 
hospital. Follow-up of a representative cohort confirmed that the majority (78%) of 
survivors of a severe head injury were either moderately or severely disabled but produced 
a surprising finding that disability was also common in survivors of a moderate (54%) and 
mild (51%) head injury. In accord with this finding, reports of various specific problems 
were found to be frequent in patients with a mild injury, 79% of whom had persistent 
headache, 59% memory problems and 34% were unemployed. (Thornhill et al. 2000) The 
findings of this and similar studies questions the categorisation of patients admitted to 
hospital who have lost consciousness but recovered to a GCS of 13-15 as a mild injury. 
(Pettigrew et al. 1998; Teasdale et al. 1998) Patients with so-called mild and moderate 
TBI may represent a previously under-investigated subgroup that may potentially benefit 
from neuroprotective measures. Furthermore, the possibility that so called mild or
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moderate injury may accelerate chronic neurodegeneration has not been conclusively 
investigated.
1.2 The response of the brain to injury
1.2.1 Classification
Evidence from experimental brain injury, and the all too frequent observation that after 
acute brain injury patients "talk and die", support the concept that brain injury stimulates a 
complex dynamic cascade of events which culminate in an accumulative burden of 
neuronal loss greater than that resulting from the initial injury. Thus damage occurring at 
the time of injury is referred to as primary injury, and that resulting from the cascades 
unleashed by the injury is referred to as secondary injury. More recently the concept of 
tertiary injury has emerged, which refers to the immunological and inflammatory changes 
in response to the primary and secondary injury. Neuroprotective strategies targeted at 
ameliorating secondary injury, though successful in experimental brain injury, have not 
translated to improved outcome after human brain injury. (Graham et al. 1995; Graham et 
al. 2000; Teasdale and Graham, 1998)
1.2.2 Primary injury
Primary injury results from the physical effects of tissue strain. Though tissue strain occurs 
after SAH due to raised intracranial pressure, brain shift and intraparenchymal 
haemorrhage, the effects have been more extensively characterised in experimental TBI. 
Tissue strain is the final common pathway for the forces of inertia and/or contact resulting 
from TBI. Contact may result in scalp laceration, skull fracture (and possibly extra-dural 
haematoma), cerebral contusions/laceration and intracerebral haematoma. Rapid 
acceleration or deceleration may result in forces of inertia causing subdural bridging veins 
to tear (and subdural haematoma formation) and widespread damage to white matter. 
Slower rates of tissue deformation tend to be tolerated better than rapid loading. Thus static 
loading, where the force is applied relatively slowly (more than 200 milliseconds) may 
only result in multiple comminuted skull fractures with little underlying brain injury. More 
commonly loading is dynamic (occurring in less than 200 msec and often <20 msec) due to 
impact (e.g. blunt object striking head) and/or impulsive (head moved or arrested rapidly, 
with or without contact). If a blunt object impacts the head a combination of contact and 
inertial forces result in tissue strain the nature of which depends on the mass, velocity and 
force of impact. Impulsive dynamic loading occurs when the head is rapidly accelerated or
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decelerated and the brain injury results from inertial forces of translation, rotation and 
angulation. There is considerable variability in the types of tissue strain encountered in real 
life, which often occur in combination. Though primary injury may be further classified as 
open or closed injury, and focal or diffuse injury, such explicit categorisation may become 
impossible as the injury severity increases. (Graham et al. 1995; Graham et al. 2000; 
Teasdale and Graham, 1998)
1.2.3 Secondary injury
1.2.3.1 Hypoxic injury
Hypoxic and ischaemic injuries are major secondary events that occur after both TBI and 
SAH, and substantially influence clinical outcome. (Chesnut et al. 1993a; Chesnut et al. 
1993b) Sustained global ischaemia occurs in the very early phase (i.e. 4-8 hours) after 
acute brain injury and before evacuation of mass lesions. (Marion et al. 1991) Ischaemic 
injury has been identified in 90% of patients dying after TBI, and episodes of transient 
diffuse ischaemia occur in 90% of patients in the highest quality neuro-intensive care units. 
(Graham et al. 1989; Jones et al. 1994) Focal ischaemia occurs in the surrounding area 
adjacent to cerebral contusions, intracerebral haemorrhage, beneath subdural haematomas, 
and tissue rendered ischaemic due to vasospasm. Hypoxic brain injury may also result 
from a wide range of aetiologies outside the CNS, which cause significant 
cardiopulmonary insufficiency, and from epileptiform seizures. Cardiopulmonary 
insufficiency and epileptiform seizures also occur after TBI and SAH (e.g. neurogenic 
pulmonary oedema) and may add to the burden of ischaemic insults in these patients.
The major component of hypoxic injury occurring after TBI and SAH is that due to 
reduced cerebral blood flow (CBF) due to the sudden increase in intracranial pressure at 
the time of haemorrhage or trauma. (Bouma et al. 1992a; Bouma et al. 1992b; Obrist et al. 
1984; Schroder et al. 1996; Symon et al. 1974) The effects of the primary ischaemic 
injury, like the effects of tissue strain, are highly variable depending on the severity, 
duration, and type of hypoxic insult. Cerebral blood flow studies in the non-human primate 
determined the effects of reduced CBF and introduced the concepts of ischaemic 
thresholds, and selective neuronal vulnerability. The mean blood flow through the brain is 
approximately 50ml/100g/min (grey matter 80ml/100g/min: white matter 20ml/100g/min). 
In the healthy normally autoregulating brain cortical flow reduction (with normal arterial 
oxygen tension) down to 20ml/100g/min may be tolerated without functional consequences 
though the electro-encephalogram (EEG) may slow and the subject may develop anxiety
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and drowsiness. Just below this level consciousness is lost and the brain loses the capacity 
to make neurotransmitter substances resulting in coma. The threshold of electrical failure 
has been reached resulting in flattening of EEG, and loss of evoked potentials. When flow 
falls below 18ml/100g/min the threshold for energy failure is reached resulting in 
mitochondrial dysfunction and failure of the Na+/K+ ATPase pump system resulting in 
potassium release. Between these thresholds there is a penumbra of brain that is electrically 
silent with normal or slightly raised potassium content, and though non-functioning is said 
to be capable of full recovery provided sufficient blood supply is maintained. At flows of 
lOml/lOOg/min membrane integrity is lost, massive Ca influx begins and the biochemical 
cascade of neuronal destruction begins. This cascade involves neuronal membrane 
deformation, cytoskeletal disintegration, ionic flux (Na+, K+, Ca2+, H+) disturbance and 
depolarisation/energy failure. Neurochemical, neurovascular, neurotransmitter and receptor 
changes occur due to disturbances involving catecholamine neurotransmitters, monoamine 
neurotransmitters, excitatory amino acids, nitric oxide, endogenous opioid peptides, 
platelet activating factor and various ion such as Mg2+ and Ca2+. These mediators give rise 
to lipolysis, proteolysis, oxidation, phosphorylation activity, and cytoskeletal 
disintegration. This culminates in cell swelling, further membrane damage, free radical 
production with lipid peroxidation, proteolysis, axonal swelling and culminates in acute, 
delayed or programmed cell death (PCD). If flow is profoundly reduced e.g. to 
5ml/100g/min within the distribution of one cerebral end artery for more than 60 mins, 
infarction is inevitable. However, when flow reduction is less marked e.g. 15ml/100g/min 
for 30 mins then selective neuronal loss may occur.
The most vulnerable neuronal types are:
• Hippocampal neurons (CA1).
• Cerebellar Purkinje cells.
• Cortical neurons, particularly the larger cells in the cuneate visual cortex.
• Basal Ganglia.
Classically selective neuronal loss is seen among patients who die after an episode of 
global ischaemia associated with cardiopulmonary arrest after which circulation has been 
restored. Neuronal groups may be selectively vulnerable due to differences in the 
microvascular anatomy that supply them (e.g. watershed changes at arterial boundary 
zones), though more recently evolved regions appear to be selectively vulnerable due to the 
physicochemical properties of the neurons themselves. A variety of phenotype differences 
have been postulated to account for selective vulnerability including differences in receptor 
expression e.g. selectively vulnerable neurons express glutamate receptors increasing
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vulnerability to excitotoxicity. Other postulates include differences in cellular stores of 
adenosine triphosphate (ATP), or antioxidants, or apoptosis related proteins. Selective 
neuronal loss may be particularly important in patients with raised intracranial pressure 
where cerebral perfusion pressure may be marginal (e.g. 30-40 mmHg) for many hours or 
even days resulting in ischaemic neuronal loss especially in the hippocampus. Such 
bilateral hippocampal and cerebellar damage explains the high frequency of memory 
disorders and co-ordination difficulty seen in so many survivors of severe head injury. 
Even though local cerebral blood flow may not reach sub-therapeutic levels it is 
hypothesised that acute brain injury increases neuronal vulnerability to secondary insult. 
(DeGirolami et al. 1984; Pulsinelli et al. 1982; Symon, 1993; Teasdale and Graham, 
1998)
1.2.3.2 Cytoskeletal injury
Cytoskeletal injury and disintegration has devastating consequences for the brain-injured 
patient. The original description of Diffuse Axonal Injury (DAI) defined focal lesions in 
the corpus callosum, focal lesions in one or both dorsolateral regions of the rostral 
brainstem adjacent to the cerebellar peduncles, and diffuse damage to axons that occurred 
after TBI. This anatomical distribution of injury accounts for the coma of brain injured 
patients, but has been reproduced in only one animal model of non human primates, 
limiting the rate of progress in understanding the underlying mechanisms. (Gennarelli et al. 
1982) The term Traumatic Axonal Injury (TAI) is currently applied to animal models of 
axonal injury after trauma. In TAI, within two hours of injury the injured axons form focal 
swellings at intervals along their length which increase in size until the axons undergo 
disconnection four to six hours after injury. (Maxwell et al. 1997) This is called secondary 
axotomy and is distinct from primary axotomy where the axolemma is fragmented 
resulting in rapid loss of the axonal cytoskeleton. Secondary axotomy appears to result 
from damage to the axolemma with loss of the ionic gradient homeostatic mechanisms 
necessary for axonal electrical activity. Thus Ca2+ influx causes mitochondria to swell, 
microtubules to depolymerize, calpain activation and disruption of fast axonal transport. 
(Buki et al. 1999; Maxwell et al. 1997; McCracken et al. 1999) The definite 
identification of retraction bulbs (the hallmark of DAI) under the light microscope can be 
made approximately eighteen to twenty-four hours post injury. However, 
immunocytochemistry (ICC) using an antibody to Amyloid Precursor Protein ((3-APP) 
shows evidence of axonal damage after two to three hours of survival and can be used to 
identify injured axons scattered amongst the population of uninjured axons. (Sherriff et al.
1994) As many axons appear to be unaffected by injury, the concept of selective neuronal
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vulnerability appears to apply to cytoskeletal injury too. Possible explanations for this 
observation are that axons in a particular orientation relative to the axis of strain, or those 
changing direction and decussating, are more prone to injury. In the days following injury 
many irregular swellings are noted on the axons associated with oval or rounded bulbs at 
the end of the axon. Over the ensuing weeks these features dissipate and clusters of 
microglia in the white matter dominate the field as the damaged axons are phagocytosed. 
Months after the injury Wallerian degeneration of the white matter is noted which at the 
severe end of the spectrum is associated with a clinical vegetative state. (Graham et al. 
1995; Graham et al. 2000) It is now recognised that axonal injury, as identified by p-APP 
ICC, occurs after a variety of different types of brain injury, and is not specific for TBI. 
(Dolinak et al. 2000a; Dolinak et al. 2000b; Geddes et al. 2000)
1.2.3.3 Vascular injury
Studies using contrast enhanced magnetic resonance imaging (MRI) and, single photon 
emission computed tomography (SPECT) have been used to demonstrate breakdown of the 
blood-brain barrier (BBB) after human acute brain injury. (Bullock et al. 1990; Lang et al. 
1991; Marmarou et al. 2000) Gadolinium enhanced MRI and pertechnetate enhanced 
SPECT scan studies show the majority of early brain oedema, both global and focal, to be 
cytotoxic. Vasogenic oedema associated with opening of the BBB is seen at later time 
points around contusions and intracerebral haemorrhage, and is absent from patients with 
diffuse non-focal injury. Acute brain injury causes complex neurovascular changes 
resulting in altered cerebral blood flow at a number of levels. The cerebral 
microvasculature, which is more resistant to shear damage than axons, tends to stretch and 
leak rather than tear or burst. Pial vessels at the tip of the frontal poles and temporal lobes 
are subjected to greater focal concentrations of force and have a tendency to form 
contusions. Such injury to the microvasculature results in:
• Swelling of perivascular astrocytic end feet narrowing the vessel lumen.
• Increased endothelial microvacuolation and micro pseudopodial activity from increased 
trans endothelial flux of intravascular components.
• Perivascular haemorrhage and transvascular diapedesis of red cells.
• Increased intravascular leukocyte adherence as a result of cytokine activation due to 
free radical release.
In addition changes in these and larger vessels may occur due to alterations in vasomotor 
tone. Increased tone results in vasospasm, which may occur after both SAH and TBI, and 
is a major contributory factor to death and disability. Vasospasm is reported to occur in
A D Kay 2003 Chapter 1 30
70% of patients presenting with aneurysmal SAH, and results in symptomatic ischaemia or 
infarction in 36% of cases. (Biller et al. 1988) The biological mechanisms underlying 
vasospasm are poorly understood and treatment options are limited. The presence of blood 
in the subarachnoid space is the key initiator of vasospasm, and it is postulated that the 
oxyhaemoglobin (oxy-Hb) in subarachnoid blood induces vessel wall contraction. 
(Macdonald and Weir, 1991) Oxyhaemoglobin may act as a scavenger of Nitric Oxide 
(NO), and inactivate guanylate cyclase (GC) by oxidising a ferrous haeme group linked to 
the enzyme, and increases the production of radical species. NO has been identified as the 
major endothelial derived relaxing factor (EDRF) which upon release from endothelial 
cells diffuses to adjacent smooth muscle cells where it activates soluble GC resulting in 
production of cGMP. The cGMP activates intracellular sarcoplasmic reticulum bound
• j i
calcium pumps sequestering free Ca into intracellular stores relaxing the smooth muscle 
cell through reduced calmodulin mediated myosin light chain kinase activation. After SAH 
the released oxy-Hb may bind NO resulting in vasoconstriction and/or add to the burden of 
oxidative stress due to the production of globin free haemin released from Hb in the 
presence of H2O2, or oxidation of ferryl haeme, or formation of apoprotein radicals. In the 
absence of NO, endothelium derived constricting factors (EDCF) such as endothelin (ET), 
angiotensin II, prostaglandin F2a and thromboxanes operate unopposed constricting the 
vessel wall. In addition, other factors such as ion channel activation, contractile protein 
phosphorylation, and conducted vasomotor responses may play important roles in the 
development of vasospasm after SAH. (Dietrich and Dacey, 2000; Laher and Zhang, 2001; 
Sobey, 2001) In addition to vessel spasms, acute brain injury may result in loss of 
autoregulation of cerebral blood flow and vasoparesis. Many patients, particularly after 
evacuation of intracranial haematomata, develop a phase of hyperaemic cerebral blood 
flow from the second through to the seventh day post injury. These cerebrovascular 
abnormalities following reperfusion have been attributed to the generation of oxygen- 
derived free radicals, and mediators of the inflammatory response.
1.2.3.4 Inflammatory response to injury
Injury results in a co-ordinated cellular response organised to clear both blood clot and 
necrotic brain tissue, and to reconstitute the glia limitans. The acute phase lasts until the 
blood clot within the subarachnoid, subdural, intraventricular or parenchymal spaces has 
dissolved, and serves to deliver serum, and haematogenous cells including platelets, 
neutrophils, monocytes, and macrophages. Cytokines are released stimulating glial 
reactions such that astrocytes upregulate expression of S100B and glial fibrillary acidic 
protein (GFAP), and microglia become active amoeboid-like cells, with shortened
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processes, that actively migrate into the neuropil. The activated astrocytes play a key role 
in:
• Remodelling of the extracellular matrix by protease secretion
• Clearance of debris.
• Mediation of inflammation by release of transforming growth factors (TGFs) and 
Interleukins (ILs).
• Enhancement of neuronal survival by secretion of fibrosing growth factors (FGFs) and 
insulin like growth factors (IGFs).
• Metabolism of excitatory amino acids.
Demyelination of degenerating axons is initiated, but many of the processes of 
oligodendrocytes maintain contact with fragmenting intemodal myelin segments and do 
not change morphologically. Clot lysis is followed by the subacute phase, which terminates 
with the formation of the accessory glia limitans from astrocyte processes forming a 
condensed layer, bound together by tight junctional complexes. Fibroblasts, which by now 
are more frequent than macrophages, deposit matrix and neovascularization occurs. The 
consolidation phase results in scar formation, and down regulation of astrocyte and 
macrophage activity. However, microglia appear to populate the perilesional tissue in 
increased numbers for a prolonged period the limit of which is yet to be defined. (Holmin 
et al. 1998; Logan et al. 1994)
Whilst there is little doubt that post injury immunoactivation mediates delayed neuronal 
damage the exact function of each mediator or activated cell type is less clear. Indeed 
inflammatory events after injury appear to display dual and opposing roles promoting the 
repair of injured tissue but also causing additional brain damage mediated by the numerous 
neurotoxic substances released. Most of the data supporting these hypotheses derive from 
experimental work based on both animal models and cultured neuronal cells. Recent 
evidence suggests that elimination of selected inflammatory mediators is detrimental 
resulting in attenuation of neurological recovery. In the peripheral nervous system, post 
injury inflammation is a prerequisite for regeneration and restoration of function. In the 
CNS the glial reaction after injury and glial scar formation inhibits axon regeneration. 
(Fawcett, 1997; Fawcett and Asher, 1999; Fitch and Silver, 1997) Presumably, in the CNS 
where regeneration is limited, the purpose of the inflammatory response is to facilitate the 
removal of debris in order to minimise further neuronal injury due to chronic inflammation 
and/or neurotoxic effects of debris degradation products. It seems likely that inflammatory 
mediators regulate the production or release of effectors involved in the clearance of debris 
after brain. (Lenzlinger et al. 2001; McIntosh et al. 1998; Morganti-Kossmann et al.
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2001; Morganti-Kossmann et al. 2002; Stoll et al. 2002) We may speculate that debris 
removal via inflammatory processes is important for the removal of degradation products, 
which over time could accumulate and exert an osmotic effect resulting in raised intra­
cranial pressure.
1.2.3.5 Programmed cell death
The form of cell death that occurs from primary injury is necrosis. Necrotic cell death is 
characterised by a loss of ionic homeostasis. The membranes of dying cells are leaky 
resulting in swelling and fragmentation of the cells and their organelles with spillage of 
their contents into the surrounding tissues damaging it, and stimulating an inflammatory 
response. In contrast, apoptosis (or programmed cell death, PCD) is an active orderly 
process by which the cell undergoes an intrinsically programmed transition from an intact, 
metabolically active state to cellular breakdown. Membrane bound fragments (or apoptotic 
bodies) contain intact cellular organelles and masses of condensed DNA that are released 
and quickly phagocytosed by macrophages or microglia cells. This occurs without lysis of 
organelles or spillage of intracellular contents and without an accompanying inflammatory 
response. Apoptotic cells are found singularly or in small groups and are reduced in 
volume. A characteristic feature of apoptotic cell death is that cellular DNA is cleaved at 
intemucleosomal linkages generating fragments that are multiples of the intemucleosomal 
length which produce a laddering appearance when separated by agarose gel 
electrophoresis. Programmed Cell death is classically associated with normal CNS 
development. However, there is an increasing literature that supports the concept that PCD 
may be triggered directly after acute brain injury by some biochemical mediators of 
secondary injury or indirectly as a result of secondary pathophysiological processes such as 
ischaemia or inflammation. Thus terminal deoxynucleotidyl transferase (TdT) mediated 
biotinylated deoxyuridine triphosphate (dUTP) nick end labelling (TUNEL) positivity, a 
marker of PCD, has been identified in neurons and oligodendrocytes after both 
experimental and human brain injury. (Rink et al. 1995; Smith et al. 2000) In addition, 
anti-apoptotic cell death regulatory genes which are involved in development (e.g. the Bcl- 
2 superfamily) have been implicated in the regulation of PCD in experimental models of 
ischaemic, excitotoxic, and TBI. Transgenic mice over expressing human Bel-2 protein 
have significantly less neuronal loss after experimental brain injury. (Raghupathi et al. 
1998) It is postulated that Bcl-2 proteins modulate cell death and survival via 
mitochondrial cytochrome c, an activator of the caspase family of death related proteases. 
Activated caspase-1 (IL-lp converting enzyme) and caspase-3 cleave proteins that are 
important in maintaining cytoskeletal integrity and DNA repair, and activate
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deoxyribonucleases, producing cell death with morphological features of apoptosis. 
Caspase-3 activation has been identified after experimental and human TBI, and central 
administration of a caspase inhibitor is reported to reduce post-traumatic apoptosis and 
neurological deficits. (Clark et al. 1999; Pike et al. 1998; Yakovlev et al. 1997) The 
tumour suppresser gene p53 which is typically induced and upregulated in response to 
DNA damage, is also activated in experimental brain injury in regions exhibiting TUNEL 
positive apoptotic cells. (Kaya et al. 1999; Napieralski et al. 1999) After experimental 
global cerebral ischaemia, base excision repair (BER) pathways are reported to decrease 
suggesting that neuronal apoptosis may result from a failure to repair damaged DNA. 
(Kawase et al. 1999) Furthermore, the nuclear protein Poly (ADP ribose) polymerase 
(PARP), which detects BER of double and single stranded DNA breaks is activated after 
experimental TBI and inhibition of PARP is reported to be neuroprotective. (LaPlaca et al. 
1999; LaPlaca et al. 2001) In addition to the programmed cell death response of the brain 
to injury, there is evidence to support a co-ordinated intrinsic neuroprotective response, 
which facilitates the survival of viable neurons. Thus, proteins that modulate oxidative 
stress (glutathione peroxidase, and superoxide dismutase), and nitric oxide (inducible nitric 
oxide synthetase) production are induced after acute brain injury. Other factors produced 
by neurons and glia include trophic factors such as nerve growth factor, brain derived 
neurotrophic factor, insulin-like growth factor, etc. Examples of other genes identified as 
important for survival of the injured neuron include the "Immediate Early Genes" 
(activated within five minutes of an insult) fos/jun, and the so-called stress proteins such as 
hsp 70. It is postulated that these proteins activate downstream processes or act as 
molecular chaperones stabilising other proteins such as those making up the cytoskeleton 
or mobilising cell defences. However, it is estimated that there are 20,000 different 
proteins in the brain underlying the challenge involved in unravelling their relative 
contribution to intrinsic neuroprotection. (Graham et al. 2000)
1.2.4 Limitations in improving outcome after acute brain injury
Advances in understanding the chain of dynamic events that follow brain injury has 
prompted the development of so called "neuroprotective agents". Recognition of secondary 
processes and the vulnerability of the injured brain to these delayed insults suggests an 
opportunity to alter the "milieu" after the primary injury as a pre-treatment to the 
subsequent secondary insults. Recognition of the importance of ischaemia in head injury 
has encouraged the use of pharmacological agents developed with a view to treatment of 
stroke. Other approaches included hypothermia and corticosteroids. Efficacious in the 
controlled experimental conditions of the animal model, these agents underwent Phase II
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studies with acceptable levels of safety and tolerability and in some cases preliminary 
evidence of improvement in outcome. However, Phase III studies have now been 
completed and no "neuroprotective agents" so far have reached the selected threshold for 
demonstrating a 10% improvement in favourable outcome. The reasons for the apparent 
failure of these studies are complex and require careful consideration in order to advance 
our understanding of the problems involved and how best to tackle them. These problems 
relate to heterogeneity of the target population and biological processes coupled to a 
dichotomous outcome whereby a relatively small proportion of patients have an 
intermediate outcome upon which a neuroprotective agent must exert its effect. 
Multicentred studies have identified prognostic factors determining outcome, however, 
increasingly, clinical information is less conspicuous given the earlier and increased use of 
ventilation. CT scanning reveals a heterogeneous array of abnormalities associated with 
mortalities ranging several fold. Continuous monitoring enables capture and analysis of 
hypoxic and hypotensive episodes that also influence outcome. Techniques such as 
stratification at the time of randomisation and statistical modelling are necessary to refine 
treatment and placebo groups for the purposes of comparison. Heterogeneity in patient 
management is an additional complexity, which could be minimised by adherence to 
guidelines. Centres where guidelines are not followed may have the greatest burden of 
secondary insults. Exclusion of these centres from "neuroprotection trials" may result in 
loss of the population of patients most likely to benefit from intervention. Not only is the 
brain injury population variable, so is the biological process that follows. The relevance of 
any particular pathophysiological or biochemical process that follows brain injury is 
uncertain. Hence, administration of a Glutamate antagonist, which may be of benefit in 
focal ischaemia predominated by excitotoxicity and intermittent depolarisation, is unlikely 
to benefit a population of patients with diffuse cerebral hypoxic insults. It may be that 
some of the failure to show clinical benefit of "neuroprotective agents " resulted from 
failure to meet the required criteria:
• The agent has been shown to have an effect on the relevant pathophysiological process 
in brain injury models
• The process is known to occur in human brain injury
• The agent can be safely administered in a regimen that is appropriate therapeutically in 
terms of dosage, brain penetration and time scales.
It may be that different agents are beneficial at different stages of the injury process or that
multiple agents are required at a given time (a "cocktail") to minimise the multiple
processes that are ongoing. A further difficulty that these trials have encountered relates to
"end points" and quantification of effect. As many as 40% of patients with severe head
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injury die and approximately 40% recover to independence. Hence the remainder are left in 
a dependent state in the "U-bend" of the outcome distribution. Given that independence is 
the goal, not survival in dependency, improving outcome by 1 0 % requires "shifting” large 
proportions in each category up by two categories. Therefore a target of 10% improvement 
in favourable outcome may be unrealistic. It can be argued that the failure to show any 
adverse effect of the various agents supports some effect, not statistically significant at the 
chosen threshold that may be of benefit to the greater population of head injured patients. 
Furthermore, some trials were abandoned due to "futility analysis" and because of the 
experience of parallel trials in stroke patients. This is unfortunate given the profound 
differences in biological process, patient population and management of stroke and severe 
head injury. It is now recognised that increased focus is required upon the phase of 
translation from experimental brain injury to human brain injury. (Maas et al. 1999; 
Teasdale et al. 1999) Thus the requirement for in-vivo clinical research, despite the 
scientific challenges involved, is greater if progress in treatment of acute brain injury is to 
be achieved.
1.3Apolipoprotein E
Although first described nearly thirty years ago, current understanding of the molecular 
and cellular biology of this 34 Kilo-Dalton (KDa) glycoprotein is far from complete. 
(Shore and Shore, 1973) While the relevance of apoE to clinical disorders such as 
atherosclerosis is now well established, a substantial body of evidence supporting a role for 
apoE in central nervous system (CNS) disease is accumulating. (Mahley and Huang, 1999) 
In relation to atherosclerosis, molecular genetic studies have established three key 
functions for apoE that are atheroprotectant. First, plasma apoE maintains overall plasma 
cholesterol homeostasis through efficient hepatic uptake of cholesterol containing 
lipoprotein remnants, mediated by apoE functioning as a ligand for the low density 
lipoprotein (LDL) family of receptors. Second, apoE (working in concert with the 
cholesterol esterification enzyme activator, apoAI) facilitates cellular cholesterol efflux 
from macrophage foam cells in the blood vessel intima. Third, apoE, by modulating both 
T-lymphocyte and macrophage cytokine production, influences the chronic inflammatory 
response integral to atherosclerosis. (Curtiss and Boisvert, 2000) However, the complexity 
and relevance of apoE to human disease is not limited to its range of biological functions, 
since in humans the gene coding for the apoE protein is polymorphic. Point mutations, at 
codons 112 and 158, in the APOE gene (on chromosome 19) result in amino acid 
substitutions in the protein, altering the tertiary structure. It is postulated that this natural,
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genetically based, variation in the apoE protein tertiary structure underlies the risk 
stratification for ischaemic Heart disease (IHD), Alzheimer’s Disease (AD) and recovery 
from TBI, and SAH. Although rare APOE alleles (e) have been described in humans, three 
(s2, e3, s4) predominate. (Kamboh et al. 1999) The APOE e3 allele has the highest 
population frequency of approximately 77% while APOE s4 and APOE s2 comprise about 
15% and 8 % respectively with significant ethnic variations in the allele distribution around 
the world. (Mahley and Rail, 1999) In contrast to humans, other species, including great 
apes, do not display this genetic polymorphism; their gene product has sequence homology 
resembling apoE4 with arginine at the position corresponding to residue 112 in human 
apoE. (Finch and Sapolsky, 1999; Weisgraber, 1994) The two polymorphic sites in human 
APOE are CPG sequences, which are regarded as mutation "hot spots". Thus, the 
methylation of C in the CPG sequences, and their ready deamination to T, make a C to T 
mutation more likely than T to C, which would be necessary to obtain APOE e4 from 
APOE s3. (Hanlon and Rubinsztein, 1995) Although the APOE e4 allele is less common 
than APOE s3, it is probably the ancestral/wild type allele with APOE s3 resulting from 
one mutational event, and APOE e2 resulting from two such events. These specific point 
mutations enable the determination of APOE genotype using Restriction Fragment Length 
polymorphism (RFLP). Alternatively, the apoE protein phenotypes may be identified by 
iso-electric focussing (IEF). Functional consequences result from differences in intra­
protein amino acid-amino acid interactions dictating isoform dependent lipoprotein 
preference and receptor binding. The amino two thirds of apoE (residues 1-191) contains 
both the Heparin Sulfate Proteoglycan (HSPG) binding site and the receptor binding 
region, of which the side chain of Arginine 150 forms a component. The carboxy terminal 
domain contains the major lipid-binding site. ApoE3, which has arginine at residue 158, 
forms a salt bridge with aspartic acid 154. This is not possible in apoE2, which has a 
cysteine at residue 158, instead a salt bridge forms between aspartic acid 154 and the 
receptor binding residue arginine 150 reducing the affinity of apoE2 for the LDL receptor. 
In contrast to apoE isoforms 2 and 3, which have cysteine at residue 112, apoE4 has 
arginine here which forms a salt bridge with glutamic acid 109 re-orientating the side chain 
of arginine 61 such that it interacts with glutamic acid 255 in the carboxyl terminus. This 
determines the preference of apoE4 for very low density lipoprotein (VLDL), while apoE3 
and apoE2 prefer smaller, phospholipid rich high density lipoprotein (HDL). This might 
also account for differential association with the high capacity, low affinity cell surface 
HSPGs in the HSPG-LRP pathway. (Mahley, 1988; Mahley and Huang, 1999; Mahley et 
al. 1996)
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1.3.1 Apolipoprotein E and the central nervous system
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In contrast to the periphery where a variety of apolipoproteins are found, there are 
relatively few apolipoproteins in the CNS. Though mRNA has not been detected for 
apoAI, apoAII, apoAIV, apoB, apoCII, apoCIII, apoF and apoH in the brain, apoE mRNA 
expression in the brain is second only to the liver. (Elshourbagy et al. 1985) CNS apoE is 
synthesised entirely intrathecally since CSF apoE isoform type is unaltered by liver 
transplantation from a donor of different genotype. (Linton et al. 1991) ApoE, which does 
not cross the intact "blood brain barrier", is synthesised by astrocytes and microglia; 
neurons probably do not synthesise apoE under normal circumstances. (Boyles et al. 1985; 
Diedrich et al. 1991; Elshourbagy et al. 1985; Poirier et al. 1991; Stone et al. 1997; 
Zlokovic, 1996) However, neurons do have the capacity to internalise apoE-containing 
lipoproteins and apoE has been localised within neurons of apparently normal brains, and 
in response to acute and chronic injury. (Beffert et al. 1998; Han et al. 1994; Horsburgh et 
al. 1997; Horsburgh et al. 2000b; Horsburgh and Nicoll, 1996; Metzger et al. 1996; 
Schmechel et al. 1993) Using immuno-electron microscopy on human brain sections from 
young epileptic patients, apoE is reported to localise to the cytoplasm of cell bodies and 
proximal dendrites in association with the external membrane surface of some organelles 
supporting the concept of intracellular apoE trafficking. (Han et al. 1994; Nicoll et al. 
2001) Thus apoE appears to play a principal role in the CNS in the transport of cholesterol 
and lipid from glial cells to the neuronal cytoplasm. The vehicle in which the lipid and 
cholesterol are transported is the apoE lipoprotein particle (LpE).
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Figure 1 Lipoprotein Particles
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Five classes o f lipoprotein particle are described in plasma. Chylomicrons have the lowest 
density (d): < 0.95 g/mL and a mean particle diameter of 500 nm. They are rich (85%) in 
triglyceride, but have the lowest (2%) apoprotein (Cl, CII, CIII, B-48, E, Al, and All) 
content. Very low density lipoproteins (VLDL) have smaller diameter (43 nm) and d < 
1.006 g/mL. They have less triglyceride (50%), more cholesterol (7%), cholesteryl ester 
(13%) and phospholipid (20%) and the same apoproteins as chylomicrons. Intermediate 
density lipoproteins (IDL) arise from the catabolism of chylomicrons and VLDL. IDL 
density = 1.006 - 1.019 g/mL, and mean diameter = 27 nm. They contain a higher 
proportion (18%) of apoprotein (apoB-100 and apoE), and lipid, but less triglyceride 
(26%). Low density lipoproteins (LDL) arise from the catabolism of VLDL and comprise 
three subfractions (LDL I, II, III). Apoprotein (apoB-100 and apoE) represents 25%, 
triglyceride 10% and cholesteryl ester 37% o f the composition. LDL I has a diameter of 27 
nm (d = 1.02 - 1.03 g/mL), LDL II = 26.6 nm (d = 1.03 - 1.04 g/mL) and LDL III = 26 nm 
(d = 1.04 - 1.06 g/mL). High density lipoproteins (HDL) occur as three main subfractions 
(HDL|, HDL2 , and HDL3); HDLi is rarely seen in human plasma. HDL2 has a mean 
particle diameter o f 9.5 nm and density range of 1.063 - 1.125 g/mL. HDL3 has a mean 
particle diameter o f 6.5 nm and density range o f 1.125 - 1.210 g/mL. HDL has the highest 
(55%) apoprotein (Al, All, D, CII, CIII, and E) and phospholipid (24%) content and the 
lowest (4%) triglyceride. See also figures 21 and 22.
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1.3.1.1 CSF lipoprotein particles
As in plasma, apoE forms a key component of CSF lipid transport vesicles known as 
lipoprotein particles (Lps), which facilitate the solubilisation of lipids within an aqueous 
environment, and their transport to appropriate metabolic pathways. In plasma, these 
vesicles have a nonpolar core containing triglyceride and cholesteryl esters, surrounded by 
a monolayer of phospholipid (see figure 1). The polar head groups of the phospholipids are 
orientated toward the aqueous environment stabilising the lipoprotein particle allowing 
them to remain in solution. The surface monolayer contains unesterified cholesterol and 
the apoproteins, which function as ligands for cell surface receptors and regulators of 
enzymes involved in particle remodelling. (Mahley et al. 1984) Phospholipid is the most 
abundant lipid in CSF lipoproteins followed by cholesterol and cholesteryl esters. The 
CNS accounts for 2% of body mass and 25% of total body free cholesterol. The cholesterol 
content of brain tissue is high making up 1% of grey matter (wet weight) and 4% of white 
matter. The CNS cholesterol pool is non-exchangeable with the plasma and its 
interchangeable pools. Evidence from experimental cholesterol turnover studies suggests 
that brain cholesterol demand for development and day to day maintenance is met entirely 
by intrathecal cholesterol synthesis. (Dietschy and Turley, 2001) Though the CNS apoE 
lipoprotein particle most likely plays a key role in regulating cholesterol homeostasis, as it 
does in plasma, differences between the plasma and CSF particles have been identified and 
have been an area of focus for those researching neuronal degeneration. (Montine et al.
1997) In contrast to plasma where five different lipoprotein classes exist, Lps in the CSF 
are more homogeneous having a size similar to plasma HDL. At least two subclasses of 
HDL- like CSF Lps have been identified which appear to be either relatively rich apoAI or 
apoE. CSF HDL contrasts plasma HDL in that the larger apoE rich HDLi- like particle 
found in CSF are a very minor component of plasma HDL where smaller HDL2 and HDL3 
particles predominate. There is very little HDL] in human plasma as cholesteryl ester is 
transferred via cholesteryl ester transferase protein (CETP) to the larger apoB containing 
lipoprotein, LDL. Normal CSF does not contain apoB so apoE lipoproteins play a special 
role in cholesterol transport by virtue of their ability to expand to HDLj. Other smaller Lps 
have been identified in the CSF but are yet to be fully characterised. In contrast to plasma, 
the concentration of apoE in CSF is reported not to vary according to genotype. (Rebeck et 
al. 1998; Schiele et al. 2000a; Vincent-Viry et al. 1998) ApoE phenotype has been 
reported to affect the distribution profile of apoE containing lipoproteins in the CSF 
suggesting that metabolism of apoE containing lipoproteins depends on the apoE isoform 
present. ApoE2 and apoE3 (but not apoE4) can form heterodimers with apoAII, which 
have greatly diminished LDL receptor binding compared to apoE. Therefore apoE4 Lps,
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which do not form apo (E-AII) and apo (AII-E-AII) complexes, may be metabolised more 
efficiently than apoE3 and apoE2 containing lipoproteins. CSF associated with apoE4 is 
reported to have a lower cholesterol concentration (contrasting the situation in plasma) 
than CSF associated with apoE3 and apoE2. (Borghini et al. 1995; Borghini et al. 1993; 
Guyton etal. 1998; Montine et al. 1998; Montine et al. 1997; Pitas et al. 1987) However, 
others have found no significant differences between CSF Lps with respect to the different 
apoE isoforms. (Fagan et al. 2000; Koch et al. 2001) CSF Lps may not be representative 
of the population of Lps present in the neuropil. Lps isolated from serum free rat astrocyte 
culture media (ACM) contain only apoE and apoJ in contrast to human CSF Lps, which 
contain apoE and apoA. Rat astrocyte Lps are discs that contain less cholesteryl and have 
the potential to accumulate cholesterol ester via lecithin, cholesterol acyltransferase 
(LCAT) and CETP and remodel to cholesterol ester laden CSF spheres. Thus these 
particles may represent a population of particles participating in the recycling of 
cholesterol within the brain parenchyma. (Albers et al. 1992; Smith et al. 1990) ApoE 
appears to be important to the regulation of cholesterol cycling as APOE -/- (knockout) 
mice serum free ACM contains little or no free cholesterol or phospholipid and lipoprotein 
particles were not detectable under the electron microscope. (Fagan et al. 1999)
1.3.2 Apolipoprotein E and neuronal plasticity
In contrast to the CNS, peripheral nerves have the capacity to regenerate. Following rat 
sciatic nerve crush injury, macrophage apoE secretion increases one hundred fold, reaching 
a peak one week after injury and normalises within a few months when regeneration is 
largely complete. The secreted apoE facilitates the recycling of cholesterol from the 
degenerating neuron, which may then be used by the growth cones of neurites via 
upregulated LDL receptors at their tips. (Goodrum, 1990; Goodrum, 1991; Goodrum et al. 
2000a; Goodrum et al. 2000b; Ignatius et al. 1987a; Ignatius et al. 1987b) However, 
when APOE -/- (knockout) mice undergo peripheral nerve injury, there is no apparent 
reduction in regeneration suggesting that in the mouse peripheral nervous system, 
lipoproteins other than apoE (e.g. apoJ) may be utilised for the same purpose. (Goodrum et 
al. 1995; Popko et al. 1993) The CNS of APOE knockout mice are reported to have 
synapto-dendritic structural abnormalities, measured using Microtubule-Associated Protein 
(MAP-2) and synaptophysin immunoreactivity, in hippocampal and cortical areas, which 
increase with age. Amelioration of these changes by intraventricular infusion of exogenous 
apoE or endogenous expression of human apoE3 (but not human apoE4) suggests there is a 
degree of synaptic plasticity that is apoE dependent. (Masliah et al. 1996; Masliah et al.
1997) If these apoE knockout mice experience hippocampal injury, then clearance of lipid-
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laden products of neurodegeneration is impaired supporting the concept that apoE plays a 
role in lipid and cholesterol recycling. (Fagan et al. 1998; White et al. 2001a) A number 
of in- vitro studies utilising peripheral and central nervous system cell cultures, and more 
recently organotypic hippocampal cultures from human APOE transgenic mice, have 
shown that apoE3 promotes neurite extension to a greater extent than apoE4. The effect 
requires the apoE to be associated with a lipoprotein transport vehicle directing it to the 
HSPG-LRP pathway. The mechanism by which apoE promotes neurite extension and the 
reason for greater effect with apoE3 has not been conclusively elucidated. (Bellosta et al. 
1995; DeMattos et al. 1998; Fagan et al. 1996; Holtzman et al. 1995; Nathan et al. 1994; 
Nathan et al. 1995; Sun et al. 1998) In vitro studies support a role for apoE in the 
stabilisation and remodelling of the neuronal cytoskeleton. Binding of apoE3 to the 
microtubule associated protein Tau stabilises the microtubules and prohibits 
hyperphosphorylation. It has been postulated that deficient apoE4- Tau interactions result 
in Tau self association and hyperphosphorylation, laying down the foundations for Paired 
Helical Filament (PHF) formation and thereafter neurofibrillary tangles (NFT). If cultured 
Neuro-2a cells are treated with neurite outgrowth inhibiting lipidated apoE4 there are 
fewer microtubules, and a lower ratio of polymerised to monomeric tubulin, compared to 
cultures treated with neurite outgrowth promoting lipidated apoE3 treated cells. (Nathan et 
al. 1995) There is additional evidence to support a role for apoE in cytoskeletal 
remodelling from the APOE transgenic and knockout mice. In addition to cytoskeletal 
abnormalities, APOE knockout mice have increased phosphorylated Tau immunoreactivity 
compared to wild-type mice. (Genis et al. 1995; Masliah et al. 1995) The transgenic mice 
expressing human APOE&4 have more cytoskeletal abnormalities than those expressing 
APOEz3. (Buttini et al. 1999) However, the relevance of these cytoskeletal-remodelling 
observations to human pathology such as Alzheimer's Disease (AD) is uncertain given the 
failure to demonstrate apoE in the neuronal cytosol, and the lack of consistent evidence 
supporting an association between APOE genotype and NFT burden in AD brain. (Beffert 
et al. 1998; DeMattos et al. 1999)
1.3.3 Apolipoprotein E and amyloid p protein
The function of the transmembrane protein beta-amyloid precursor protein (P-APP) is not 
known. However, as a part of normal cellular processing, secretase enzymes cleave 
specific regions of the protein generating peptides, known as amyloid beta-protein (Ap), of 
varying length, e.g. APmo and AP1.42. For unknown reasons these hydrophobic peptides 
form a major component of AD plaques. Although the 42 amino-acid peptide ( A p i . 4 2 )
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constitutes the minority (10%) of Ap, it is the most hydrophobic species, and forms the 
seed of the amyloid plaque. The Ap peptides are known to be chaperoned by apoE (and 
apoJ) containing HDL-like lipoprotein particles in the CNS, and the proportion of Api-40 
appears to be influenced by APOE genotype. Thus CSF Lps isolated from APOE e4 
subjects have significant elevation of the Api-40 ratio than CSF Lps from non-APOE s4 
subjects. (Biere et al. 1996; Fagan et al. 2000; Koudinov et al. 1996; LaDu et al. 1995; 
Tokuda et al. 2000; Wisniewski et al. 1993) There is therefore evidence to support direct 
interactions between apoE and Ap, which results in the formation of insoluble aggregates. 
However, human in-vivo evidence for such an interaction is sparse. Microglia scavenge 
Ap-apoE aggregates via scavenger and lipoprotein receptors and deliver it to the lysosomal 
pathway for degradation. Microglia have the capacity to secrete apoE which may then 
capture Ap for internalisation by these receptors (secretion capture), possibly in 
conjunction with HSPGs. (Cole and Ard, 2000) Interest in Ap degradation has increased 
following reports that Ap immunization not only reduces Ap deposit formation, but also 
established Ap deposits. (Schenk et al. 1999) Although it is not clear whether apoE 
directly regulates Ap degradation or indirectly regulates degradation by promoting 
aggregation and deposition, evidence from human post-mortem studies and work with 
transgenic mice support a role for apoE controlling the ultimate fate of Ap. (Bales et al. 
1999; Bales et al. 1997) In vitro studies provide supporting evidence for both the 
chaperone role and an effect of apoE directly promoting assembly of Ap into amyloid 
fibrils, though the effects appear to be dependent on the lipidation and oxidation status of 
the apoE. (Sanan et al. 1994; Wisniewski et al. 1994) In vitro apoE4 is more 
amyloidogenic than apoE3 and apoE2, which is consistent with reports that APP TG mice 
expressing human APOE4 exhibit accelerated Ap deposition. (Holtzman et al. 2000a; 
Holtzman et al. 2000b; Ma et al. 1994) In addition, apoE may indirectly influence APP 
processing via the regulation of cellular cholesterol, which is reported to regulate the 
activity of the intra-membranous secretase APP cleavage enzyme. (Dodart et al. 2002b; 
Simons et al. 1998) The concept that cholesterol reduction may decrease Ap production 
has received recent attention due to the observation that cholesterol-lowering agents may 
reduce the risk of Alzheimer's disease. (Jick et al. 2000; Wolozin et al. 2000)
1.3.4 Apolipoprotein E and oxidative stress
Given that apoE2 possesses two cysteine residues, at positions 112 and 158, apoE3 has one 
at position 112 while both these positions are arginine in apoE4, it has been suggested that 
differences in free radical scavenger ability exist between isoforms. Differences in
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oxidative stress have been identified in TG mice but the relevance to human brain injury is 
unknown. The APOE -/- transgenic (TG) mice are reported to be in a state of chronic 
oxidative stress resulting with increased protein nitration in the cortex, hippocampus, 
cerebellum and brainstem, indicating formation of the neurotoxic free radical, 
peroxynitrite. (Lomnitski et al. 1999; Matthews and Beal, 1996) APOE knockout and 
APOE4 transgenic mice are reported to be more susceptible to closed head injury and some 
of this effect is reported to be attributable to reduced anti-oxidant activity. (Chen et al. 
1997; Lomnitski et al. 1997; Sabo et al. 2000) Furthermore, APOE -/- knockout and wild- 
type (WT) mice, when subjected to global cerebral ischaemia, show reduced neuronal 
damage and lipid peroxidation if apoE is infused into the ventricle supporting a role for 
apoE as an antioxidant. (Horsburgh et al. 2000a; Kitagawa et al. 2002)
1.3.5 Apolipoprotein E and Alzheimer's Disease
Alzheimer’s disease (AD) accounts for 70% of late onset dementia and 100,000 deaths per 
year in the USA. Clinical features include personality change, language and visuo-spatial 
problems, memory loss and global cognitive decline. The neurological deficit results from 
selective neuronal dropout and synaptic loss. (DeKosky and Scheff, 1990; DeKosky et al. 
1996) Currently, the clinical diagnosis of probable AD can only be confirmed post­
mortem, by the presence of abundant neurofibrillary tangles (NFTs) and (3-Amyloid (AP) 
plaques distributed in characteristic and specific brain regions, cells types and laminae. 
Though the pathology of AD is characterised by the accumulation of these insoluble 
aggregates, and despite compelling evidence supporting their role in the pathogenesis of 
AD, neither has been universally accepted as the primary aetiological factor. NFTs are the 
insoluble intracellular structures consisting of abnormal cytoskeletal elements, called 
paired helical filaments (PHFs), the major component of which consists of abnormally 
phosphorylated microtubule associated Tau protein. (Goedert, 1993) Hyper­
phosphorylation of Tau results in reduced flexibility disrupting axonal transport and 
microtubule binding, resulting in intra-neuronal accumulation. NFTs are not diagnostic of 
AD since they are seen in other neurodegenerative disorders (Tauopathies) such as 
progressive supranuclear palsy, cortico-basal degeneration, Pick's disease, Parkinson- 
dementia complex of Guam, post-encephalitic Parkinsonism and the chronic TBI disorder, 
dementia pugilistica. (Goedert, 1999) Tangle formation appears to represent a stereotypical 
cellular reaction to a range of pathological initiators. (Wisniewski et al. 1979) In addition 
to NFTs, two other neurofibrillary structures are recognised which, despite morphological 
differences, share Tau epitopes and occur in the same neuronal pool. These are neuropil 
threads, which are the distal dendrites of tangle containing neurons, and dystrophic
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neurites, surrounding senile plaques and neuropil threads. (Braak and Braak, 1988) The 
second major manifestation of AD is the senile or neuritic plaques comprising extracellular 
lesions containing a dense central core of (3-amyloid protein, surrounded by dystrophic 
neurites, reactive astrocytes and microglia. The p-amyloid protein is a hydrophobic 
fragment of the transmembrane glycoprotein Amyloid Precursor Protein (APP), which 
although its' function is uncertain, appears to be up regulated by a wide range of 
pathologies causing axonal injury. (Graham et al. 1995)
1.3.5.1 Apolipoprotein E and AD-epidemiological evidence
Although several genetic loci, including APP, Presenilin-1 (PS-1) and PS-2 contribute to 
Familial Alzheimer’s disease (FAD), the commonest known genetic susceptibility factor 
for the population at large is APOE. (Adroer et al. 1995; Basun et al. 1995; Corder et al. 
1993; Frisoni et al. 1995; Goate et al. 1991; Levy-Lahad et al. 1995; Lucotte et al. 1993; 
Mayeux et al. 1993b; Okuizumi et al. 1994; Payami et al. 1994; Saunders et al. 1993a; 
Sherrington et al. 1995; St et al. 1995; Strittmatter et al. 1993). Estimates of attributable 
risk as high as 50% have been reported for the development of AD based on APOE 
genotype. (Corder et al. 1993) In both sporadic and familial late-onset AD, the prevalence 
of the e4 allele is increased from approximately 15% to 40%. (Poirier et al. 1993; 
Saunders et al. 1993b) Approximately 80% of familial and 64% of sporadic late-onset AD 
cases carry at least one copy of the APOE e4 allele compared to 30% of controls. 
Possession o f APOE s4 reduces the age of onset of AD and thus the frequency of this allele 
is low in the very elderly. Thus APOE e4 homozygotes represent 40% of AD patients at 55 
years of age but less than 5% over 91 years of age. (Corder et al. 1993; Rebeck et al.
1994) In contrast APOE s2 is protective in that it delays the onset and reduces the risk of 
AD. (Corder et al. 1994; Talbot et al. 1994; West et al. 1994) For patients with FAD, age 
of onset appears to be influenced by APOE e4 in patients with APP mutations but not PS-1 
mutations. (St George-Hyslop et al. 1994; Van et al. 1994) However, the APOE s4 allele 
does not appear to influence the rate of disease progression once started. (Beffert et al.
1998) A meta-analysis of 5930 AD patients for APOE genotype AD associations, found 
APOE s4 to be a risk factor for AD across a wide range of ethnically different groups, but 
that though women were more likely to develop AD, this was not attributable to 
differences in APOE genotype frequency. (Farrer et al. 1997)
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After Strittmatter reported the overrepresentation of the APOE s4 allele among AD 
patients, several studies examined the relationship between possession of the APOE s4 
allele and markers of AD pathology such as amyloid containing senile plaques (SP) and 
intra-neuronal neurofibrillary tangles (NFT). (Beffert et al. 1999; Beffert and Poirier, 
1996; Berg et al. 1998; Chen et al. 1999; Gearing et al. 1996; Gomez-Isla et al. 1996; 
Marz et al. 1996; McNamara et al. 1998; Nagy et al. 1995; Ohm et al. 1995; Polvikoski 
et al. 1995; Schmechel et al. 1993; Strittmatter et al. 1993) Senile plaque density is 
reported to correlate with APOE s4 in a dose dependent manner while APOE e2 is reported 
to be associated with less amyloid deposition. (Lippa et al. 1997) The association between 
APOE e4 and amyloid deposition has not been reported unanimously though some of the 
inconsistency may be attributable to different methods for labelling amyloid deposits as 
immunostaining with Ap identifies the correlation between APOE s4 and Ap better than 
silver stains. (Berg et al. 1998; Chen et al. 1999) Furthermore, few studies discriminate 
between APmo and ApM2 plaque, the former of which increase with APOE e4. (Gearing et 
al. 1996) Although the presence of abundant amyloid plaques is a prerequisite for the 
pathological diagnosis of AD, they may be present in cognitively normal individuals and it 
is the presence of intracellular neurofibrillary lesions that correlate best with the presence 
of dementia. (Arriagada et al. 1992a; Arriagada et al. 1992b). However, there is even less 
correlation between NFTs, which are generally regarded as correlating with AD severity 
better than SPs, and possession of APOE s4 and NFTs. (Beffert et al. 1998) Thus, there 
appears to be some evidence in humans that APOE e4 is relatively more amyloidogenic 
and may influence formation of tangles, yet some continue to question this and the 
relevance to the aetiology of AD.
1.3.6.1 Apolipoprotein E and Ap deposition in transgenic mouse models of AD
Prior to the creation of transgenic (TG) mice, recreating AD pathology in animal models of 
AD has been unsuccessful. These TG mice overexpress a mutant form of the human 
amyloid precursor protein (APP) gene known to cause FAD (APP V7i7p) and develop age 
related and region specific Ap immunoreactivity, fibrillar amyloid deposition, glial 
activation and neuritic dystrophy similar to that observed in AD. (Games et al. 1995) 
Crossing these APP mutant mice with APOE -/- knockout mice results in reduced Ap 
immunoreactivity, compared to age matched littermates expressing wild-type mouse apoE,
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providing in vivo evidence for mouse apoE promoting amyloid deposition. (Bales et al.
1999) When APPy717F transgenic mice are crossed with APOE transgenic mice expressing 
either human APOE3 or APOE4, there is almost no detectable A(3 immunoreactivity unless 
15 month old mice are used, which develop fibrillar Ap deposits associated with greater 
neuritic plaque density in APOE s4 crosses compared to APOE e3. (Holtzman et al. 
2000a; Holtzman et al. 2000b)
1.3.7 Apolipoprotein E and Traumatic Brain Injury
1.3.7.1 Pathological studies
The brains of approximately 30% of patients who die after TBI have deposits of Ap in the 
cerebral cortex; patients younger than 60 years of age only have Ap if they die after TBI. 
The APOE e4 allele frequency in Ap positive cases is significantly higher than in the Ap 
negative cases. There is also an allele dosage effect in that 10% of patients without APOE 
e4 had Ap compared to 35% with one copy and 100% with two copies of the e4 allele. One 
interpretation of this association is that TBI is an acute trigger for deposition of Ap and this 
occurs predominantly in patients with the APOE s4 allele. (Nicoll et al. 1995) 
Alternatively, age related Ap deposition may occur in individuals with the APOE e4 allele, 
and patients with the APOE s4 allele are more likely to die after TBI. (Roses and Saunders,
1995) Some support for the argument of increased mortality in TBI patients possessing the 
APOE s4 allele comes from the higher frequency of this allele in the ninety patients with 
fatal TBI than in the control population. (Nicoll et al. 1995) Studies of patients who die 
after hypoglycaemia, status epilepticus, herpes encephalitis and global ischaemia identify 
selective neuronal injury with increased neuronal apoE immunoreactivity within a few 
days of injury. (Horsburgh et al. 1999a; Nicoll et al. 2001) It should be noted that these 
intriguing findings have not been extensively replicated by others, and the possibility exists 
that findings from the West of Scotland population may not reflect the brain injury 
population at large. The influence of environmental factors (e.g. diet, ischaemic heart 
disease, cigarette smoking etc) upon brain apoE and Ap are not known.
1.3.7.2 Human APOE transgenic mice and TBI
The majority of studies using human APOE TG or knockout mice models of experimental 
brain injury focus upon AD pathology and ischaemia. (Chen et al. 1997; Genis et al. 
2000; Horsburgh et al. 1999b; Horsburgh et al. 2000a; Horsburgh et al. 2000b;
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Laskowitz et al. 2000; Laskowitz et al. 1997; Lomnitski et al. 1999; Lomnitski et al. 
1997; Lomnitski et al. 2000; Sheng et al. 1998; Sheng et al. 1999) The absence of 
association between possession of APOE s4 and poor outcome after human ischaemic 
stroke questions the relevance of findings from experimental models of ischaemia to 
human TBI, even though both focal and global ischaemia are major components of TBI. 
(Graham et al. 1995; McCarron et al. 2000) Nevertheless studies of global ischaemia in 
APOE4 TG mice suggest they have greater neuronal vulnerability than APOE3 TG mice, 
suggesting that APOE4 is less protective than APOE3. (Horsburgh et al. 2000a; Horsburgh 
et al. 2 0 0 0 b)
1.3.7.3 Clinical studies
Following on from the human APOE transgenic mice, and human neuropathology studies, 
prospective observational studies in TBI patients have identified an association between 
possession of the APOE s4 allele and an unfavourable outcome (dead or severely disabled) 
six months after TBI. In the Glasgow study, after correcting for age and injury severity, the 
likelihood of an unfavourable outcome was doubled by possession of the APOE s4 allele. 
(Friedman et al. 1999; Teasdale et al. 1997) A separate study of TBI patients completing 
a rehabilitation program also associated possession of the APOE e4 allele with reduced 
functional recovery. (Lichtman et al. 2000) Possession of the APOE s4 allele has also 
been associated with more severe chronic TBI in boxers. High exposure boxers (i.e. those 
with 12 or more professional bouts) have significantly higher Chronic Brain Injury (CBI) 
scores compared to low exposure boxers, and boxers with APOE s4 have significantly 
greater CBI scores than high exposure boxers without APOE e4. Furthermore a gene 
dosage affect is apparent as boxers with severe impairment have at least one copy of the 
APOE s4 allele. (Jordan, 2000) Possession of APOE e4 has also been associated with 
reduced cognitive performance in older football players, and patients who undergo 
cardiopulmonary bypass for cardiac surgery. (Kutner et al. 2000; Newman et al. 1995; 
Tardiff et al. 1997) Other studies have identified associations between possession of the 
APOE s3 allele and more favourable outcome following non-TBI such as SAH, 
spontaneous intracerebral haemorrhage, cardiopulmonary bypass and resuscitation. 
(Alberts et al. 1995; Niskakangas et al. 2001; Schiefermeier et al. 2000; Tardiff et al. 
1997; Schiefermeier et al. 2000; Schiefermeier et al. 2000)
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1.3.8.1 Epidemiological evidence supporting TBI as a risk factor for AD
Compared to other risk factors for AD such as age, sex, level of education and family 
history epidemiological evidence consistently supporting an association with TBI is 
lacking. This may be partly due to the failure to conduct rigorous long-term prospective 
studies exploring this specific hypothesis. Conducting these studies presents several 
challenges to the epidemiologist. First, the diagnosis must be defined using the criteria of 
the American Psychiatric Association (DSM-III-R) to diagnose dementia, and those of the 
National Institute of Neurological and Communicative disorders and Stroke/Alzheimer's 
Disease and Related Disorders Association, to diagnosis probable AD. (Letenneur et al. 
2000; McKhann et al. 1984) Second, pathological confirmation of the diagnosis of AD has 
often not been established. (Mendez et al. 1992). Third, TBI among probable AD cases is 
often identified on the basis of patient, spouse or sibling reported measures introducing 
recall bias, or from medical register data which may also be unreliable. Unfortunately there 
is relatively little high quality information concerning long term outcome years or decades 
after TBI and though some studies have stratified injury severity according to the presence 
or absence of loss of consciousness, the degree and duration of unconsciousness is often 
not described. Thus many case control studies have shown no significant risk for AD after 
TBI. (Broe et al. 1990; Chandra et al. 1989; Chandra et al. 1987; Ferini-Strambi et al. 
1990; Fratiglioni et al. 1993; Li et al. 1992; Mendez et al. 1992; Ryan, 1994) Some 
studies do report an association between TBI and the development of AD but several of 
these are of borderline significance (Breteler et al. 1995; French et al. 1985; Graves et al. 
1990; Guo et al. 2000; Mayeux et al. 1993a; Mortimer et al. 1985; Mortimer et al. 1991; 
None, 1994; OMeara et al. 1997; Rasmusson et al. 1995; Salib and Hillier, 1997; Shalat 
et al. 1987; van et al. 1992). Few longitudinal cohort studies report increased risk of AD 
in patients with a history of TBI, though some of these studies have short follow-up 
intervals. (Katzman et al. 1989; Launer et al. 1999; Mehta et al. 1999; Schofield et al. 
1997; Williams et al. 1991) Nemetz reports that TBI reduces the age of onset of AD by 8  
years in individuals susceptible to the disease. (Nemetz et al. 1999)
1.3.8.2 Pathological evidence linking TBI to AD
The brains of people dying with AD share some pathological features with those dying 
after TBI. Plaque-like deposits of Ap are found in the cerebral cortex of 30% of fatal cases 
of TBI. Amyloid is derived from the cleavage of APP, a transmembrane protein, by a,p,y
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secretases to form mostly A(3 1.40 and Ap m2 the latter of which is insoluble and deposited 
as p amyloid. Immunostaining for Ap 1.42, the earliest cleavage product species deposited 
in AD brain, is also the predominant species after fatal head injury. (Gentleman et al. 
1993; Gentleman et al. 1997; Gentleman et al. 1993; Gentleman et al. 1995; Graham et 
al. 1995; Graham et al. 1996; Horsburgh et al. 2000; McKenzie et al. 1994; McKenzie et 
al. 1996; Roberts et al. 1991; Roberts et al. 1994) However, a study of twenty one long­
term survivors of TBI, who died from other causes up to twenty years later, failed to 
identify more Ap deposits compared to controls. (Macfarlane et al. 1999) Thus it is 
possible that deposits of Ap present after TBI are at a later stage cleared via inflammatory 
pathways including activated microglia, which are upregulated in the acute phase after 
TBI. (Griffin et al. 1994) Chronic Traumatic Brain Injury (CTBI) e.g. due to boxing, 
where in its' most extreme form it is referred to as dementia pugilistica, also shares 
pathological features with AD. Extensive plaques and NFTs with the same PHF formation 
as in AD have been observed in the brains of boxers with dementia pugilistica. Repetitive 
head injury in young adults appears to be associated with neocortical NFT formation 
around blood vessels particularly penetrating vessels in the depths of the sulci contrasting 
AD where cytoskeletal pathology does not cluster around blood vessels. Furthermore, 
repetitive head injury pathology in young adults does not appear to be associated with Ap 
deposition, which along with the early involvement of the neocortex would be unusual in 
AD. The absence of amyloid in repetitive head injury patients contrast dementia pugilistica 
where amyloid is often but not always noted. (Corsellis, 1989; Dale et al. 1991; Jordan, 
2000; Roberts, 1988; Roberts et al. 1990)
1.3.8.3 Animal model evidence linking AD to TBI
Attempts to reproduce these human pathological observations in rodent models of TBI 
have largely failed though a diffuse increased expression in p-APP is observed. Using a 
nonimpact head rotation acceleration model to generate DAI in pigs, Ap, Tau and NF are 
reported to co-localise to damaged axons throughout the white matter 3-10 days after 
trauma. A proportion of the pigs with DAI had diffuse Ap-containing plaque-like profiles 
in both the grey and white matter, and accumulations of Tau and NF rich inclusions in the 
neuronal perikarya. (Smith et al. 1999) TG mice expressing excessive levels of heavy 
chain neurofilament protein (NFH-LacZ mice) are more histologically and behaviourally 
vulnerable to TBI than wild type mice supporting the concept that neurofilament rich 
intraneuronal inclusions have deleterious effects on neuronal function. (Galvin et al. 2000) 
When the APP7 1 7 (PDAPP) TG mice, which overexpress APP ten fold, are subjected to
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Controlled Cortical Impact (CCI) both young (4 months of age) and older (2 years of age) 
APP7 1 7 TG mice undergo prominent loss of neurons, gliosis and atrophy near the site of 
CCI. When the cortex of young mice eight months after injury is compared to the 
contralateral unlesioned cortex, Ap deposition is reduced in the ipsilateral hippocampus 
and cingulate cortex and there is hippocampal atrophy. In contrast, hippocampal atrophy 
and reduced Ap deposits are not seen in hippocampus or cingulate cortex of sham-injured 
(PDAPP) APP7 1 7  TG mice or in any WT mice. The older mice too, four months after injury 
demonstrate marked regression in ipsilateral hippocampal Ap plaque burden compared to 
the contralateral hippocampus. This work supports the possibility that plaque resulting 
from progressive amyloidosis in AD brain may be reversible. (Nakagawa et al. 1999; 
Nakagawa et al. 2000) Furthermore, non injured PDAPP mice have impaired memory 
function compared to non injured wild-type littermates and brain-injured PDAPP mice had 
more profound memory dysfunction than brain-injured wild-type littermates. (Smith et al.
1998) When young PDAPP transgenic mice are immunized with Api_42> amyloid 
deposition is prevented; astrocytosis is dramatically reduced as is the Ap-induced 
inflammatory response. In addition, AP1.42 immunization appears to arrest the progression 
of amyloidosis in older PDAPP mice. Thus AP1.42 immunization (e.g. administered via a 
nasal spray) appears to increase clearance of amyloid plaques, and is a potential therapeutic 
or preventative strategy for AD. (Bard et al. 2000; Games et al. 2000; Janus et al. 2000; 
Schenk et al. 1999; Weiner et al. 2000) To date the clinical trial assessing the safety and 
efficacy of Api.42 immunization in patients with AD has halted due to adverse events 
underlining the requirement for increased understanding of Ap biology. If such a treatment 
strategy proves beneficial in AD then consideration could be given to extending the 
application to patients with TBI.
1.4CSF proteins and the response of the brain to injury
All of the currently available research tools used to investigate the in-vivo response of the 
human brain to injury have limitations, and these must be taken into account when 
interpreting findings from studies in acute brain injury. Imaging type investigations, such 
as XeCT, PET, MRI, SPECT and MRS, allow in vivo studies of metabolic processes and 
alterations in cerebral blood flow, but require substantial financial investment and are 
limited to single or a few time points after injury. These techniques have not yet been 
applied to large-scale studies of human brain injury. Techniques for continuous monitoring 
of physiological and biochemical parameters are available, but these are restricted to 
patients with severe brain injury, and for limited time intervals. Although multimodal
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monitoring and capture of physiological variables such as intracranial pressure (cerebral 
perfusion pressure), cerebral oxygen content and pH, and jugular bulb oxygen saturation 
(SjV0 2 ) enables trend analysis, it is often challenging to correlate these observations with 
clinical end points such as clinical outcome six months after injury. Microdialysis can be 
used to continuously monitor biochemical changes after brain injury such as glutamate, 
lactate, and aspartate but substantial variations are observed depending on the location of 
the microdialysis membrane in relation to the area of injured brain monitored. Uncertainty 
regarding the true location of the dialysis membrane in relation to the area targeted for 
monitoring compound these problems. Analysis of CSF is limited to patients who require 
CSF access for the purpose of treating acute hydrocephalus, or the monitoring of 
intraventricular pressure after acute brain injury. Analysis of the constituents of ventricular 
CSF at best facilitates a global reflection of upstream (parenchymal) events. In contrast to 
microdialysis CSF analysis allows larger molecules such as structural proteins to be 
assayed, and is a relatively cheap and simple technique. Through the analysis of CSF 
proteins in the first instance, CNS proteins have been identified and in some cases their 
release has correlated with injury severity and outcome. The identification of proteins in 
the CSF that act as surrogate markers of brain injury may in the future be extrapolated to 
studies in plasma and serum, which would be applicable to a wider spectrum of brain 
injured patients, including those with "mild” injury.
1.4.1 Cerebrospinal Fluid
Cerebrospinal Fluid (CSF) is essentially an ultrafiltrate of plasma. In normal CSF eighty 
percent of proteins are transudated from plasma and the remainder are synthesised by the 
brain. All known proteins pass from plasma into CSF, but do so in inverse proportion to 
their molecular size. In addition lipophilicity, hydration, and charge influence transfer to 
the CSF. The term "barrier" should not be taken literally to mean "impervious" as this is 
not in fact the case. There are six main "barriers":
• Blood-CSF barrier-choroid plexus accounts for sixty percent of CSF production.
• Blood-brain barrier-the remainder of the brain vasculature accounts for one third of
CSF production.
• Blood-dorsal root barrier-representing the vasculature within the dorsal root ganglion, 
which is more permeable than the rest of the brain vasculature.
• Meninges-(do not normally produce CSF)
• Wandering cells-normal CSF contains a cell ratio of two thirds lymphocytes (blood 
derived) and one third monocytes (blood derived and from microglia) (blood contains 
mainly granulocytes which are essentially absent from normal CSF).
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• Structural cells-neurons, astrocytes, oligodendrocytes, and microglia.
The adult CSF space is a volume of approximately 140 ml whilst CSF is produced at a rate 
of approximately 500ml per day, which equates to a four times a day turnover rate. Thus a 
sample of CSF will reflect brain protein concentration at that particular point in time. 
Serial sampling shows whether the protein concentration is changing, and over what time 
interval. Although proteins have been identified in the CSF, which have been described as 
"brain specific", none are exclusively brain specific. A small number however, have 
emerged which almost fit this definition and are under evaluation as research tools for the 
investigation of a variety of neurological disorders. Though none appear to be of sufficient 
specificity or sensitivity for the purposes of disease diagnosis, some have been correlated 
with injury severity and outcome, and may reflect cell-specific response to injury. 
Neuronal markers include "neuron specific enolase" (NSE or Protein 14-3-2), Protein 14-3- 
3 (y isoform the most brain specific), Tau (discussed below) and many others. 
Measurement of these proteins in CSF is limited by the availability of antibodies specific 
for the "brain specific" isoforms, availability of purified proteins, quality control, reagent 
cost, and physicochemical properties of the analyte (e.g. NSE is unstable). CSF protein 
markers for astrocytic cells include Glial Fibrillary Acidic Protein (GFAP), and S100B 
(discussed below), both of which are amenable to assay. CSF Ferritin measurement reflects 
microglial activity in response to brain injury. A CSF marker protein for Oligodendrocytes 
is myelin basic protein. (Thompson and Keir, 1990)
1.4.2 S100 protein
SI0 0  belongs to a family of low molecular weight acidic calcium binding proteins, which 
are found in much higher concentrations in the CNS then in any other tissues. (Donato, 
1991; Hidaka et al. 1983; Kindblom et al. 1984) S I00 proteins contain no carbohydrate, 
lipid, nucleic acid or phosphate and exist as homodimers or heterodimers of two subunits a  
and p, which have molecular weights of 10.5 and 10.4 KDa respectively. (Fano et al.
1995) These subunits contain hydrophobic regions in both the C and N termini and a Ca2+
• 94-binding site which when occupied by Ca causes conformational changes in the protein 
with the exposure of some aromatic amino acids, hydrophobic residues and two sulphydryl 
groups. (Baudier and Cole, 1988b; Heizmann and Hunziker, 1991) The subunits share 45% 
sequence homology, but have been shown by complement fixation and cross- 
immunofixation to be antigenically different. The subunits are the product of two separate 
genes, the locus of the a subunit beinglq2 1  and that for the p subunit being 2 1 q2 2 .2 - 
21q22.3. The classical S I00 proteins are S100B (pp), S-lOOao (aa) and S-lOOa (ap).
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S100B is found in Schwann cells and within the astrocytes (90% cytosolic, 10% membrane 
bound) where it reaches the concentration of lOpM. Approximately 90% of the total 
S100B pool is found within the brain, with the remainder being located in non-neuronal 
tissues such as the testes, melanocytes and T-lymphocytes. (Fano et al. 1995; Hidaka et al. 
1983; Kindblom et al. 1984) SlOOao is found in neuronal cells, particularly the 
hippocampal neurones, of the central nervous system in much lower concentrations than 
S100B. Outside the CNS, S-lOOao is found in high concentrations in cardiac and skeletal 
muscle, and within the kidneys. S-lOOa is found within astrocytes but not Schwann cells. 
(Kato and Kimura, 1985; Takashi et al. 1988) Thus it is the S-lOOp subunit which is 
regarded as a protein marker for the astrocytic cells of the CNS.
In-vitro studies suggest both intracellular and extracellular functions for S I00. Intracellular 
S100B appears to modulate the activity of target proteins through calcium-dependent 
interactions effecting cell-signalling systems, cell metabolism and cell structure. For 
example, in the presence of GTP, S100B can stimulate the activity of the cerebral cortex 
membrane adenylate cyclase system, and inhibits membrane bound phospholipase-C thus 
influencing membrane-induced transduction. (Fano et al. 1995; Zimmer et al. 1995) In- 
vitro, S100B binds fructose-1, 6-bisphosphate aldolase suggesting a role in the regulation 
of astrocytic energy production via the glycolytic pathway. (Zimmer and van, 1986) S100B 
may influence cell morphology through interactions with protein like Tau preventing 
phosphorylation, and GFAP preventing polymerisation. (Baudier and Cole, 1988a; Bianchi 
et al. 1993) Both interleukin-1 (IL-1) and cAMP are reported to stimulate astrocytic 
S100B expression. (Kahn et al. 1991) The extracellular effects of S100B are to stimulate 
astrocyte proliferation and hypertrophy, promote neuritic growth, increase neuronal 
survival, and elevate neurone and glial intracellular calcium concentrations. (Selinfreund et 
al. 1991; Whitaker-Azmitia et al. 1990) S100B has also been reported to cause apoptosis. 
(Fano et al. 1993) The effect of S100B on cell proliferation appears to be dose dependent 
with cells increasing in number at lower doses of S100B but when the concentration is 
increased the effect is reversed, resulting in cell death. S100B has been shown to stimulate 
inducible nitric oxide synthase (iNOS) in rat cortical astrocytes, and to cause the death of 
neurones co-cultured with astrocytes by the production of nitric oxide. (Hu et al. 1996; Hu 
et al. 1997)
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Raised concentrations of S100B have been reported to occur in the CSF of patients with a 
wide variety of neurological disorders including strokes, encephalitis, meningitis, 
Creutzfeld-Jakob disease, brain tumours, Guillain-Barre syndrome, epilepsy, Parkinson’s 
disease and dementia. (Jimi et al. 1992; Mokuno et al. 1983; Noppe et al. 1986; Otto et 
al. 1997; Persson et al. 1987; Sindic et al. 1982) Elevated concentrations of CSF S100B 
have been found in the acute phase of Multiple Sclerosis (MS) but only marginally 
increased concentrations in the non-acute phase of the disease. (Massaro et al. 1985; 
Michetti et al. 1980; Mokuno et al. 1983; Noppe et al. 1986; Sindic et al. 1982) The
raised concentration of S100B in the CSF may result from cell damage, or be due to an
active response from the brain to the injury. (Jongen et al. 1997; Mokuno et al. 1983).
Raised concentrations of S100B have been reported in the CSF of patients with large
cerebral infarcts, but not in smaller infarcts or transient ischaemic attacks. Thus, S100B has 
emerged as a surrogate marker for injury severity. In addition, the concentrations of S100B 
in the CSF within twenty-four hours of SAH has been correlated with clinical outcome 
assessed using the GOS. (Persson et al. 1987) The utility of measuring S100B in CSF is 
limited by the invasive means required to obtain samples. A number of studies report 
elevated S100B concentrations in plasma or serum after stroke, cardiac arrest, cardio­
pulmonary bypass, TBI and SAH, corroborating the findings in CSF. (Abraha et al. 1997; 
Blomquist et al. 1997; Buttner et al. 1997; Ingebrigtsen and Romner, 1996; Missler et al. 
1997; Rosen et al. 1998; Taggart et al. 1997; Waterloo et al. 1997; Westaby et al. 1996; 
Wiesmann et al. 1997) Thus plasma S100B measurement as a surrogate marker for acute 
brain injury is emerging as a useful research tool to be used as an adjunct to injury severity 
classification.
1.4.3 Tau protein
Tau protein is a microtubule-associated phosphoprotein found predominantly within the 
axons of CNS neurons, although a form of Tau, known as big Tau, has been found within 
the peripheral nervous system. Tau promotes the assembly and stabilisation of neuronal 
microtubules. Six isoforms are found in the CNS of healthy adults, which range from 352- 
441 amino acids in length, and differ from each other by the size of the N-terminal inserts, 
and the presence of three or four tandem repeat regions of 31-32 amino acids in the 
carboxyl terminal end. Studies with recombinant Tau have shown that it is in these repeat 
regions in the carboxyl terminal regions which are the microtubule binding domains and
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each contain a characteristic Pro-Gly-Gly-Gly motif. The Tau gene is located on 
chromosome 17q21 and contains 15 exons, 11 of which are used to encode the major Tau 
protein isoforms. (Goedert et al. 1991; Goedert et al. 1989; Hardy et al. 1998) The one or 
two phosphorylation sites on each isoform are serine or threonine residues followed by 
proline, suggesting that protein kinases with a specificity for seryl-proline and threonyl- 
proline residues are responsible for phosphorylation. Protein kinases such as mitogen- 
activated protein (MAP) kinase, glycogen synthase kinase-3 and proline-directed protein 
kinase have been shown to phosphorylate recombinant Tau on at least some of the residues 
seen in adult or foetal Tau. The phosphorylation status of a protein depends on a balance of 
phosphorylation and dephosphorylation and Tau phosphorylation by MAP kinase is only 
dephosphorylated by phosphatase 2A. (Goedert et al. 1992) The phosphorylation status of 
Tau affects its ability to bind to microtubules, such that, Tau phosphorylated by MAP 
kinase has one-tenth the ability of non-phosphorylated Tau, to bind to microtubules. 
(Drechsel et al. 1992) The relevance of these observations to neurodegeneration and 
cytoskeletal disintegration after acute injury is not currently known.
There are a number of degenerative diseases of the CNS, which are associated with the 
intracellular or extracellular inclusion bodies consisting of a hyperphosphorylated form of 
Tau protein. These include Alzheimer’s disease (AD), Pick’s disease (PiD), and 
progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). Although 
methods are available for the determination of CSF Tau concentration, it is not possible to 
reliably differentiate between these conditions. As with S100B, CSF Tau is elevated by a 
wide range of neurological conditions. (Jensen et al. 1995; Vandermeeren et al. 1993; 
Vigo-Pelfrey et al. 1995) Thus the utility of measuring CSF Tau for the purpose of 
diagnosing dementia is limited. To date only one systematic study reports CSF Tau 
concentration after TBI, utilising an in-house ELISA to quantify axonal injury. (Zemlan et 
al. 1999)
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1.5 Study hypotheses
• Alterations in the concentration of apoE occur in the CSF reflecting the role of apoE in 
the response to CNS injury.
• Altered CSF apoE concentration after CNS injury is related to injury severity and 
clinical outcome.
• After CNS injury altered CSF apoE concentration is related to changes in CSF 
amyloid-beta concentration.
• Alterations in CSF lipoprotein particles occur reflecting the role of apoE in cholesterol 
recycling in response to CNS injury.
2 Materials and Methods
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This chapter describes the subjects investigated, and the methods used for CSF analysis. 
The subjects investigated comprise a control group of patients without acute brain injury, 
and an acute brain injury group. The acute brain injury group comprises patients with 
either TBI or SAH. The CSF of these patient groups was investigated in two ways. First, 
quantification of apoE, S100B, Tau, Ap, albumin, and total protein was undertaken on 
CSF. In addition, the time course of these alterations was investigated in a subgroup of 
patients for whom serial CSF samples were available. The relationship between the 
concentration of the proteins assayed and clinical measures of injury severity, and outcome 
were determined. Second, CSF lipoprotein particles were isolated and analysed from a 
subgroup of patients from the control and brain injury groups to determine whether 
differences observed in the concentration of apoE in nascent CSF were paralleled by 
changes in CSF lipoprotein particle composition.
2.1 Patients investigated
CSF from three categories of patients were investigated:
• Patients with no acute brain injury-the control group.
• Patients with TBI.
• Patients with SAH.
The control CSF samples were obtained from patients admitted to the Institute of 
Neurological Science (INS) in Glasgow (discussed later). SAH CSF for the analysis of 
lipoprotein particles by size exclusion chromatography (discussed later) was obtained from 
patients admitted to the INS in Glasgow. The remainder of the brain injury CSF analysis 
was performed on CSF from the Neurosurgical Unit at the University Hospital, Pittsburgh, 
Pennsylvania, USA.
An absolute requirement for participation in the study was the granting of informed 
consent by patients (or assent from next of kin of patients incapable of giving informed 
consent) participating in the study. The study had approval from the local hospital ethics 
committee.
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2.1.1 Ethics and Consent
58
This study commenced immediately after the Medical Research Council (MRC) issued 
Interim Operational and Ethical guidelines for use o f human tissue and biological samples 
in research. (Medical Research Council, 1999) A summary of the issues to address when 
obtaining consent, as outlined in the MRC guidelines, is given in the appendix. The 
consent form was based upon that recommended by the MRC (see appendix for consent 
form and patient information sheet).
Consent was sought for:
• Collection, storage and analysis of residual CSF for apoE determination.
• Determination of APOE genotype using DNA isolated from CSF, or a buccal swab 
from the oral cavity.
• Collection, storage and analysis of residual CSF for other protein relevant to brain 
injury.
• Analysis of other genes of relevance to brain injury.
• Retrieval, analysis and storage of relevant personal (e.g. age, sex) and clinical (e.g. 
diagnosis) information.
• Publication, and presentation of anonymised data resulting from the study.
Patients were given assurances regarding confidentiality and restriction of access to data 
collected to members of the research team. Patients were given a written information sheet 
stating the goals of the research, the types of tests to be done, the diseases to be 
investigated, and how the results might affect their interests. In addition patients were 
informed that the study had local ethics committee approval. The patient information sheet 
was approved by the local ethics committee, and was adapted from that used in previous 
studies undertaken at the Southern General Hospital, University Department of 
Neurosurgery, investigating the association between APOE genotype and recovery after 
acute brain injury. In addition the study was approved by the consultant neurosurgeons and 
neurologists at the Institute of Neurological Sciences.
Informed consent was undertaken by face to face interview in the majority of patients. 
Where patients were incapable of giving informed consent, assent from the next of kin was 
obtained. Many patients were discharged from hospital before it was possible to obtain 
informed consent by face to face interview and these patients were contacted by post, and 
of those who were contactable the majority returned the signed consent form. These 
patients (and those consented by face to face interview) were encouraged to telephone or 
write if they had any questions or required more information. Consent to perform APOE
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genotype determination, and retain and analyse CSF in Pittsburgh was undertaken by the 
Pittsburgh research team. The study protocol had approval of their local ethics committee.
2.1.2 Selection and characteristics of controls
Sampling CSF requires the use of invasive techniques such as lumbar puncture, cistema 
magna puncture, or ventricular puncture. The risks associated with these invasive 
techniques limit the sampling of CSF to patients for whom the potential clinical benefits of 
the procedure outweigh the small, but definite risks. The risks of CSF sampling preclude 
the study of healthy, asymptomatic "normal" subjects. Control group CSF was selected 
according to the results of CSF analysis and clinical exclusion criteria. Thus a substantial 
number of consecutive CSF samples sent to the department of neuropathology for analysis 
were used to create a population from which a smaller control population was selected on 
the basis of "normal" CSF analysis (see below). In addition, from knowledge of the 
patients’ clinical diagnosis, it was possible to select patients according to clinical indication 
for CSF analysis, and estimate the effect of confirmed neurological disease upon the study 
parameter. This approach enabled identification of an age and sex matched control group 
of similar size to the acute brain injury groups.
2.1.2.1 CSF exclusion criteria for control group
The control group was selected by excluding patients with CSF indices as follows:
• Presence of xanthochromia.
• Nucleated cell count greater than five cells per cubic millilitre.
th• Albumin concentration outside the 95 centile of the population (CSF samples with no 
xanthochromia, and cell count less than 5 nucleated cells per mm3) mean (i.e.> 273 
mg/1).
tfi• Total protein concentration outside the 95 centile of the population mean (i.e.> 576 
mg/1).
• S100B greater than the 95th centile of the population mean (>0.39 ng/ml).
• Presence of Oligoclonal bands.
2.1.2.2 Control group clinical exclusion criteria
These included patients with clinical features consistent with SAH, TBI and, for "health 
and safety reasons", microbiological infection and transmissible spongiform 
encephalopathy (TSE). Patients investigated for demyelination or dementia formed a 
separate subgroup for comparison with the control group to estimate the impact of these
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disorders upon CSF parameters. Clinical information was obtained prospectively from the 
patients' clinical records, and from discharge summaries.
2.1.3 Patients with acute brain injury
The availability of CSF is limited due to the tendency to restrict ventriculostomy to 
patients with severe brain injury. It is argued that in this category of patients, the risk of 
ventriculostomy is outweighed by the benefits of CSF drainage for the treatment of raised 
intracranial pressure/or hydrocephalus. In the USA, intraventricular pressure monitoring is 
considered the gold standard and is recommended for patients with severe brain injury. 
(Brain Trauma Foundation, 1996) In the UK intracranial pressure monitoring is usually 
undertaken using intraparenchymal pressure sensors because ventricular cannulation is 
generally regarded as having an unacceptably high risk of brain injury secondary to 
cannulation and infection. The quantification of CSF proteins in CSF after SAH and TBI 
was therefore limited to CSF obtained by the neurosurgical unit in Pittsburgh, USA. CSF 
was available from all patients within three days of injury, and in a subgroup serial samples 
were available for as long as two weeks after injury. CSF lipoprotein particles were 
isolated and analysed from SAH and control CSF from patients at the INS, Southern 
General Hospital, in Glasgow. The studies of TBI CSF lipoprotein particles utilised CSF 
from the Neurosurgical unit in Pittsburgh, USA.
2.1.3.1 Characteristics of TBI patients
CSF samples were available from 27 TBI patients within three days of injury, and serial 
samples from 13 TBI patients for up to one week after injury. The characteristics of these 
patients are summarised in table 5. In addition to the demographic and clinical features of 
the TBI patients, radiological features were classified according to the CT findings at 
admission. The radiological features of the TBI patients are summarised in table 6 .
2.1.3.2 Characteristics of SAH patients
Serial CSF was available from 19 SAH patients for up to two weeks after haemorrhage. 
The clinical and radiological characteristics are summarised in table 7. Ruptured 
intracranial aneurysms were identified in 18 SAH patients (16 anterior circulation, 2 
posterior circulation), and one patient was unfit for investigation.
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Table 5 Characteristics of TBI patients
Characteristic Number of patients (%)
CSF within 
three days of TBI
Serial TBI CSF
Age (years)
Average 32 33
Median 25 37
range 16-65 16-65
Gender
Male 2 2  (81) 10(77)
Female 5(19) 3 (23)
Total 27 13
APOE genotype
s33 20 (74) 10(77)
s34 5(18) 1 (8 )
832 2(7) 2(15)
Best GCS
Average 5 6
Median 5 6
range 3-8 3-8
Mechanism of TBI*
RTA** 18(67) 8(62)
Fall 6 (2 2 ) 3(22)
Other 2(7) 1 (8 )
Assault 1(4) 1 (8 )
*TBI: Traumatic Brain Injury
**RTA: Road Traffic Accident 
GCS: Glasgow Coma Score
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Table 6 Radiological features of TBI patients
Marshall
Grade
Classification Number of patients
within 3 days serial
1 Diffuse injury 1 1
2 Diffuse injury
a) 1 only
b) > 2  unilateral
c) Bilateral
0 0
3 Diffuse injury + swelling 1 1
4 Diffuse injury + shift 1 1
5 Evacuated mass lesion
a) Extradural 3 2
b) Subdural 0 0
c) Intracerebral 2 0
d) > 2  lesions 5 3
6 Nonevacuated mass lesion
a) Extradural 1 0
b) Subdural 3 1
c) Intracerebral 3 2
d) > 2  lesions 7 2
CT: computerized tomography
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Table 7 Characteristics of SAH patients including radiological features
Characteristic N (%)
Age (years)
Average 56
Median 54
range 35-74
Gender
Male 6(32)
Female 13 (6 8 )
Total 19
APOE  genotype
s33 11 (58)
s34 7(37)
unknown 1(5)
Best GCS
Average 1 0
Median 1 0
range 3-15
Fisher CT Grade
1 0
2 1
3 9
4 9
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2.1.4 Assessment of clinical outcome after acute brain injury
Clinical outcome was assessed using the Glasgow Outcome Scale (GOS). Outcome was 
assessed six months after TBI injury and three months after SAH. Outcome assessments 
were determined by Dr Marion (blinded to the results of CSF analysis) at the outpatient 
clinic review at the Department of Neurosurgery in Pittsburgh.
2.2 Analysis of CSF proteins
2.2.1 CSF collection, storage and analysis
CSF was collected from the lateral ventricle in all acute brain injury patients, and the 
lumbar subarachnoid space for the majority of the controls. Ventricular CSF was obtained 
from ventricular catheters sited for the purposes of intraventricular pressure monitoring in 
patients with acute brain injury. CSF samples from patients with suspected hydrocephalus 
or shunt dysfunction, but no acute brain injury, were used as ventricular CSF controls for 
comparison with control CSF obtained by lumbar puncture, and as the control group for 
comparison with serial brain injury CSF samples. CSF obtained from the lumbar 
subarachnoid space was obtained by lumbar puncture for the purpose of assessing 
intrathecal pressure, treatment of communicating hydrocephalus or benign intracranial 
hypertension, or for analysis of CSF for investigation of suspected neurological disease.
CSF was collected in Polypropylene tubes and centrifuged at approximately 450g at 4° C 
for 1 0  minutes to eliminate cells and debris and was aliquoted prior to freezing and storage 
at -80° C until subsequent analysis. CSF from brain injury patients and controls was 
processed and stored identically for simultaneous analysis at a later date. Analysis of CSF 
from controls and acute brain injury patients was performed simultaneously with cases and 
controls on each analysis plate. It was not possible to blind the observer to sample type due 
to the difference in macroscopic appearance of CSF from controls and patients with acute 
brain injury. CSF samples underwent one freeze-thaw cycle prior to analysis, and 5 pi of 
protease inhibitor cocktail (Product number P 2714, SIGMA, Missouri, USA) was added at 
a final concentration of ImM.
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2.2.2 Determination of CSF apoE concentration
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A method for assaying apoE of sufficient sensitivity for the concentration range present in 
CSF was not readily available and was therefore developed for the purpose of this study. 
The technique used was Enzyme Linked Immunosorbant assay (ELISA) based upon the 
method described by Stark and Siest. (Starck et al. 2000) The results of the assay 
evaluation for the purposes of this study are described in detail in the chapter 3. The 
principal of the assay involves binding a capture antibody to the surface of a microtitre 
plate, which specifically captures apoE from the CSF. This antibody-apoE complex is then 
bound by a second (detection) antibody, to which a third antibody is targeted. The third 
antibody is conjugated to horseradish peroxidase (HRP) which catalyses the peroxidation 
of a substrate to a coloured product detectable spectrophotometrically.
2.2.2.1 CSF ELISA method
In brief, the capture antibody for the apoE assay was rabbit polyclonal anti-human apoE 
antibody (Dako, Ely, UK), diluted in 0.02 M Citrate buffer. The coated plate was washed 
with Phosphate Buffered Saline (PBS) and non-specific binding sites were blocked with 
2% bovine serum albumin (BSA). The blocked plate was washed with PBS/Tween, prior 
to incubation at 37°C with diluted CSF samples and the apoE standard curve (1.5-100 
ng/ml) in duplicate. After further washing with PBS/Tween, goat anti-human apoE 
antibody (Chemicon, Harrow, UK) was used as detection antibody, followed by HRP 
conjugated rabbit anti-goat IgG as the secondary antibody for the colour reaction. A 
detailed description of the apoE ELISA is given in the appendix. There was parallelism 
between the apoE calibration curve and serial dilutions of control CSF, brain injury CSF, 
brain homogenate and mixtures of CSF and plasma or lysed red blood cells. The range of 
assay recovery was 92-98%. The intra-assay and inter-assay coefficients of variation were 
7.4% and 8 . 6  % respectively. These data are presented in chapter 3.
2.2.3 S100B ELISA
The S100B ELISA used was a previously established, and extensively evaluated, in house 
assay for the determination of S100B in CSF. (Green et al. 1997) In brief, 96 well micro­
titre plates were coated with 200pl of 0.05M carbonate buffer containing monoclonal anti- 
S100B (Affinity Research Products, Exeter, UK). The plates were washed with 0.67 M 
Barbitone buffer containing 5mM Calcium Lactate, 0.1% BSA, and 0.05% Tween, and 
then blocked with 2% BSA and washed again. CSF samples diluted in 0.67 M Barbitone
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buffer containing 5 mM Calcium Lactate were added in duplicate. After incubation and 
washing, HRP conjugated polyclonal anti S100B (Dako, Copenhagen, Denmark) was used 
as detecting antibody. The cr-phenylenediamine (OPD) colour reaction was stopped with 
1M hydrochloric acid and the absorbance read at 492 nm and 405 nm. The antigen 
concentration was calculated from an internal standard curve ranging from 0.01 to 2.5 
ng/ml. The intra and inter-assay coefficient of variation for the S100B assay was 9.3% and 
8.1% respectively. The recovery of S100B added to CSF was 94%.
2.2.4 Tau ELISA
CSF Tau measurements were performed using the Innotest hTau Antigen, and enzyme- 
linked immunoassay supplied by Innogenetics, Belgium (UK suppliers: Autogen Bioclear, 
Wiltshire, UK). This assay uses a monoclonal capture antibody (AT 120) which reacts with 
both the normal and the hyperphosphorylated forms of Tau. (Vandermeeren et al. 1993) 
The microtitre plates are supplied pre-coated with this monoclonal antibody, and after 
blocking of the unbound protein sites on the microtitre plate wells, standards and CSF 
samples were added in duplicate. Tau calibrants were prepared from recombinant Tau 
protein and a series of calibrants 0, 75, 150, 300, 600 and 1200 pg/ml were used for the 
standard curve. A pair of biotinylated monoclonal antibodies (HT7 and BT2) were added 
to each well of the microtitre plate and the plate incubated over night at room temperature. 
The HT7 monoclonal antibody reacts with both normal and phosphorylated Tau protein, 
whilst the BT2 monoclonal antibody reacts preferentially with the hyperphosphorylated 
Tau protein. (Goedert et al. 1994) After overnight incubation the microtitre plate was 
washed and peroxidase conjugated streptavidin added. The streptavidin binds to the biotin 
on the monoclonal antibodies to form a complex, the quantity of which is proportional to 
the amount of Tau protein in the standard or CSF sample. The microtitre plate was washed 
and the substrate containing 3', 3', 5', 5' tetramethylbenzidine (TMB) and hydrogen 
peroxide added. The peroxidase activity converts the colourless TMB into an insoluble 
blue precipitate. The peroxidase activity was stopped by the addition of sulphuric acid, 
converting the insoluble blue precipitate to a soluble yellow product. The absorbance of the 
yellow product was measured at 450 nm being proportional to the amount of Tau protein 
originally present in the sample. The manufacturer claims the lower limit of detection to be 
59 pg/1. The intra and inter assay coefficient of variation are both reported to be below 6 %, 
and the recovery of Tau added to plasma is reported to be 92%. Detailed evaluation of this 
commercial ELISA was beyond the scope of this study.
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Ap 1-40 and Ap 1-42 peptides were also assayed using commercially available ELISA kits 
(BioSource International, Inc. California, USA) according to manufacturers instructions. 
The kits were identical for each peptide other than the antibody specificity. In brief, 100 pi 
of Ap standard (0-1000 pg/ml) and CSF samples were aliquotted in duplicate into the wells 
of the 96 well microtitre plate. Control and brain injury CSF samples were distributed 
within the same plate. The wells, which were pre-coated with capture antibody specific for 
Ap 1 -4 0  (or Ap 1 . 4 2 ) ,  were incubated for two hours, at room temperature, on a plate shaker. 
After washing, rabbit anti human Ap detection antibody was added to each well and 
allowed to incubate for a further two hours. After this incubation and further washing, HRP 
conjugated anti-rabbit antibody was added and incubated for a further 2 hours. After 
further washing steps, chromogen (OPD) was added, and after 30 mins (in the dark) the 
reaction was stopped with acid, and the absorbance read at 450 nm. The coefficient of 
variation for intra-assay precision is claimed by the manufacturer to be 3.6%, and inter­
assay precision 3.7%. The recovery of Ap added to serum is reported to be approximately 
100%. Again detailed evaluation of these commercial ELISAs was beyond the scope of 
this study.
2.2.6 CSF total protein concentration
The concentration of protein in the CSF was determined using a turbidimetric assay in 
which protein precipitation was achieved using benzethonium chloride, EDTA, and NaOH. 
(Luxton et al. 1989) To a volume of 10 pi of CSF was added 190 pi of precipitating 
reagent (5.0 g of benzethonium chloride, 20 g of EDTA, and 10 g of NaOH per litre). The 
plate was left at room temperature for 15 minutes before the absorbance of each well was 
measured at 410 nm (Dynatech MR700 microtitre plate reader) after blanking the 
instrument with precipitating reagent. The amount of precipitated protein (e.g. albumin and 
globulin) is proportional to the concentration of protein present in the CSF, and results in 
proportionate absorbance to light. The method is rapid, requires only 10 pi of CSF, and can 
be performed in a microtitre plate with between batch coefficient of < 5%. The protein 
calibration standards used were prepared by dissolving 150mg of human albumin (Sigma, 
Poole, UK) and 50 mg of human gamma globulin (Sigma, Poole, UK) in 100ml of isotonic 
saline (NaCl 0.85 g/1) containing 10 g of sodium azide per litre to give a stock 2000 mg/1 
standard for total protein. From this solution serial dilution was performed to create a set of 
working standards in the 50 to 1500 mg/1 concentration range.
A D Kay 2003 Chapter 2
2.2.7 CSF Albumin rocket electrophoresis
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CSF albumin concentrations were determined using rocket electrophoresis as detailed in 
the appendix. In brief, CSF and an albumin standard curve are loaded onto an agarose gel 
containing polyclonal anti-human albumin antibody and electrophoresed overnight, 
washed and stained for protein with brilliant Coomassie blue. The distance (measured in 
mm) migrated from the well is proportional to the albumin concentration and values 
derived from the albumin standard curve electrophoresed in parallel to the CSF samples.
2.3 Detection of CSF apoE by SDS-PAGE and Western blotting
SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) was performed on control and acute 
brain injury CSF samples in order to:
• Identify the presence of small molecular weight apoE epitopes/fragments, which might 
conceivably arise from proteolysis.
• Estimate the influence of apoE denaturation (SDS and thermal energy) upon 
immunoreactivity (i.e. evidence for epitope masking).
• Obtain an approximate corroboration of the CSF concentration obtained by the ELISA 
method, and the semi-quantitative SDS-PAGE method.
2.3.1 SDS-Polyacrylamide gel electrophoresis
SDS-PAGE separates proteins according to their molecular weight, independent of 
intrinsic electrical charge. Prior to electrophoresis the CSF sample is diluted with a buffer 
containing sodium dodecyl sulphate (SDS), and a reducing agent, and the mixture is heated 
to 100°C. The reducing agent breaks inter and intra subunit disulphide bonds, and the SDS 
(an anionic detergent) denatures the protein by wrapping around the polypeptide backbone. 
As a result the proteins in the sample become rods of negative charge with equal charge 
per unit length. Acrylamide is used for preparing electrophoretic gels for separating 
proteins by size. A mixture of acrylamide and bis-acrylamide polymerises to form a cross- 
linked network with a pore size that is dependent on the concentration of acrylamide used. 
The higher the concentration of acrylamide, the smaller the pore size. The migration of the 
protein in the gel is thus a function of its size and the intensity of the band when visualised 
gives a semi-quantitative estimate of the amount of protein present in the CSF sample. The 
gel used for this investigation was a 10% running gel, and 4% stacking gel assembled 
according to manufacturers instructions (Amersham Pharmacia Biotech, Herts, UK).
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2.3.1.1 Sample preparation
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Seven CSF samples with known apoE concentration (determined by ELISA) were run on 
the gel. Three were control CSF samples: one with high apoE concentration (ventricular 
CSF), one with intermediate apoE concentration, and one with low apoE concentration. 
Four TBI samples were run: two with low apoE concentration and two with intermediate 
apoE concentration. For each CSF sample 60pL was diluted with an equal volume of 
sample diluent (0.125 M Tris-Cl, 4% SDS, 20% v/v glycerol, 0.2 M dithiothreitol, 0.02% 
bromophenol blue, pH 6 .8 ) and placed in a boiling water bath for 4 minutes.
2.3.1.2 Running the SDS-PAGE gel
The comb was carefully removed from the stacking gel and the wells were rinsed with 
electrophoresis buffer (0.025 M Tris, 0.192 M glycine, 0.1 % SDS, pH 8.3). After fitting 
the gaskets to the upper tank chamber it was placed onto the gel and secured using the 
cams supplied. The lower tank chamber was filled with 3 L of electrophoresis buffer and 
the gel plus upper chamber were lowered into the lower tank chamber, being careful to 
avoid trapping any bubbles at the bottom of the gel. The upper chamber was filled with 
electrophoresis buffer, making sure that there was no leakage of buffer into the lower 
chamber. To each well 100 pL of diluted CSF was added and molecular weight markers 
were included on each run. The gel was run at 250 V, 50mA for 3 hours using an EPS 200 
power supply (Amersham Pharmacia Biotech, Herts, UK).
2.3.2 Western blotting
"Western blotting" or electroblotting refers to the process of transferring the separated 
proteins from the gel onto a nitrocellulose matrix to which they bind and become 
immobilised. It is necessary to transfer the proteins to the nitrocellulose matrix from the 
gel matrix because the gel matrix restricts access to the detecting antibody. In addition to 
the accessibility of protein immobilised on the nitrocellulose matrix to the detecting 
antibody, nitrocellulose is less fragile.
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2.3.3 Gel to nitrocellulose protein transfer step
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At the end of the electrophoresis, the gel was removed from the electrophoresis system and 
the lane containing the molecular weight markers were removed and placed in Coomassie 
Brilliant Blue stain for 1 hour and destained using deionised water. The remaining gel was 
placed into a pre-chilled transfer buffer for 30 minutes. Two pieces of filter paper and a 
piece of nitrocellulose were cut to the same dimensions of the gel and placed into the 
transfer buffer, along with two fibre pads supplied with the Trans-blot® Electrophoretic 
Transfer cell (Bio-Rad, Herts, UK). After 30 minutes one fibre pad was placed onto the 
plastic gel holder and onto this was placed a piece of wet filter paper ensuring that there 
were no trapped air bubbles. The gel was removed and placed on top of the filter paper. A 
piece of pre-wetted nitrocellulose was placed on top of the gel, being careful not to trap 
any bubbles. The remaining filter paper and fibre pad were placed on top of the gel, all 
bubbles removed and the gel holder closed. The transfer cell was filled with pre-chilled 
transfer buffer (0.025 M Tris, 0.192 M glycine, 0.1 % SDS, pH 8.3, containing 20% 
methanol) and the cooling coil was placed inside the cell and attached to a free flowing 
water system. The gel holder was placed into the Trans-blot® Electrophoretic Transfer cell 
with the gel facing the cathode. The transfer of proteins was carried out using a constant 
currant of 400 mA and a starting voltage of 50 V for 16 hours.
2.3.4 ApoE immunoblotting technique
After transferring the apoE onto nitrocellulose, empty protein binding sites were blocked 
by incubating the membrane in 2% non-fat milk in PBS for 30 minutes at room 
temperature. The nitrocellulose membrane was rinsed with running water and then washed 
with PBS containing 0.05% Tween 20 (wash solution), and placed in 50 mL PBS/milk 
containing rabbit anti-human apoE. After incubating the nitrocellulose membrane 
overnight at 4°C, the membrane was rinsed with running water and washed and then 
placed into 50 mL PBS/milk containing swine anti-rabbit immunoglobulin HRP conjugate. 
After incubating the nitrocellulose membrane for 1 hour at room temperature, the 
membrane was rinsed with running water and washed with several changes of wash 
solution over 1 hour. The membrane was developed with aminocarbazole colour regent for 
20-30 minutes at room temperature, then rinsed under running water and then washed for 
30 minutes before being dried.
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2.4 Isolation and analysis of CSF lipoprotein particles
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In addition to the quantification of apoE of controls and patients with SAH or TBI, CSF 
lipoprotein particles were isolated from the CSF, and their composition analysed. Because 
the concentration of these particles in the CSF is low, a substantial volume (excess of 20 
ml) of CSF is required. The volume of residual CSF obtained from control and TBI 
patients is relatively low (e.g. 1 ml), therefore it was necessary to pool CSF from at least 
twenty patients. The approach of pooling CSF to generate the volume required for the 
isolation of CSF lipoprotein particles has been used by others for the same reasons. 
(Demeester et al. 2000; Koch et al. 2001) Obtaining sufficient volumes of CSF from 
patients with SAH is less problematic as a daily drainage volume of approximately 200 ml 
of CSF is not unusual.
2.4.1 CSF size exclusion chromatography
Twenty millilitres of CSF was concentrated 50 times by filtration through Centricon YM- 
10 concentration filters (Amicon, Beverly, MA, USA). These filters have a pore size 10 
KDa (Molecular weight of apoE protein is 34.2 KDa) and a recovery of 99.9%. The 
concentrated CSF was fractionated by size exclusion chromatography as follows. The 
concentrated CSF (500 pi) was loaded onto a Superdex 200 size exclusion chromatography 
column (sepharose 6 HR 10/30) and eluted with elution buffer (lOmM Tris, 150mM NaCl, 
0.01% EDTA, ImM NaN3) at a flow rate of 0.25ml/min, and flow pressure of 0.5 Mpa. 
Fractions of 250 pi were collected and assayed for a free cholesterol (FC), phospholipid 
(PL), triglyceride (TG), apoE, and apoAI as follows. Lipid and lipoprotein concentrations 
were determined from the elution profile by calculating the area under the curve (AUC). 
Molar concentrations and ratios were calculated from the molecular weight (KDa) of apoE 
(34.2), apoAI (30.7), apoB (549), FC (38.6), and PL (77.4). The control CSF pools had no 
detectable apoB confirming the absence of plasma contamination.
2.4.2 Free cholesterol assay
Free cholesterol was determined colorimetrically using a commercially available kit (Wako 
Chemicals, Japan) according to manufacturer's, instructions. In this assay free cholesterol 
is oxidised by cholesterol oxidase to 4-cholestenone generating hydrogen peroxide. The 
hydrogen peroxide formed, in the presence of peroxidase, oxidises phenol and 4 - 
aminoantipyrine resulting in a red colour product. The amount of free cholesterol in the 
test sample is determined by measuring the absorbance of the red colour at the maximum
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absorption wavelength of 505 nm on a Hitachi 704-auto analyser. The coefficient of 
variation for the assay was 1.9%.
2.4.3 Phospholipid assay
Phospholipid was determined colorimetrically using a commercially available kit (Roche 
Diagnostics GmbH, Germany) again using the hydrogen peroxidase reaction, measuring 
the absorbance of the coloured product at 505 nm on Hitachi 704-auto analyser. The 
coefficient of variation for the assay was 1.5%.
2.4.4 Triglyceride assay
Triglyceride was also assayed using the Hitachi 704 auto-analyser using a commercial 
Triglyceride kit (Roche Diagnostics GmbH, Germany). In this case Lipoprotein lipase 
hydrolyses triglyceride to glycerol, which is oxidised to dihydroxyacetone phosphate and 
hydrogen peroxide which is measured as above. The coefficient of variation for the assay 
was 2 .1%.
2.4.5 Apolipoprotein turbidimetric immunoassay
Commercially available turbidimetric immunoassay kits are commonly used in clinical 
laboratories for the determination of plasma apoE, apoB, apoAI, apoAII, apoCI, apoCII 
and apoCIII. The concentration of these proteins in native CSF is generally below the limit 
of detection of this method. However, the method can be used to assay the concentration of 
these proteins in concentrated CSF fractionated by size exclusion chromatography. The 
principle of the assay is identical for all the proteins analysed. The concentrated CSF 
fraction is mixed with the buffer and a solution containing antibody to the lipoproteins. 
The apolipoprotein in the sample then combines with anti-human antibody specific for that 
apolipoprotein in the reagent to yield an insoluble aggregate, which causes an increase in 
the turbidity of the sample. The degree of turbidity is measured optically and is 
proportional to the amount of analyte in the sample. These kits are compatible with the 
Hitachi 704 auto-analyser. The linear range of detection for apoE, apoAI and apoB were 0- 
12 mg/dl, 0-70 mg/dl and 25-200 mg/dl respectively.
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2.5 APOE  genotyping
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APOE genotyping was performed, blind to the CSF concentration, using a hot start 
polymerase chain reaction (PCR) method. DNA was extracted from the buffy coat layer of 
haemolysed blood, or CSF, by ethanol extraction. Residual ethanol wash was removed by 
vacuum desiccation for 15 minutes, or overnight evaporation. To each sample was added 
50 j l l 1 of proteinase K (800 pg/ml), 20 pi of 10X PCR buffer, and 130 pi of Analar water. 
The solutions were overlaid with 100 pi of mineral oil and incubated at 37°C overnight. 
The samples were then heated to 95 °C for 10 minutes to inactivate the proteinase K, and
2.5 pi of the resulting solution was used as a target for PCR with the APOE primers. 
(Wenham et al. 1991) The reactions took place in a total volume of 50pl comprising 35pl 
of master mix A (see below), which was separated initially by a wax barrier to allow a "hot 
start", from 12.5pi of master mix B (see below) and 2.5pi of target. Master mix A 
contained the following reagents, in volumes multiplied by the number of samples to be 
amplified: 19.5 pi Analar water; 3.5 pi 10X PCR buffer; 5 pi dNTP solution containing 2 
mM dTTP; 5 pi dimethyl sulfoxide; and lpl of each primer to give final concentrations in 
the reaction of 0.2 pM. Thirty-five microlitres of Master mix A were aliquoted to each 
500-pl reaction tube. An Ampliwax gem (Perkin Elmer Cetus) was added to each tube, 
heated to 75-80°C for 5-10 minutes to melt the gem, and cooled to allow it to resolidify. 
Master mix B contained the following reagents, in volumes multiplied by the number of 
samples to be amplified: 10.75 pi of Analar water, 1.5pl 10X PCR buffer, and 0.25 pi Taq 
polymerase; 12.5pi of Master mix B was added to each reaction tube overlying the 
Ampliwax gem followed by 2.5 pi of target, prepared as described above. The samples 
were heated to 95°C for 7 minutes, followed by 40 cycles of 95°C for 1 minute, 65°C for 1 
minute and 70°C for 2 minutes. Ten units Hhal was added directly to the PCR product and 
incubated overnight at 37°C. The products of the digestion were separated on a 10% 
polyacrylamide gel, stained with ethidium bromide and visualised by ultraviolet-induced 
fluorescence. (Nicoll et al. 1997)
2.6 Data collection, storage and protection
2.6.1 Clinical data
Clinical (and demographic) data was collected prospectively from clinical case notes and 
entered onto a paper proforma. Patients were assigned an anonymous study identity
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number, and this was entered, with the clinical data of relevance to the study, to an 
ACCESS database minus the patients name, address, and hospital number, which were 
stored separately. The study identity number was used to link the clinical data to the 
relevant CSF sample. This data was stored on a network-protected system, and access to 
the database was password protected.
2.6.2 CSF analysis data
Data from analysis of CSF was recorded in paper copy form as raw data, which was 
imported manually to an EXCEL database for analysis of mathematically derived values
from standard curves etc. The CSF samples were labelled with the identity number only.
This data was also stored on a network, and password, protected system.
2.7 Statistical Analysis
2.7.1 Statistical software
Statistical analysis was performed using Microsoft Excel, GraphPad Prism and InStat 
software.
2.7.2 Types of data analysed
2.7.2.1 Categorical data
• Male/female
• TBI, SAH, control
• Glasgow Coma Score (ordered categorical)
• WFNS grade (ordered categorical)
• Glasgow Outcome Score (ordered categorical)
• Marshall/Fisher CT grade (ordered categorical)
• APOE genotype (nominal)
2.7.2.2 Numerical
• Number of patients (discrete)
• Age (continuous)
• Cell count, albumin, total protein, apoE, S100B, Tau, Ap etc.
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Ratios and percentages are used to describe relative frequency. Examples include:
• ApoE to albumin ratio, apoE to total protein ratio
• Molar ratios of lipoprotein particle constituents
2.7.3 Data description
2.7.3.1 Measures of central tendency
• Arithmetic mean (average) e.g. CSF apoE concentration (pg/1)
• Median e.g. CSF concentration (pg/1)
2.7.3.2 Description of variability
Variability was described by plotting the continuous data using relative frequency
histograms. The approximation of the data distribution to a Gaussian distributed was
estimated using Dallal and Wilkinson's approximation to Lilliefors' method (mindful of 
the limitations of this test when the sample size is small). Log transformation of positively 
skewed data was performed to approximate normality where necessary.
2.7.3.3 Quantification of variability
• Range e.g. GCS, GOS, and age.
• Centiles-95th centile.
• Standard deviation (SD).
• Coefficient of variation (standard deviation divided by the mean and expressed as a 
percentage). This was used to describe the precision of the assays.
• 95% confidence intervals.
2.7.4 Comparing groups of data
The analysis performed depended upon the data type, the distribution, and the variance.
2.7.4.1 Comparing group parameters to parameters of one sample
The one sample t-test was used to compare concentrations derived from the area under the 
curve of a variable from one pool of TBI patients (comprising 27 patients) with that of 
several (6 ) pools of control patients (comprising 2 0  patients in each control pool).
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2.7.4.2 Comparing two groups (unpaired) of continuous data
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If the data was normally distributed or could be normalised, t-tests (with Welch's 
correction if the variance of the two groups was significantly different) were used to 
compare group means. If the data did not pass the normality test and/or log transformation 
failed to normalise the data, or the sample size was small and appeared not to have a 
Gaussian shaped frequency distribution histogram, or the group variances were 
significantly different, the Mann-Whitney test was used. For example, comparing the 
median ventricular CSF apoE with lumbar CSF apoE.
2.7.4.3 Comparing three (or more) groups of continuous data
Normally distributed data was analysed using parametric ANOVA with Tukeys multi­
comparison test. However, non-parametric analysis was performed for all the data for 
consistency of approach, as some data sets did not satisfy the criterion for parametric 
analysis. Data groups, which did not pass the normality test or where the difference 
between group variances was significant, were compared using the Kruskall-Wallis test, 
with Dunn's multi-comparison test to compare group medians.
2.7.4.4 Comparing groups of categorical data
Fisher's exact test was used to compare the proportions within columns and rows of 
frequency tables. For example, APOE genotype and GOS (dichotomised into favourable 
and unfavourable) after SAH. In addition, continuous data was assigned to a category 
according to an arbitrarily selected threshold and analysed as categorical data according to 
the proportion of values above or below the threshold. For example, the proportion of TBI 
patients with CSF apoE concentration below the lowest value observed in controls. Where 
all brain injury CSF values were above the highest control value, the daily mean CSF Tau 
concentration after TBI (or SAH) was determined, and patients were categorised according 
to whether the value recorded on that day was above or below the mean value for all TBI 
patients that day. The proportion of patients above or below the daily mean was then 
compared with the proportion of patients with favourable or unfavourable outcome (or 
injury severity) using Fisher's exact test.
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2.7.4.5 Relation between two variables
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The association between two variables was analysed using Spearmans' rank correlation 
(Spearman rank correlation coefficient). The results are summarised in the form of a 
correlation matrix, and the data plotted using scatter diagrams.
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3 Results
This chapter comprises four sections. The first section presents the results from the 
evaluation of the ELISA used to assay apoE in the CSF. The second section presents the 
results of the analysis of CSF from different categories of control patients. The third 
section presents the results of the analysis of apoE and other proteins in CSF from TBI, 
SAH patients, and selected controls. The final section presents the results from the 
isolation and analysis of CSF lipoprotein particles in control, SAH and TBI CSF.
3.1 Apolipoprotein E ELISA evaluation
3.1.1 Calibration of the apoE ELISA
Recombinant human apoE3 (Panvera, U.S.A.) was serially diluted in the dilution buffer to 
give concentrations of 100, 50, 25, 12.5, 6.2, and 3.1 pg/1. Aliquots of these were stored at 
-20° C. Each batch of standards was calibrated by analysing the new batch in parallel with 
the old batch on at least 20 separate occasions. One way analysis of variance demonstrated 
that there was no statistically significant difference between consecutive calibration curves. 
See figure 2, panel A. There was no significant difference between calibration curves using 
recombinant apoE3, apoE4 or apoE2.
3.1.2 The lower limit of detection of the apoE ELISA
The lower limit of detection was calculated from the mean plus three standard deviations 
of 40 separate consecutive replicate analysis of apoE free sample (incubation buffer). The 
lower limit of detection was 2.9 pg/1. See figure 2, panel B.
3.1.3 The linearity of the apoE ELISA and the presence of parallelism
CSF was serially diluted with dilution buffer and the apoE concentration of the diluted 
CSF was determined confirming the presence of linearity. Parallelism was investigated by 
assaying doubling dilutions of control, TBI, SAH CSF and the apoE3 calibration standard. 
The resulting optical densities were normalised by expressing the absorbance obtained for 
each dilution as a percentage of that given by the highest value for that series. Analysis of 
covariance confirms that the slopes are not different and are therefore parallel. In addition 
serial dilution of CSF mixed with plasma, or lysed red cells, demonstrated parallelism with
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the calibration curve. Thus there are no systematic differences in the ability of the assay to 
detect apoE in a variety of matrices over a range of concentrations.
3.1.4 Within and between batch precision of the apoE ELISA
One hundred control CSF samples were pooled and diluted (1 in 250) such that the 
absorbance from the apoE assay was in the upper region of the linear portion of the 
standard curve. This diluted pool was then aliquotted and frozen simultaneously with the 
calibration curve aliquots, under identical storage conditions. These aliquots represent the 
high CSF quality control (high CSF QC). One hundred patient plasma samples were 
pooled and diluted (1 in 2500) such that the absorbance from the apoE assay was in the 
upper region of the linear portion of the standard curve. This diluted pool was then 
aliquotted and frozen simultaneously with the calibration curve, and CSF QC aliquots, 
under identical storage conditions. These aliquots represent the high plasma quality control 
(high plasma QC). The within batch precision (intra-assay coefficient of variation = CV%) 
was calculated from the mean and standard deviation of 40 replicate analysis of the CSF 
and plasma QC performed on one micro-titre plate. The intra-assay variation for the CSF 
and plasma QCs were 8.5% and 7.3% respectively. The scatter plot of the apoE 
concentration of the QCs versus position of the QC on the ELISA plate illustrates the low 
variability within the plate. See figure 3. Statistical analysis of the regression line 
confirmed that the slope of the line was not significantly different from zero. In addition, 
the variation in apoE concentration attributable to the position of the sample on the ELISA 
plate is estimated to be less than 10% (CSF and plasma QC: R2 = 0.08).
The between batch precision was calculated from 20 replicate analyses of the plasma and 
CSF QCs performed on consecutive microtitre plates. See figure 3. The between batch 
precision (inter-assay variation) for the CSF and plasma QC were 9.6% and 9.4% 
respectively. The regression line for serial apoE measurements is not significantly different 
from zero, and estimates that less than 5 % of the variation in apoE concentration is 
attributable to plate order (CSF and plasma QC: R = 0.004). Furthermore, there was no 
statistically significant reduction in the apoE signal of the QCs with time, indicating that 
the apoE was stable in CSF and plasma under the conditions of storage (-20°C) used for 
the period of storage (6 months).
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Figure 2 ApoE ELISA precision and linearity
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Figure 2A: Precision of the apoE ELISA from the mean (SD) normalised absorbance ratio 
relative to the highest standard of 20 consecutive calibration curves. There was no 
significant difference between the slope of each calibration curve (ANOVA).
Figure 2B: Linearity of the assay for the measurement of CSF apoE over a range of 
dilutions.
Figure 2C: There is linearity of the control CSF dilution curve, which is parallel with that 
of the calibration curve, and that of brain injury CSF.
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Figure 2A : ApoE ELISA callibration curve
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Figure 3 ApoE ELISA intra and inter-assay variation
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Figure 3A: Scatter diagram of CSF quality control (QC) determinations within one ELISA 
plate.
Figure 3B: Scatter diagram of plasma quality control (QC) determinations within one 
ELISA plate The intra-assay coefficient of variation (CV% = SD/mean * 100) of the CSF 
and plasma QC were 8.5 % and 7.3 % respectively.
Figure 3C: Scatter diagram of CSF QC determinations from 20 consecutive ELISA plates.
Figure 3D: Scatter diagram of plasma QC determinations from 20 consecutive ELISA 
plates. The inter-assay coefficient of variation (CV% = SD/mean * 100) of the CSF and 
plasma QC were 9.6 % and 9.4 % respectively. From linear regression analysis there was 
no significant variation between each microtitre plate.
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Figure 4 Recovery of apoE added to CSF and absence of albumin interference
Figure 4A: The column bar graph demonstrates that apoE added to CSF and brain 
homogenate can be efficiently detected, and is not significantly different between the 
mixtures to which the apoE spike is added.
Figure 4B: There was no significant decrease in the apoE signal in the presence of 
increasing albumin concentration.
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Figure 4A : Recovery of apoE added to  CSF and brain homogenate
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3.1.5 The recovery of apoE added to CSF and white matter homogenate
The ability of the apoE ELISA to measure apoE added to TBI, SAH, and control CSF was 
tested by analysing CSF to which a known amount of apoE had been added. In addition the 
recovery of apoE added to human cerebral white matter homogenate, obtained post 
mortem, was determined (see appendix). Both the spiked and unspiked samples were 
analysed and the difference in apoE concentration calculated as a percentage of that added 
to the spiked sample. An equal volume of the apoE top standard (100pg/l) was added to 
equal volumes of TBI (n=3), SAH (n=3), control (n=6 ) CSF, and white matter homogenate 
(n=3). The mean recovery (SD) in TBI CSF was 98% (10%), in SAH CSF was 97% (7%), 
in control CSF was 95% (10%), and white matter 97% (16%). The difference between 
mean values is not statistically significant. See figure 4.
3.1.6 The specificity of the apoE ELISA for apoE
The specificity of the apoE ELISA for apoE has been extensively investigated. (Starck et 
al. 2000) No interference in blank values, or apoE spiked samples, was detected when 
increasing concentrations of apoAI, apoAII, apoB, apoCI, apoCII or apoCIII were added 
indicating that the assay is specific for apoE. In the present study there was no significant 
difference between the calibration curves obtained using recombinant apoE3, apoE4, or 
apoE2, justifying the use of apoE3 as the calibrant for the quantification of apoE in CSF 
from patients of different genotype. In addition, there was no significant interference from 
human albumin or protein (as used for albumin and total protein standard curves) added at 
increasing concentrations (to levels encountered in brain injury CSF) to the apoE 
standards. See figure 4.
3.1.6.1 Summary of evaluation of apoE ELISA
In summary, the apoE ELISA developed for the quantification of apoE in CSF from 
control, TBI, and SAH patients was robust, sensitive, precise, and specific. Importantly, 
there was no significant interference from substances present in brain injury CSF that are 
not present in control CSF.
3.2 Determination of CSF apoE concentration in controls
This section presents the results from the analysis of control CSF
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3.2.1 Control selection according to CSF analysis
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It is not ethical to sample CSF in humans unless there are substantial clinical indication for 
CSF analysis. The control group for this study was selected from a population of 229 
consecutive patients admitted to the neuroscience unit for investigation of suspected 
neurological disease, and this included analysis of CSF. None of these patients had a recent 
history of SAH or TBI. CSF analysis using spectrophotometry confirmed the absence of 
xanthochromia. Microscopic examination of the CSF enabled exclusion of CSF containing 
more than five nucleated cells per cubic millilitre. Analysis of the total protein and albumin 
concentration of the CSF enabled identification and exclusion of CSF with values beyond 
the 95% confidence interval of the sample population. The results of the selection of 
controls according to this analysis are summarised in table 8 .
Displaying these data as a column scatter graph illustrates the wide concentration range for 
apoE in control CSF. See figure 5. Of the 39 CSF samples with normal cell count, and total 
protein and albumin concentration within the 95% confidence interval of the population 
mean, the oligoclonal band status was determined in 28, and found to be negative. The 
mean apoE for this group was 12.4 mg/L (median 12.1, SD: 4.8 mg/L). Inspection of the 
frequency distribution histogram for the control subgroups shows that the distribution of 
the mean concentrations of apoE in control CSF is positively skewed. Analyte 
concentrations are often positively skewed, and appear more Gaussian after log 
transformation. The advantage of the log transformation is that parametric tests can be 
used, which are more sensitive than non-parametric tests, and provide a confidence interval 
(geometric mean ratio). However, the number of patients in the brain injury groups is 
small, and normality tests become even less reliable with small sample sizes. Data, which 
passed the normality test, sometimes appeared to be skewed on the frequency distribution 
histogram, even after log transformation. In addition, there was data, which appeared to be 
parametrically distributed, but had more than twice the variance of the control group. 
Therefore, one way analysis of variance was performed using non-parametric tests. One­
way analysis of variance using the Kruskall-Wallace test with Dunn's post- test found no 
statistically significant difference in the median CSF apoE concentration of these control 
CSF subgroups.
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Table 8 CSF apoE according to biochemical analysis
Control CSF 
category
Number Mean ± SD 
apoE 
mg/L
Median
apoE
mg/L
95 % Cl
!A11 CSF 229 11.8 ±7.4 11.3 10.9-12.8
zCell count 
<5/mm3
138 13 ±6.9 1 2 . 0 11.9-14.2
3Total protein 
<576 mg/L
117 13.5 ±6.0 1 2 . 8 12.2-14.8
4Albumin 
<273 mg/L
82 12.5 ±5.5 11.9 10.7-14.3
SD: Standard Deviation.
95 % Cl: ninety-five percent confidence interval.
1 No xanthochromia present but cell count not known in 91 patients
2 No xanthochromia present, and cell count less than or equal to 5 / mm3
3 CSF with mean total protein within 95% Cl of the <5 cells/mm3 group (21 not known)
4 CSF with mean albumin within 95% Cl of the group with <5 cells/mm3, and total protein within 95%CI (35
not known)
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The concentration of apoE in the CSF according to the various indications for lumbar 
puncture are summarised in table 9. Displaying the raw data as a column scatter plot again 
shows a wide range for apoE concentration across diagnostic groups and a lower median 
apoE concentration in CSF from patients with definite MS. As discussed above the 
frequency distribution histograms of the clinical subgroups also demonstrate that CSF 
apoE concentration has a positively skewed distribution, and this appears more Gaussian 
with log transformation. As justified above, for consistency of approach, non-parametric 
tests were used for analysis of variance. Using the Kruskal-Wallace test, the difference 
between the median apoE in CSF from patients with definite MS and other control groups 
is statistically significant (p<0.001). There is no significant difference between the median 
CSF apoE concentration in the other control subgroups.
3.2.2 The relationship between site of CSF sampling and apoE 
concentration.
The median concentration of apoE in ventricular CSF is higher than that of lumbar CSF, 
and using the U-Mann-Whitney test, this difference is statistically significant (p=0.036). 
The albumin and total protein concentration was higher in the lumbar CSF, but the 
difference was not statistically significant. See figure 6 , panel A.
3.2.3 The relationship between gender and CSF apoE concentration
The mean (SD) apoE concentration in CSF from female controls (n=57) was 12.5 (6.4) 
mg/L, and 13.8 (8.1) mg/L in the CSF of (n= 33) males. The difference between the 
median concentration of apoE in CSF from male versus female controls was not 
statistically significant. See figure 6 , panel B.
3.2.4 The concentration of apoE during continuous CSF drainage
ANOVA found there was no statistically significant change in the concentration of apoE in 
CSF when sampled daily for seven consecutive days from six patients undergoing 
continuous CSF drainage for management of CSF rhinorrhoea. There was no significant 
decrease in CSF apoE concentration in-vitro between CSF before and after passage 
through a ventricular drainage catheter. In order to investigate the possibility that CSF 
apoE is lost from the supernatant during centrifugation, CSF was assayed before and after 
centrifugation and was found not to be significantly different. See figure 7.
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Table 9 CSF apoE in controls according to indication for CSF analysis
Mean ± SD Median 95 % Cl
Indication for CSF Number apoE apoE
examination mg/L mg/L
5N o d isease identified 14 15.7 ±9.6 13.4 10.2-21.3
6O ther 23 14.317.5 13.7 11.1-17.6
7BIH 7 11.317.6 10.4 4.2-18.3
8D em entia 82 13.516.9 11.5 12.0-15.0
9PossibIe
MS
18 12.413.9 12.4 10.5-14.3
10ProbabIe
MS
1 0 15.217.1 11.9 10.1-20.3
n D efln ite
MS***
44 6.514.5 5.8 5.1-7.9
***P<0.001
SD: Standard Deviation.
95 % Cl: ninety-five percent confidence interval.
5 All Investigations negative
6 CSF leak, Guillan Barre Syndrome, ?malignancy, ?Vasculitis,
7 BIH-'Benign" Intracranial Hypertension
8 Dementia=all types (un-specified)
9 Possible MS
10 Probable MS
11 Defmate MS
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Figure 5 Concentration of apoE in the CSF of non-acutely brain injured subjects
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Figure 5A displays the column scatter plots for CSF apoE concentration from potential 
control subjects categorised according to:
• Nucleated cell count of<5/mm3.
o th
• Nucleated cell count of<5/mm and CSF total protein within 95 centile of population.
<5 it.
• Nucleated cell count of<5/mm , CSF total protein within 95 centile of population, and 
CSF albumin within 95th centile of population.
• Nucleated cell count of<5/mm3, CSF total protein within 95th centile of population, 
CSF albumin within 95th centile of population, and oligoclonal bands absent.
Figure 5B displays column scatter plots for CSF apoE concentration from potential control 
subjects categorised according to indication for CSF analysis as follows:
• No objective evidence of neurological disease identified.
• Benign Intracranial Hypertension (BIH).
• Dementia (type unspecified)
• Possible Multiple Sclerosis (MS).
• Probable MS.
• Definite MS. The concentration of apoE in definite MS CSF is significantly (p<0.001) 
lower than in the other groups.
• Other (e.g. CSF leak).
Horizontal bar represents the median concentration (mg/L)
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Figure 6 Column scatter plot of CSF apoE concentration according to anatomical sampling 
site and gender
Figure 6 A: Column scatter plot for CSF apoE concentration (mg/L) in lumbar and 
ventricular CSF from control subjects without evidence for acute brain injury or raised 
intracranial pressure. The median apoE concentration (represented by horizontal bar) was 
significantly (Mann-Whitney, p=0.036) higher in ventricular CSF than CSF sampled via 
the lumbar subarachnoid space. The apoE concentration gradient is the result of intrathecal 
synthesis of CSF apoE. The nucleated cell count of the ventricular and lumbar CSF 
samples was <5/mm . The ventricular CSF albumin and total protein concentrations were
if.
within the 95 centile of the control group mean.
Figure 6 B: Column scatter plot for CSF apoE concentration (mg/L) in male and female 
subjects. There is no significant difference in control CSF apoE concentration according to 
gender.
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Figure 7 The concentration  o f CSF apoE during continuous drainage
There was no significant change in CSF apoE concentration relative to the initial value 
obtained on the first day after initiation of continuous external CSF drainage. The CSF was 
obtained from patients undergoing continuous CSF drainage as treatment for or prevention 
of CSF leakage. The patients (n=6) had no neurological deficits, no acute brain injury, and 
the CSF concentration o f albumin and protein was within normal limits.
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Figure 8 Relationship between CSF apoE, albumin, and apoE to albumin ratio and subject 
age
Figure 8 A: Scatter plot of CSF apoE concentration in controls of different ages, with the 
linear regression line and the 95% confidence interval for the slope of the regression line 
(dotted line). Spearman rank correlation failed to reach statistical significance at the p<0.05 
level.
Figure 8 B: Scatter plot of CSF albumin concentration in controls of different ages, with the 
linear regression line and 95% confidence interval for the slope of the regression line. 
There was significant (p< 0.0001) correlation between CSF albumin concentration and age.
Figure 8 C: Scatter plot of CSF apoE to albumin concentration ratio in controls of different 
ages, with the linear regression line and the 95% confidence interval for the slope of the 
regression line. Spearman rank correlation failed to reach statistical significance at the 
p<0.05 level.
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3.2.5 The relationship between APOE  genotype and CSF apoE 
concentration
There were no e44 or s22 controls, and only one s24 control. There was no significant 
difference between s33 (average ± SD apoE = 10.1 ± 4.7 mg/L), s34 (6 . 6  ± 4.5 mg/L) and 
s23 (7.3 ± 2.4 mg/L) CSF apoE concentration.
3.2.6 The relationship between CSF apoE and albumin concentration
There is no significant rank correlation (Spearman r = 0.267, P = 0.0176, 95% Cl: 0.042 to 
0.466) between CSF apoE and albumin concentration in 79 controls. Regression analysis 
suggests that only 2% of the variation in apoE is due to variation in albumin in controls (R 
= 0 .02).
3.2.7 The relationship between age and CSF apoE concentration
The association between age and CSF concentration was determined using rank correlation 
analysis of a group of 90 control CSF samples with known age, apoE and albumin 
concentration. There was no significant correlation between CSF apoE and age (r = 0.23, 
P=0.116). See figure 8 , panel A. There was statistically significant correlation between 
CSF albumin and age (r = 0.55, P0.0001, 95% Cl: 0.30-0.72). See figure 8 , panel B The 
correlation between the ratio of CSF apoE to albumin and age (r = -0.27, P = 0.067, 95% 
Cl: -0.52 to 0.03) just failed to reach statistical significance. See figure 8 , panel C. 
Regression analysis suggests that approximately 5% of the variation in CSF apoE 
concentration is attributable to age (R2 = 0.055). In contrast, approximately 25% of the 
variation in CSF albumin is attributable to age (R2 = 0.245).
Using the Mann-Whitney test, there is no statistically significant difference between the 
median apoE/albumin ratio of non-demented controls compared to patients investigated for 
dementia.
3.2.8 Summary of quantification of control CSF apoE
The concentration range for apoE in the CSF of controls is wide, but the difference 
between diagnostic groups is not significant except for patients with definite MS. The
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concentration of apoE in controls is not significantly affected by age, CSF albumin 
concentration, APOE genotype, or continuous CSF drainage. The concentration of apoE in 
ventricular CSF is higher than that from the lumbar subarachnoid space.
3.3 The concentration of apoE and brain specific proteins in the 
CSF after TBI and SAH
This section presents the results of quantification of apoE, and other proteins, in the CSF of 
TBI, SAH, and control patients. Due to the limited availability of CSF from patients with 
acute brain injury, particularly TBI, the investigation comprises two data sets. The first is 
the analysis of twenty-seven TBI, and nineteen SAH patients for whom CSF was available 
within three days of brain injury. The second data set investigates a subgroup of these 
patients for whom serial CSF samples were available for up to two weeks after brain 
injury. Due to the expense of the commercial assay kits used for A0 and Tau fewer time 
points were assayed using these kits compared to assays done using in house techniques 
(i.e. apoE, S100B, albumin, and total protein).
3.3.1 CSF protein concentrations within three days of TBI and SAH
3.3.1.1 The control group
The control group used for this analysis was matched for age (mean age 40, median 37, 
and range 19-73 years) with the acute brain injury group. It was selected from the larger 
control population of non-xanthochromic CSF samples, with less than five nucleated cells 
per cubic millilitre, on the basis that oligoclonal bands were known to be absent, and the 
albumin and total protein concentration were within the 95 centile of the control 
population mean. This resulted in a control group of similar size (n=28) to the brain injury 
group. The median concentration of apoE in this control group was 12.1 mg/L.
3.3.1.2 CSF apoE within three days of TBI and SAH
The characteristics of the patients in this TBI and SAH group are summarised in tables 5, 6  
and 7. The mean concentration of apoE in the CSF (one CSF sample per patient) sampled 
from patients within three days of TBI or SAH is approximately one third that of the 
control group. The median concentration of apoE in the CSF from TBI patients was 1.9 
mg/L, and 3.9 mg/L in SAH patients. These data are summarised in table 10. ANOVA 
using the nonparametric Kruskall-Wallis test, with Dunn's post test, determined that the
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median concentration of apoE in control CSF was significantly higher than in TBI 
(P<0.001), and SAH (PO.OOl) CSF. In addition Dunn's post test determined that the 
median concentration of apoE in TBI and SAH CSF was not significantly different. See 
figure 9.
3.3.1.2.1 Estimation of CSF apoE concentration in control, TBI, and SAH CSF using PAGE
In addition to apoE quantification using ELISA, denaturing PAGE was used to determine 
the relative amount of apoE in control (n=3), TBI (n=3), and SAH (n=3) CSF as described 
in methods. Denaturing PAGE is at best semi-quantitative, but is capable of detecting apoE 
epitopes present due to proteolysis. In addition, because denaturing conditions are used the 
possibility that signal loss due to epitope masking may be evaluated. We found the signal 
intensity from the denaturing PAGE approximately correlated with the apoE ELISA 
determined concentration. No immunoreactive proteolytic fragments were identified. See 
appendix.
3.3.1.3 The ratio of CSF apoE to albumin within three days of TBI or SAH.
The mean (SD) concentration of albumin in control CSF was 177 (40) mg/L, in SAH CSF 
was 957 (1610) mg/L, and TBI CSF was 716 (1096) mg/L. Thus, the concentration of 
albumin in the acute brain injury CSF is approximately three times higher than in the 
control group. From the Kruskall-Wallis ANOVA the median CSF albumin concentration 
is significantly increased in TBI (PO.OOl) and SAH (PO.OOl) compared to control CSF. 
Although the CSF albumin concentration after SAH is higher than after TBI, the difference 
is not statistically significant. The mean (SD) apoE to albumin ratio of control CSF was 
0.07 (0.03) and was seven times higher than that in TBI and SAH CSF (mean ratio 0.01, 
SD: 0.02). Thus, after acute brain injury, compared to controls, the seven-fold decrease in 
the apoE to albumin ratio is disproportionate to the three-fold increase in albumin 
concentration. From the ANOVA for the apoE to albumin ratio, the ratio is significantly 
decreased after TBI (PO.OOl and SAH PO.OOl) but the difference between TBI and SAH 
is not significant. See figure 10.
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Table 10 ApoE, S100B, albumin and total protein in controls, SAH and TBI CSF
CSF
Concentration
Patient group
Control
N=28
SAH
N=19
TBI
N=27
ApoE (mg/L)
12.4 (12.1) ±4.7 
[0.34]
4.6 (3.9) ±3.8 
[0.13]
3.7 (1.9) ±4.2 
[0 .1 0 ]
S100B ( pg/L)
0.39 (0.29) ± 0.37 
[0.018]
19.9 (5.8) ±30.1 
[1.5]
23.3 (14.7) ±21.7 
[1.76]
Albumin (mg/L)
177 (171) ±40 
[2.7]
957 (359) ± 161 
[14.5]
716 (330) ±1096 
[1 0 .8 ]
Total protein (g/L) 0.32 (0.27) ±0.12. 1.97 (1.81) ± 1.34. 3.34 (1.57) ±5.37
Mean (median) CSF protein concentration ± standard deviation is given. Micromolar (pM) 
concentration is given in square brackets.
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Figure 9 CSF apoE and S100B concentration in controls and patients within three days of 
TBI and SAH
Figure 9A: Column scatter plot of apoE concentration in control CSF and CSF from 
patients within three days of TBI or SAH. Horizontal bar represents the group median.
Figure 9B: Column scatter plot of S100B (Log concentration) in control CSF and CSF 
from patients within three days of TBI or SAH. From ANOVA using the Kruskall-Wallis 
test the median concentration of apoE and S100B in TBI (p<0.001) and SAH (p<0.001) 
CSF is significantly different from controls. CSF apoE is less than controls after acute 
brain injury contrasting S100B, which is increased. The controls were age matched lumbar 
CSF samples from patients without acute brain injury with no objective clinical or 
biochemical evidence of CNS disease.
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Figure 10 Ratio of apoE/albumin and apoE I total protein in CSF fom controls and patients 
within three days of TBI and SAH
Figure 10A: Column scatter plot of apoE/ albumin concentration ratio in CSF from 
controls and patients within three days of TBI and SAH.
Figure 10B: Column scatter plot of apoE/ total protein concentration ratio in CSF from 
controls and patients within three days of TBI and SAH.
From ANOVA using the Kruskall-Wallis test the ratio for TBI and SAH CSF is 
significantly different (p<0.001) from controls for each ratio. After TBI or SAH CSF 
albumin and total protein concentration increase compared to control CSF. Despite the 
release of plasma apoE into CSF after brain injury, CSF apoE concentration is decreased. 
The controls were age matched lumbar CSF samples from patients without acute brain 
injury with no objective clinical or biochemical evidence of CNS disease.
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Figure 11 Relationship between CSF apoE, injury severity and clinical outcome
Figure 11 A: Relationship between CSF apoE concentration and best recorded level of 
consciousness (GCS) within 24 hours of SAH.
Figure 11B: Relationship between CSF apoE concentration and clinical outcome (GOS) 
three months after SAH.
Figure 11C: ApoE concentration in the CSF of patients with favourable and unfavourable 
outcome after SAH. Patients with unfavourable outcome scores have significantly lower 
CSF apoE within three days of SAH (Mann-Whitney, p=0.03).
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3.3.1.4 The ratio of CSF apoE to total protein within three days of TBI or SAH
Within three days of injury, the mean concentration of total protein in the CSF is 
substantially higher than that of the control group. The mean (SD) concentration of total 
protein in control CSF was 324 (273) mg/L, in SAH CSF was 1974 (1343) mg/L, and TBI 
CSF was 3399 (5367) mg/L. From the Kruskall-Wallis ANOVA the median CSF protein 
concentration is significantly increased after TBI (P<0.001) and SAH (P<0.001) compared 
to control CSF. Although the total protein concentration is substantially higher in TBI CSF 
compared to SAH CSF, the difference is not statistically significant. The mean (SD) apoE 
to total protein ratio in control CSF was 0.044 (0.023), in SAH CSF was 0.0045 (0.0046), 
and in TBI CSF was 0.0023 (0.0028). Thus after SAH, there is approximately six fold 
greater total protein concentration and ten fold decrease in the apoE to total protein ratio. 
After TBI, the total protein concentration increases by order of magnitude but there is 
nearly a twenty fold decrease in the apoE to total protein ratio. From the ANOVA for the 
apoE to total protein ratio, the ratio is significantly decreased after TBI (P<0.001), and 
SAH (P<0.001), but the difference between TBI and SAH is not significant. Thus the 
reduction in the CSF apoE after brain injury is substantially greater than the increase in 
total protein. See figure 10.
3.3.1.5 The concentration of S100B in the CSF within three days of TBI and SAH
CSF S100B increased substantially after acute brain injury. The mean (SD) concentration 
of S100B in control CSF was 0.39 (0.37) pg/1, in SAH CSF was 19 (30) pg/1, in TBI CSF 
was 23 (22) pg/1. ANOVA using the Kruskall-Wallis test determined that there was a 
statistically significant difference between group medians (P<0.0001). Dunn's multiple 
comparison test determined this difference to be significant for TBI (PO.OOl) and SAH 
(PO.OOl) compared to controls, but not between TBI and SAH. See figure 9.
3.3.1.6 The relationship between CSF apoE and S100B within three days of injury 
and GCS and GOS
The proportion of patients in coma (GCS<8 ) after TBI was significantly higher than the 
proportion after SAH (Fishers' exact test, p = < 0.0001). The injury severity (GCS) after 
TBI did not correlate significantly with clinical outcome (GOS). The correlation between 
GCS and GOS after SAH failed to reach statistical significance (Spearman r = 0.4, 95%
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Cl: -0.08 to 0.73, p = 0.09). There was no significant correlation between CSF S100B and 
apoE, GCS, or GOS after TBI or SAH. There was no significant correlation between CSF 
apoE and GCS, or GOS, and there was no significant difference between the concentration 
of apoE (or S100B) in the CSF of patients with favourable versus unfavourable outcome 
after TBI. After SAH, there was significant correlation between CSF apoE concentration 
and injury severity (Spearman r = 0.5, p<0.03, 95% Cl: 0.04-0.78). See figure 11, panel A. 
However, there was no significant difference between the concentration of apoE in the 
CSF of SAH patients in coma, and those with GCS of 9-15. There was significant 
correlation between the concentration of apoE in the CSF of SAH patients and clinical 
outcome (Spearman r = 0.53, p = 0.018, 95% Cl: 0.09-0.80). See figure 11, panel B. The 
concentration of apoE in the CSF of SAH patients with unfavourable outcome was 
significantly lower than the concentration of apoE in the CSF of patients with favourable 
outcome (Mann-Whitney: p = 0.03). The proportion of patients with unfavourable outcome 
and CSF apoE concentration below the lowest control value, was significantly greater than 
those with favourable outcome (Fishers' exact test: p = 0.02). See figure 11, panel C. The 
sample size was too small to determine any possible influence of APOE genotype upon any 
of these data.
3.3.1.7 Summary of findings
The concentration of apoE in the CSF within three days of acute brain injury is 
substantially less than that of controls. The concentration of albumin, total protein, and 
S100B increase substantially. The decrease in apoE is far greater than the increase in 
albumin and total protein. Decreased CSF apoE concentration is associated with more 
severe injury and outcome after SAH. The results from the investigation of the time course 
of these changes in apoE are presented in the next section, and are related to changes in 
other proteins.
3.3.2 Temporal alterations in CSF proteins after TBI and SAH
In addition to the proteins assayed at one time point within three days of injury, Tau, Api_ 
40, and APi.42 were assayed in serial CSF samples from the nineteen SAH patients and a 
subgroup of thirteen TBI patients for whom serial samples were available. The 
characteristics of the patient subgroups are summarised in tables 5,6 and 7. The proportion 
of patients in coma (GCS<8 ) after TBI was significantly (Fishers exact test pO.OOOl) 
greater than after SAH. The median concentration of protein at each time point was 
compared to the control group median using non-parametric ANOVA, assuming that the
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concentration of the various proteins in the CSF of non-brain injured individuals does not 
vary significantly with time. From analysis of the change in concentration with time after 
injury, the maximum or minimum value for each patient protein time series was identified 
and used to determine the time from brain injury to the minimum/maximum value. In 
addition the maximum or minimum values were used to investigate the relationship 
between injury severity and outcome with the magnitude of the change in protein 
concentration. The control group comprised 13 patients (mean age 36, median 32, range 
16-61 years) with suspected shunt dysfunction, or chronic hydrocephalus, with no history 
of acute brain injury or impaired conscious level, requiring drainage/examination of 
ventricular CSF. CSF found to have a cell-count greater than five cells per millilitre,
tlixanthochromia, or albumin and total protein concentration above the 95 centile of the 
population, were excluded to produce a group of controls with "normal" ventricular CSF 
parameters as far as was feasible.
3.3.2.1 The change in CSF concentration of apoE with time after TBI and SAH
After TBI, the decrease in CSF apoE concentration compared to controls was not 
statistically significant one day after injury, but was significant on day two (p<0.01), day 
three (p<0.001), day four (pO.OOOl) and day five (p<0.05). After SAH, the decrease in 
CSF apoE concentration compared to controls was not significant on day two and days five 
to twelve. However, the decrease was statistically significant (p<0.05) on days three and 
four after SAH. See figures 12 and 13, panel A.
3.3.2.2 The change in CSF concentration of albumin and total protein with time 
after TBI and SAH
One day after TBI, CSF albumin concentration increased significantly (p<0.05) compared 
to control values. The increase in albumin after TBI is not statistically significant from day 
two to five. After SAH, the CSF albumin concentration is significantly (pO.OOOl) 
increased, compared to controls, on days one to three, and on day five, but not on day four 
or days six to eleven. The apoE to albumin ratio is significantly decreased compared to the 
control group on days two to five after TBI (p<0.01), and after SAH on days two and three 
(p<0.001), and day nine (p<0.05). The SAH apoE to albumin ratio on day ten is not 
significantly different from the controls. See figures 12 and 13, panel B.
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Figure 12 Time course fo r alterations in the CSF apoE concentration and the ratio o f apoE to 
albumin and total protein after TBI
Figure 12A: Serial column scatter plot of apoE concentration (mg/L of CSF) after TBI.
Figure 12B: Serial column scatter plot for ratio of CSF apoE to albumin concentration. 
Mean (± SD) CSF albumin concentration of control group was 135 (37) mg/L. Mean (± 
SD) albumin concentration in TBI CSF was: day 1 = 454 (457), day 2 = 221 (164), day 3 = 
193 (138), day 4 = 181 (154) and day 5 = 170 (144) mg/L.
Figure 12C: Serial column scatter plot for ratio of CSF apoE to total protein concentration 
after TBI. Mean (± SD) CSF total protein concentration of control group was 313 (112) 
mg/L. Mean (± SD) total protein concentration in TBI CSF was: day 1 = 2773 (1532), day 
2 = 995 (671), day 3 = 1170 (1621), day 4 = 683 (577) and day 5 = 761 (667) mg/L.
Non-parametric ANOVA was used to compare the median concentration (represented by 
horizontal bar) of apoE in the CSF of the TBI patients at each time point with the control 
group median. No comparison was made between serial samples from the TBI group. 
Differences that are not statistically significant are summarised as ns (i.e. p>0.05), * 
represents p<0.05, ** represents p = 0.01-0.001, *** represents p<0.001. The CSF 
albumin, and total protein, concentration increased significantly after TBI and then 
decreased towards normal thereafter. The control CSF is from the ventricles of age 
matched subjects without acute brain injury and CSF profile within normal limits (i.e. no 
xanthochromasia, < 5 nucleated cells per ml of CSF, and normal biochemical profile 
including S100B etc).
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Figure 13 Time course for alterations of CSF apoE concentration and the ratio of apoE to
albumin and total protein after SAH
Figure 13 A: Serial column scatter plot of apoE concentration (mg/L of CSF) after SAH.
Figure 13B: Serial column scatter plot for ratio of CSF apoE to albumin concentration after 
SAH. Mean (± SD) CSF albumin concentration of control group was 135 (37) mg/L. Mean 
(± SD) albumin concentration in SAH CSF was: day 2 = 1815 (1723), day 3 = 531 (507), 
day 4 = 530 (499), day 5 = 618 (303), day 6  = 357 (260) and day 7 = 306 (262) mg/L.
Figure 13C: Serial column scatter plot for ratio of CSF apoE to total protein concentration 
after SAH. Mean (± SD) CSF total protein concentration of control group was 313 (112) 
mg/L. Mean (± SD) total protein concentration in SAH CSF was: day 2 = 2214 (1574), day 
3 = 1750 (1074), day 4 = 1121 (747), day 5 = 1239 (1035), day 6  = 1163 (1141) and day 7 
= 867 (572) mg/L.
Non-parametric ANOVA was used to compare the median concentration (represented by 
horizontal bar) of apoE in the CSF of the SAH patients at each time point with the control 
group median. No comparison was made between serial samples from the SAH group. 
Differences that are not statistically significant are summarised as ns (i.e. p>0.05), * 
represents p<0.05, ** represents p = 0.01-0.001, *** represents p<0.001. The CSF 
albumin, and total protein, concentration increased significantly after SAH and then 
decreased towards normal thereafter. The control CSF is from the ventricles of age 
matched subjects without acute brain injury and CSF profile within normal limits (i.e. no 
xanthochromasia, < 5 nucleated cells per ml of CSF, and normal biochemical profile 
including S100B etc).
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Figure 13A : CSF apoE after SAH
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Compared to controls, there is significantly increased total protein concentrations in TBI 
CSF (p<0.001) on day one after injury, but not on days two to five. After SAH, the 
increase in total protein is significant on days one to four (p<0 .0 0 1 ), on days four and five 
(p<0.01), and days six and seven (p<0.05). After SAH the increase in total protein is not 
statistically significant from days eight to ten. After TBI, the apoE to total protein ratio is 
significantly decreased on days one to four (p<0.001), but not on day five. After SAH, the 
decrease in apoE total protein ratio is statistically significant on days two to eight (p<0.001 
on days two, three and four; p<0.01 on day five; p<0.05 on day six and seven). See figures 
12 and 13, panel C.
3.3.2.3 The change in CSF concentration of Api-40 and Api-42 with time after TBI 
and SAH
There is a significant decrease in CSF ApMo concentration after TBI (day one pO.OOl, 
day three pO.Ol, day five p<0.05) and SAH (day three p<0.001, day seven p<0.01) 
compared to controls. After TBI, the decrease in APi.42 is not statistically significant on 
days one and three after injury, but is significant on day five (p<0.05). After SAH, ApM 2  
concentration is significantly decreased compared to the controls on day three (pO.Ol) and 
day seven (p<0.05). See figure 14. The ratio of APmo is not significantly different from the 
control group ratio for all time points investigated in TBI and SAH CSF.
3.3.2.4 The change in CSF concentration of S100B and Tau with time after TBI 
and SAH
After TBI, there is statistically significant increase (pO.OOl) in CSF S100B concentration 
compared to non injured controls for all the time points investigated. After SAH, S100B is 
significantly increased on days one (pO.OOl) to nine, after which the increase is not 
statistically significant. See figures 15 and 16. After TBI, there is significant (day one 
pO.OOl, days three and five pO.Ol) increase in CSF Tau concentration compared to non 
injured controls. After SAH, the increase in Tau is significant (pO.OOl) for all time points 
investigated. See tables 11 and 12.
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Figure 14 Time course for alterations in CSF A|3i_4o and Api.42, concentration after
TBI and SAH
Figure 14A: Serial column scatter plots of Api-40 concentration (ng/L of CSF) in control 
and TBI CSF.
Figure 14B: Serial column scatter plots of Api-42 concentration (ng/L of CSF) in control 
and TBI CSF.
Figure 14C: Serial column scatter plots of AP1-40 concentration (ng/L of CSF) in control 
and SAH CSF.
Figure 14D: Serial column scatter plots of Api-42 concentration (ng/L of CSF) in control 
and SAH CSF.
Non-parametric ANOVA was used to compare the median concentration of Ap peptides in 
the CSF of the TBI or SAH patients at each time point (represented by horizontal bar) with 
the control group median. Differences that are not statistically significant are summarised 
as N.S. (i.e. p>0.05), * represents p<0.05, ** represents p = 0.01-0.001, *** represents 
pO.OOl. There was no significant difference between the ratio of APmo to APm2 in 
control and TBI or SAH CSF.
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Figure 14A CSF Ap after TBI
Figure 14B CSF Ap 1.42 after TBI
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Figure 15 Time course fo r alterations in CSF S100B, and Tau concentration after TBI
Figure 15 A: Serial column scatter plot of CSF S100B (Log concentration) after TBI and 
controls.
Figure 15B: Serial column scatter plot of CSF Tau (Log concentration) after TBI and 
controls.
Non-parametric ANOVA was used to compare the median concentration of S100B or Tau 
in the CSF of the TBI patients at each time point (represented by horizontal bar) with the 
control group median. S100B concentration of TBI CSF was elevated (p = 0.01-0.001) at 
each time point compared to the control group. Tau was also elevated (day 2: pO.OOl, day 
3 and 5: p = 0.01-0.001) compared to the control group.
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Figure 15A : S100B in control and serial TBI CSF
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Figure 16 Time course for alterations in CSF S100B, and Tau concentration after SAH
Figure 16A: Serial column scatter plot of CSF S100B (Log concentration) after SAH and 
controls.
Figure 16B: Serial column scatter plot of CSF Tau (Log concentration) after SAH and 
controls.
Non-parametric ANOVA was used to compare the median concentration of S100B or Tau 
in the CSF of the SAH patients at each time point (represented by horizontal bar) with the 
control group median. S100B concentration of SAH CSF was elevated (p = 0.01-0.001) at 
each time point compared to the control group. Tau was also elevated (p = 0.01-0.001) at 
each time point compared to the control group.
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Figure 16A : S100B in control and serial SAH CSF
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Figure 16B : Tau in control and serial SAH CSF
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Table 11 CSF Tau and S100B in controls and serial TBI samples
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Protein 
concentration 
Mean 
± SD
control
Time after TBI
Day 1 Day 2 Day 3 Day 4 Day 5
Tau
Hg/L 0.19 a 3.5 2.3 a 2.0
±0.2 ±2.0 ±2.2 ±2.6
S100B
ng/L 0.26 70.7 17.5 20.4 16.3 19.0
±0.1 ± 5 5 ± 14 .4 ±20.1 ±19 .6 ± 18.2
a Not determined due to limited sample volume
S100B and Tau concentrations were significantly elevated after TBI for each time 
point compared to the control value using non-parametric ANOVA (p<0.001).
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Table 12 CSF Tau and S100B in controls and serial SAH samples
Protein
concentration
Mean
± SD
control
Time after SAH
Day 2b Day 3 Day 4 Day 5 Day 9
Tau
Hg/L 0.19 3.4
a 2.7 a 2.9
± 0 . 2 4.4 ±2.9 ±1.9
S100B
Hg/L 0.26 55.7 19.7 14.4 9.6 12.3
± 0 .1 ± 4 5 ± 30 .5 ± 17 .6 ± 7 .7 ±15 .3
a Not determined due to limited sample volume 
b Limited SAH CSF day 1 after SAH.
S100B and Tau concentrations were significantly elevated after SAH for each time point 
compared to the control value using non-parametric ANOVA (p<0.001).
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3.3.2.5 Time elapsed between brain injury and maximal change in protein 
concentration in CSF
The greatest decrease in apoE (apoE min), compared to controls, occurred earlier after TBI 
(3.4 days) than apoE min after SAH (5.2 days) (P = 0.003, 95% Cl: 0.4-3.3 days). The 
greatest decrease in A P m o  (Ap 4 0 m i n ) ,  compared to the controls, occurred 2 days after TBI, 
and is not significantly earlier than Ap 40min after SAH (3.9 days). The greatest decrease in 
Api-42 (Ap 42min), compared to the controls, occurred 2.9 days after TBI, and is not 
significantly earlier than Ap 42min after SAH (4.2 days). The greatest increase in S100B 
(S100B max), compared to controls, occurred 2.2 days after TBI, and is not significantly 
earlier than S100B max after SAH (3.3 days). The greatest increase in Tau (Tau max), 
compared to controls, occurred 2.5 days after TBI, and is significantly (P = 0.008, 95% Cl: 
0.7- 4.3) earlier than Tau max after SAH (5 days). See figures 17.
After TBI there was statistically significant (r = 0.8, 95% Cl: 0.44-0.94, P = 0.001) 
correlation between the magnitude of the reduction in CSF ApMo concentration, and the 
time elapsed between injury and trough levels. Other maximal changes did not correlate 
significantly with time after injury.
3.3.3 The relationship between CSF protein concentration changes after TBI 
and SAH
Multiple correlation analysis found no statistically significant association between the 
minimum concentration of apoE in the CSF after TBI, and the maximal changes in other 
proteins. These data are presented in the form of a correlation matrix (contains r-values) in 
table 13 for TBI, and table 14 for SAH. There was significant correlation between trough 
apoE and APmo after SAH (r = 0.85, pO.OOOl). See figure 18.
3.3.4 The relationship between CSF proteins, injury severity, and outcome
3.3.4.1 The relationship between CSF protein concentration and injury severity
The relationship between CSF protein concentration and injury severity was determined by 
generating a correlation matrix for Glasgow Coma Score and the maximal change in CSF 
concentration after TBI and SAH. This is summarised in table 15 for TBI, and SAH. After
A D Kay 2003 Chapter 3 125
TBI, Ap 40min correlated significantly (Spearman r = 0.69, P = 0.0123, 95% Cl: 0.17-0.89) 
with injury severity measured using the GCS. It is estimated that approximately 47% of the 
variation in CSF Ap 40min is attributable to variation in severity of injury, or vice versa. 
There was no statistically significant correlation between injury severity and apoE min after 
SAH. This contrasts with the finding in the CSF samples analysed within three days of 
haemorrhage where apoE correlated with injury severity and outcome. From the scatter 
diagram of apoEmin versus injury severity (and outcome), there are a greater number of low 
apoE concentrations in the less severely injured patients, and these low values occur more 
than three days after injury. Injury severity correlated with Tau max (Spearman r = -0.8, P = 
0.008, 95% CI:-0. 85 to -0.19) after SAH. Approximately 64 % of the variation in CSF Tau 
and 25% of the variation in apoE is attributable to variation in injury severity after SAH. 
There was no statistically significant correlation between the other proteins and best GCS. 
Comparing the proportion of patients in coma versus the proportion with a GCS> 8  is not 
possible in the TBI group as they are all categorised as severely injured. Dichotomising 
this group into GCS 3-5, and GCS 6 -8 , identified no difference in the proportion of 
patients with S100B, or Tau, above the highest control value (all above the highest 
control), and there was no significant difference in CSF concentration between the injury 
severity subgroups. Similarly, for apoE, Ap 4omin, and Ap 42min, there was no significant 
difference in the protein concentration, or proportions below the minimum control value, 
between severe injury subgroups. After SAH, injury severity according to the GCS ranged 
from 3 to 15. There was no significant difference in the proportion of patients with protein 
concentrations above or below the limits of the control values and the proportion in coma 
or with a GCS>8 . However, there were no SAH patients in coma with CSF AP1.42 
concentration above the minimum control value, and the difference in proportions just 
failed to reach statistical significance (Fishers' exact test: p = 0.06). There was no 
statistically significant difference between the protein concentration of the SAH patients in 
coma versus those with GCS>8 , although the difference in CSF Tau concentration between 
injury severity groups just failed to reach statistical significance (Mann-Whitney: p = 
0.07).
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Figure 17 Column bar graph comparing the time elapsed between brain injury and the 
maximal change in CSF protein concentration after TBI and SAH
Figure 17A: Column bar chart of time elapsed between brain injury and trough apoE, A(3i. 
4 0 ,  and A p i - 4 2  levels after TBI and SAH. From the Mann-Whitney test, trough apoE and 
Ap ].40 levels occurred significantly earlier in TBI CSF compared to SAH CSF
Figure 17B: Column bar chart of time elapsed between brain injury and peak S100B and 
Tau levels after TBI and SAH. From the Mann-Whitney test, peak Tau levels occurred 
significantly earlier in TBI CSF compared to SAH CSF
Error bars represent the 95% confidence interval.
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Figure 17A : Time elapsed between brain injury and minimum CSF 
concentration of apoE and Ap peptides
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Figure 17B : Time elapsed between brain injury and maximum 
CSF concentration of S100B and tau
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Table 13 Correlation matrix for protein concentration change after TBI
S100B max Tau max APi-40 min APi_42 min ApoEmin
S100B „,ax 1 -0.18 -0 . 1 2 0.19 0.13
Tail max -0.18 1 0.09 0.07 0.55
APi_40 min -0 . 1 2 0.09 1 -0.05 0.08
APi-42 min 0.19 0.07 -0.05 1 0.09
Table 14 Correlation matrix for protein concentration change after SAH
S100B max Tau max APi-40 min APi-42 min ApoEmin
S100B max 1 0.44 -0.45 -0.47 -0.34
Tau max 0.44 1 -0.64 -0.60 -0.18
APi-40 min -0.45 -0.64 1 0.79 0.85
APi-42 min -0.47 -0.60 0.79 1 0.25
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Figure 18 Relationship between trough CSF apoE and trough Ap^o after SAH
There is significant correlation between the trough concentration o f apoE and Api_4 o in the 
CSF after SAH.
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Figure 19 Relationship between CSF Ap^o and in jury severity after TBI and CSF Tau and 
in jury severity after SAH
The maximal change in CSF concentration after injury was plotted against Glasgow Coma 
Score (GCS) in the form of a scatter diagram for all of the proteins analysed. Dotted line 
represents the 95% Cl of the slope of the regression line.
Figure 19A:Relationship between trough CSF Ap 1.40 concentration and injury severity after 
TBI. All TBI patients had severe (GCS <8 ) injury.
Figure 19B:Relationship between peak CSF Tau concentration and injury severity after 
SAH.
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Table 15 Correlation matrix fo r maximal change in CSF proteins and GCS
GCS TBI GCS SAH
ApoEmjn -0.35 -0.021
S100B max 0.135 -0.53
Tail max -0.25 -0.8
APi-40 min 0.69 0.27
APi-42 min 0.04 0.47
AIbuminmax -0.36 -0.37
Total
proteinmax
-0.58 -0.08
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3.3.4.2 The relation between CSF protein concentration and clinical outcome
There was significant correlation (Spearman r = -0.89, P = 0.0013) between S100B max and 
clinical outcome (GOS) six months after TBI. It is estimated that approximately 80% of 
the variation in TBI CSF S100B is attributable to variation in clinical outcome, or vice 
versa. Three months after SAH, S100B max (Spearman r = -0.5, P = 0.029, 95% Cl: -0.78 to 
- 0.04), Tau max (Spearman r = -0.63, P = 0.007, 95% Cl: -0.85 to - 0.19), AP 40min 
(Spearman r = 0.73, P = 0.015, 95% Cl: 0.13 to 0.87), and Ap 42min (Spearman r = 0.84, P= 
0.002, 95% Cl: 0.34 to 0.93), correlated with the GOS. These data are summarised in table 
16. Albumin and total protein did not correlate significantly with GOS. There was no 
significant correlation between injury severity (GCS) and outcome (GOS) after TBI. After 
SAH, GOS just failed to correlate significantly with GCS (p = 0.09). The head injured 
patients were more severely injured and a higher proportion had unfavourable outcomes 
after TBI then SAH (Fishers exact test p = 0.036). The proportion of patients with CSF 
protein concentration above or below the control limit was not significantly different 
between TBI patients with favourable versus unfavourable outcome. The concentration of 
the proteins in the CSF was not significantly different between outcome categories. After 
SAH, no patients with unfavourable outcome had Ap 42min above the minimum control 
CSF value. However, the proportion of SAH patients with CSF Ap 42min below the lowest 
control value just failed to reach statistical significance (Fishers exact test p = 0.07).
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Table 16 Correlation matrix fo r maximal change in CSF proteins and GOS
GOS TBI GOS SAH
ApoEmin - 0 .7 3 0 .5 6
S100B max - 0 .8 9 - 0 .5
T a U  max - 0 .0 0 - 0 .6 3
A P i-4 0  min 0 .3 7 0 .7 3
A P i -42 min - 0 .1 7 0 .8 4
Albuminmax -0 .4 1 - 0 .7 5
Total
proteinmax
- 0 .2 6 - 0 .6 0
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Figure 20 Relationship between CSF A fh^S IO O B , and Tau and clin ical outcome after SAH
The maximal change in CSF concentration after injury was plotted against Glasgow 
Outcome Score (GOS) in the form of a scatter diagram. The dotted line represents the 95% 
confidence interval of the slope of the regression line. GOS 4 and 5 equate to favourable 
(independent) recovery (assessed three months after SAH); GOS 2 and 3 equate to 
dependent outcome; GOS 1 equates to fatal outcome.
Figure 20A:Relationship between trough CSF Api.42 concentration and clinical outcome 
after SAH.
Figure 20B:Relationship between peak CSF S100B (Log) concentration and clinical 
outcome after SAH.
Figure 20C:Relationship between peak CSF Tau (Log) concentration and clinical outcome 
after SAH.
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Figure 20A : Relationship between 
trough CSF A p42 concentration and 
clinical outcome (GOS) after SAH
Figure 20B : Relationship between 
peak CSF S100B concentration after 
SAH and clinical outcome (GOS)
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Figure 20C : Relationship between 
peak CSF Tau concentration after SAH 
and clinical outcome (GOS)
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There were significant differences between the median concentrations of Taumax (Mann- 
Whitney: p = 0.039), Ap 40min (Mann-Whitney: p = 0.014), and Ap 42min (Mann-Whitney: p 
= 0.011) in the outcome groups after SAH.
3.3.4.3 The relationship between the temporal changes in CSF protein 
concentration and injury severity and outcome
Within 48 hours of admission all TBI patients had a best GCS recording of eight or less 
(severe head injury). Injury severity was dichotomised into groups with GCS 3-5, and GCS 
6-8. The proportion of patients in each severity group were then compared according to 
CSF levels above or below the minimum control value for apoE and Ap, and maximum 
control Tau or S100B at each time point using Fisher's exact test. There was no statistically 
significant difference in the proportion of TBI patients with CSF protein concentrations 
above or below the control limits at each time point after injury. The SAH patients were 
dichotomised into groups of GCS 3-8, and 9-15, and analysed as above. Again there was 
no statistically significant differences in CSF protein concentration over time according to 
injury severity. The same analysis was undertaken for clinical outcome, dichotomising 
GOS into favourable outcome (GOS 4, 5), and unfavourable outcome (GOS 1,2,3). For 
S100B and Tau, there were no brain injury CSF values below the maximum value of the 
control group, which prevents the comparison of proportions. In these circumstances the 
threshold selected was the median of the brain injury values. Thus the contingency table 
comprised patients categorised according to favourable and unfavourable outcome 
(columns), and CSF S100B (or Tau) above or below the brain injury group median (rows). 
There was significantly increased relative risk of unfavourable outcome after SAH for 
patients with CSF S100B above the SAH group median concentration on day three 
(Fishers' exact test: p = 0.017, RR of favourable outcome: 0.23, 95% Cl: 0.04-1.36) to day 
seven (Fishers' exact test: p = 0.046, RR of favourable outcome: 0.39, 95% Cl: 0.12-1.25). 
The difference in proportions was not significant beyond one week after injury. There was 
a significant increase in the relative risk of unfavourable outcome after SAH for patients 
with CSF Tau above the SAH group median on days six (Fishers' exact test: p = 0.027, RR 
of favourable outcome: 0.24, 95% Cl: 0.04-1.44) and day nine (Fishers' exact test: p = 
0.048, RR of favourable outcome: 0.25, 95% Cl: 0.05-1.36) after injury.
3.3.5 Summary of CSF protein concentration changes after TBI and SAH
The concentration of apoE in the CSF after TBI and SAH is substantially lower than that of 
non-brain injured controls. The reduction is apparent within three days of injury, and
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persists for at least one week after injury. Other proteins increase in the CSF after acute 
brain injury with the exception of the Ap peptides. For some proteins the magnitude of the 
maximal alteration in CSF concentration correlates with injury severity, and clinical 
outcome.
3.4Characterisation of lipoprotein particles in control, TBI and 
SAH CSF
The first section of this chapter presents the results from the development of a robust 
ELISA method for the measurement of apoE in control and brain injury CSF. The previous 
two sections present the results of the quantification of apoE in the CSF of non brain 
injured controls, and patients with TBI and SAH using this ELISA. It was found that the 
concentration of some proteins in the CSF increased after TBI and SAH compared to 
controls. In contrast, the concentration of apoE (and AP) decreased. As apoE is a major 
component of CSF lipoprotein particles, studies were undertaken to investigate whether 
reduced concentration of the apoE protein in the CSF are paralleled by changes in the CSF 
lipoprotein particles after brain injury. This section presents the findings from the isolation 
and analysis of lipoprotein particles isolated from control, TBI, and SAH CSF.
Prior to the isolation and analysis of lipoprotein particles in the CSF of non-brain-injured 
controls and patients with SAH or TBI, the size exclusion chromatography column was 
calibrated using plasma lipoprotein particles of known size and composition.
3.4.1 Characterisation of size exclusion chromatography column
Plasma derived lipoprotein particles (VLDL, LDL, and HDL), were freshly prepared by 
sequential density ultracentrifugation, and mixed in equivalent proportions. A volume of 
500pl was eluted at a rate of 0.25ml/min in fractions of 250pl. These fractions were 
assayed for apoB, total cholesterol (TC), and phospholipid (PL) as described in methods. 
In addition protein was assayed by measuring the absorbance of the fraction at 280nm. See 
figure 21.
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Figure 21 Characterisation of size exclusion chromatography column using plasma 
lipoproteins
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Figure 21 shows the plasma lipoprotein elution profile from a Sephadex 200 size exclusion 
column. VLDL (d < 1.006 g/ml) elutes from fraction 26-33, LDL (d = 1.019-1.063 g/ml) 
elutes from fraction 34-45 and HDL (d = 1.063-1.21 g/ml) elutes from fraction 46-58. The 
protein content o f the fractions eluting from the column are monitored from the absorbance 
at 280nm.
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Figure 22 Lipoprotein composition of Plasma and CSF HDL
Figure 22 displays the triglyceride (TG), phospholipid (PL), cholesterol ester (CE), free 
cholesterol (FC), apoAI and apoE composition (mg %) of plasma and CSF HDL. Plasma 
and CSF HDL differ substantially in their relative compositions as demonstrated in the bar 
chart. There is no triglyceride in CSF HDL. There is more apoE, apoAI, and free 
cholesterol in CSF HDL.
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3.4.1.1 Lipoprotein particle profile of plasma
141
The elution profile of plasma confirmed the presence of three peaks comprising particles of 
differing size: VLDL eluted in fractions 26 to 33, LDL in fractions 34 to 45, and HDL in 
fractions 46 to 58. The fractions containing the LDL particle are clearly defined, as the 
only apoprotein in LDL is apoB.
3.4.1.2 Composition of plasma lipoprotein particles
The VLDL particle is rich in triglyceride (data not shown), and has relatively little protein, 
cholesterol or phospholipid. The LDL particle is characterised by the presence of apoB, 
and has relatively more cholesterol and phospholipid. The HDL particle has no apoB, is 
protein rich, and compared to the LDL particle has proportionately more phospholipid than 
cholesterol. The composition of plasma lipoprotein particles, contrasted with CSF 
lipoprotein particles, is summarised in table 17 and figure 2 2 .
Table 17 Composition of CSF and plasma HDL lipoprotein particles
Plasma
h d l 2
Plasma
h d l 3
CSF
HDLi
CSF
h d l 2
CSF
HDL3
ApoE % (SD) 0.5 (0.3) 0 . 2  (0 .2 ) 16.1 (8 .8 ) 14.1 (6 .6 ) 5.6 (7.6)
ApoAI % (SD) 15.2 (7.4) 34.2 (3.6) 13.8(15.5) 42.8 (6.1) 54.7 (37)
FC % (SD) 4.9 (1.1) 3.0 (0.5) 13.8(15.5) 4.3 (4.9) 10.1 (11.9)
CE % (SD) 34.3 (3) 25.5 (2.9) 20.1 (18.5) 14.4 (6.4) nd
PL % (SD) 38.3 (3.0) 32.5(1.2) 47.6(15.3) 24.4 (2.9) 29.6 (23.1)
TG % (SD) 6 . 2  ( 1 .2 ) 4.7 (0.8) nd nd nd
FC = free cholesterol, CE = cholesterol ester, PL = phospholipid, TG = triglyceride, 
nd = not detected. HDL] is rarely seen in human plasma.
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3.4.2 Isolation and analysis of lipoprotein particles from control CSF
The minimum volume of CSF required for the isolation of CSF lipoprotein particles is 20 
ml. The substantial volume required was generated by pooling 1ml aliquots of CSF from 
twenty-five consecutive control patients. A total of six control pools were generated in this 
manner from one hundred and fifty of the control CSF samples. These pools had no 
detectable apoB. The mean age of the patients was 32 years (median 25 years and range 
16-65 years).
3.4.2.1 Lipoprotein particle profile and composition of control CSF
In contrast to plasma, the lipoprotein particles present in control CSF form one major peak. 
This peak occurs in fractions containing particles of similar size to the plasma HDL and 
LDL particles at the LDL/HDL boundary, which peaked at fraction 47. CSF does not 
contain apoB, thus these large CSF lipoprotein particles are known as HDLi (plasma has 
HDL2 and HDL3, but HDLi is rarely seen in plasma). Examination of the control apoE and 
apoAI elution profile indicates the presence of overlapping populations of particles 
containing both apoE and apoAI (fractions 45 to 52) and particles containing apoAI alone 
(fractions 50 to 60). Thus apoAI is present in both the HDLi and smaller HDL lipoprotein 
particle fractions and apoE is present mainly in the larger HDLi sized particle. See figure 
24.
The larger CSF lipoprotein particles contain most of the phospholipid and cholesterol 
associated with the CSF lipoproteins. The molar ratio of apoAI to apoE in control CSF was 
approximately 1:3 and that of free cholesterol to phospholipid was approximately 1: 2.
Having calibrated the size exclusion chromatography column for the fractionation of CSF 
lipoprotein particles from control CSF, isolation and compositional analysis of TBI and 
SAH CSF was performed.
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Figure 23 Lipoprotein composition of CSF HDL particles
CSF lipoprotein particles are unique in that they comprise HDLi sized particles, which are 
not normally present in human plasma. Analysis o f the HDL subgroups in control CSF, as 
displayed in the bar chart clearly shows the differences between CSF HDL subgroups. The 
smaller HDL3 have less apoE and cholesterol ester. In contrast apoAI predominates. The 
smaller HDL particles remodel through the action of the cholesterol ester forming enzyme 
LCAT, the activity o f which is promoted by the abundant apoAI present on the smaller 
HDL particles. As the HDL accumulate cholesterol ester apoAI is replaced by apoE, which 
facilitates the transport o f the cholesterol to target cells expressing the LDL family of 
receptors.
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3.4.3 Isolation and analysis of lipoprotein particles from acute brain injury 
CSF
3.4.3.1 CSF lipoprotein particle profile and composition after SAH
After SAH the CSF contains plasma lipoprotein particles released at the time of 
haemorrhage. Compared to control CSF there was a ten-fold increase in total cholesterol (p 
= 0.007), and free cholesterol (p = 0.001) in SAH CSF. Importantly, there was no 
significant difference between the ratio of FC to TC in control and SAH CSF. The FC to 
TC ratio was constant across the lipoprotein profile. The phospholipid concentration of 
SAH CSF was five times higher than that of the controls (p<0.05). The molar ratio of free 
cholesterol to phospholipid increased from 1:2 in controls to 1:1 in SAH. The apoE to 
apoAI ratio decreased from 1:3 in controls to 1:13 in SAH. In SAH CSF these changes 
were accompanied by the appearance of a population of particles of very small size 
(fractions 58-68) that are rich in phospholipid and free cholesterol. There was a significant 
increase (p = 0.04) in the total area under the curve (AUC) for apoAI associated particles 
in SAH CSF compared to control subjects, but the difference in the total AUC for the apoE 
associated particles failed to reach statistical significance. These data are summarised in 
table 18. However, near the LDL/HDL boundary in SAH CSF there was a reduction in 
apoE AUC (p = 0.13) indicating a depletion of large apoE-containing lipoproteins. In SAH 
CSF the concentration of apoB was 1.5 (± 0.5) mg/100ml; apoB was not detected in 
control CSF. Although the decrease in concentration of CSF LpE after SAH is not 
statistically significant (Mann-Whitney: p = 0.86), it is surprising that LpE does not 
increase in proportion with apoAI as they have similar proportions in the plasma. The ratio 
of LpAI to LpE is significantly lower after SAH (Mann-Whitney: p = 0.026). See figure 
24.
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Figure 24 Composition of lipoprotein particles fractionated from non-injured control and 
SAH CSF
The vertical dashed line indicates the elution intervals for LDL and HDL sized particles for 
the size exclusion column. Panels A and B correspond to total cholesterol, Panels C and D 
correspond to free (non-esterified) cholesterol, E and F correspond to phospholipid, G and 
H correspond to apoE, and panels I and J correspond to apoAI in non-injured controls and 
SAH patients respectively. After SAH, phospholipid, free cholesterol and apoAI levels 
increase and are associated with plasma VLDL, LDL and HDL sized particles. Large 
apoE-HDL particles are decreased and VLDL associated apoE appears after SAH. In 
addition very small lipoprotein particles appear in SAH CSF that are not present in control 
CSF. Profiles represent the mean of six control pools and CSF from six patients after SAH. 
CSF was obtained from six SAH patients (mean age 54, median 52, and range 26-65 years) 
admitted to the neurosurgical unit at the Institute of Neurological Science Glasgow, U.K., 
between March 2000 and February 2001. All SAH patients were in coma (Glasgow Coma 
Score < 8 ), had an aneurysmal distribution of blood in the subarachnoid space on the 
admission CT (all Fisher grade III), and required insertion of an external ventricular drain 
for the treatment of acute hydrocephalus. The SAH CSF was obtained from the cerebral 
ventricles within three days of aneurysm rupture.
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Figure 25 Composition o f lipoprotein particles fractionated from non-injured control and TBI 
CSF
CSF from 150 patients was used to generate 6  non-injured CSF pools of sufficient volume 
for CSF lipoprotein particle fractionation by size exclusion chromatography. CSF from 27 
patients with severe traumatic brain injury was pooled for comparison with the control 
pools. The vertical dashed line indicates the elution intervals for LDL and HDL sized 
particles for the size exclusion column. Panels A and B correspond to free (non-esterified) 
cholesterol, C and D correspond to phospholipid, E and F correspond to apoAI, and panels 
G and H correspond to apoE in non-injured controls and traumatic brain injury patients 
respectively. As observed in SAH CSF, there is a population of very small lipoprotein 
particles associated with free cholesterol, phospholipid and apoAI.
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Table 18 Composition o f lipoprotein particles in control and SAH CSF
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Lipoprotein
Component
Concentration 
mg/lOOml of control CSF, [pM]
Concentration 
mg/lOOml of SAH CSF, [pM]
Total cholesterol
0.13 ±0.06, [3.4] 1.28 ±1.12 [33.2] **
Free cholesterol
0.08 ± 0.04, [2.3] 0.78 ± 0.66, [20.2 ] **
Phospholipid
0.29 ± 0.08, [3.8] 1.33 ±1.12, [17.2]*
ApoAI
0.30 ±0.146, [0.1] 1.24 ±0.99, [0.4]*
ApoE
0.14 ±0.05, [0.04] 0.10 ±0.03, [0.03]
Values are means ± S.D. Significance of difference: *p<0.05, **p<0.001 control and SAH 
means compared with unpaired t-test of log transformed data
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Table 19 Composition o f CSF lipoprotein particles in control and TBI CSF
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Lipoprotein
component
Concentration 
mg/100ml of control CSF, [pM]
Concentration 
mg/lOOml of TBI CSF, [pM]
Total cholesterol 0.13 ±0.006, [3.4] 0.29, [7.5] *
Free cholesterol 0.09 ±0.04, [2.1] 0.36, [9.3] **
Phospholipid 0.29 ±0.09, [3.8] 0.44, [5.7] *
ApoAI 0.30 ±0.15, [0.1] 0.32, [0.1]
ApoE 0.14 ±0.05, [0.04] 0.01, [0.004]**
Single TBI pool compared to six control pools using the one sample t-test. 
*p<0.05, **p<0.01
3.4.3.2 CSF lipoprotein profile and composition after TBI
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The volume of TBI CSF available for size exclusion chromatography was very limited. 
One pool comprising one millilitre of CSF from each of twenty-seven TBI patients (within 
three days of injury) was fractionated for analysis of the lipoprotein particles. In CSF from 
TBI patients, there was a five-fold increase in non-esterified cholesterol compared to 
control CSF (p = 0.0001). In addition, phospholipid containing particles increased 
significantly compared to control CSF (p = 0.04). The molar ratio of free cholesterol to 
phospholipid in TBI patients increased from 3:5 in controls to 11:5 in TBI. These changes 
were accompanied by the appearance of a population of particles of very small size 
(fraction 58-63) which were phospholipid and free cholesterol rich. Large apoE- HDL 
particles were depleted in the TBI CSF as evidenced by the shift to the right of the elution 
peaks for free cholesterol and phospholipid. There was no significant change in the apoAI 
associated particles of the TBI CSF pool compared to control pools, but apoE associated 
particles were significantly decreased (one sample t-test; p = 0.002). The molar ratio of 
apoAI to apoE in TBI patients increased from 2:1 in controls to 25:1 in TBI. There were no 
apoB containing lipoprotein particles in TBI CSF. These data are summarised in table 19 
and figure 25.
3.4.4 Summary of characterisation of CSF lipoproteins after acute brain 
injury
CSF lipoproteins are distinctive from plasma lipoproteins. Substantial differences in the 
composition of the lipoprotein particles exist between control and acute brain injury CSF. 
After SAH, despite the substantial increase in lipoprotein particles originating from the 
plasma, there is a reduction in the quantity of apoE containing particles. After TBI, where 
there is a lesser release of lipoprotein particles originating from the plasma, there is even 
greater decrease in the apoE containing lipoprotein particles. The changes in the apoE 
containing lipoprotein particle composition parallel the changes identified in nascent CSF 
apoE concentration.
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4 Discussion
4.1 Principal findings of the study
4.1.1 Protein concentrations in control, TBI and SAH CSF
The principal findings in relation to the proteins selected for investigation in this study are:
• The concentrations of apoE, ApMo, and Api-42 are significantly lower in the CSF of 
patients with TBI, and SAH compared to controls.
• The decrease in these proteins occurs within days of injury and persists for at least one 
week after injury.
• The decrease in protein concentration after acute brain injury correlates with injury 
severity and clinical outcome.
• The concentrations of S100B and Tau are markedly increased in the CSF of TBI and 
SAH patients compared to controls.
• The increase in these proteins occurs within days of injury and persists for at least one 
week after injury.
• The peak CSF concentration of Tau and S100B correlates with the severity of the brain 
injury, and the clinical outcome after SAH.
4.1.2 The analysis of lipoprotein particles in control, TBI and SAH CSF
The principal findings in relation to the lipoprotein particles present in the CSF of controls 
and patients with TBI and SAH are:
• CSF contains unique lipoprotein particles.
• The apoE lipoprotein particles were depleted from brain injury CSF compared to 
controls.
• CSF lipoprotein particles undergo remodelling after acute brain injury.
• Novel lipoprotein particles are present in brain injury CSF that are not present in 
control CSF.
4.2 Interpretation of results
4.2.1 Protein concentrations in control, TBI and SAH CSF
There are a number of possible explanations for the decrease in CSF apoE, and Ap, after 
acute brain injury. These include increased clearance from CSF, decreased production, 
dilution effects, sampling artefact, and assay artefact or interference. Evaluation of the 
apoE ELISA determined that the assay has high recovery, sensitivity, and precision.
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Importantly, the recovery of apoE added to control or brain injury CSF, and white matter 
homogenate was high, and there was no significant difference between brain injury and 
control CSF. Thus there appears to be no significant interference from substances present 
in the brain injury CSF that are not present in control CSF. There was no decrease in the 
apoE signal when CSF was assayed in the presence of increasing concentrations of human 
albumin, or the total protein used for the protein standard curve (comprising human 
albumin and gamma globulin) at concentrations recorded in the brain injury CSF. In 
addition, there was linearity in the assay over a range of CSF dilutions for control and 
brain injury CSF and these dilution lines were parallel with the apoE calibration curve. 
Thus, differences detected between control and brain injury CSF are not significantly 
affected by differences in the matrices at different analyte concentration. The lower limit of 
detection of the assay was substantially lower than the lowest recorded CSF apoE 
concentration. The precision of the assay, coupled to the simultaneous assay of controls 
and brain injury CSF decreased the chance that differences between cases and controls are 
due to inter or intra assay variation. The specificity of an assay is particularly important 
when high values are observed (which is not the case here) due to concern about antibody 
cross reactivity. The specificity of the assay has been extensively described by Stark et al, 
who found no significant cross reactivity with the major lipoproteins present in plasma. 
Both in their study and the present study, there was no significant difference between 
calibration curves obtained using apoE3, apoE4 or apoE2. (Starck et al. 2000) The 
potential that other variables, such as pH, are substantially different in brain injury CSF has 
not been investigated. Although this does not affect the ability to detect apoE added to 
brain injury CSF, there is a possibility that in-vivo apoE undergoes physiochemical 
alterations resulting in an apparent decrease in the CSF due to masking of epitopes. For 
example, the apoE may form stable complexes in-vivo with Ap or components of the 
complement cascade. Formation of amyloid aggregate in-vitro appears to be pH dependent 
and the possibility that acidosis after brain injury contributes to depletion of apoE-Ap from 
CSF in-vivo requires further investigation. (Atwood et al. 1998) Although only semi- 
quantitative, denaturing SDS PAGE correlated approximately with the ELISA findings in 
the samples analysed using this method, suggesting that the decreased signal in brain injury 
CSF is not attributable to differences in secondary and tertiary structure, or detergent 
sensitive binding interactions. In addition, the apoE ELISA assay dilution buffer contains 
detergent, which results in protein unfolding and removes associated cholesterol and lipid. 
There are non-antibody based methods for the quantification of apoE such as HPLC 
(derived from phenylalanine content of apoE) and capillary electrophoresis in SDS gels 
(SDS-CGE), but these were not utilised in the present study. (Schlenck et al. 1999) It has
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not been possible to independently evaluate the amyloid beta assays due to the high cost of 
the assay. However, these commercial assay kits have been evaluated by others and have 
been used to assay amyloid beta in the CSF of patients with AD and controls, as well as 
other biological fluids. (Chishti et al. 2001; Kusiak et al. 2001) The manufacturers report 
high recovery of amyloid beta from plasma.
The possibility that apoE and amyloid beta are decreased in brain injury CSF compared to 
control CSF due to a systematic difference in CSF sample acquisition and processing 
requires evaluation. It has been demonstrated that the route of sampling influences the 
concentration of apoE such that the concentration is higher in ventricular CSF than CSF 
from the lumber subarachnoid space. CSF apoE is intrathecally synthesised accounting for 
the concentration gradient between ventricular and lumbar CSF. (Carlsson et al. 1991; 
Linton et al. 1991) The decrease in ventricular CSF apoE observed after acute brain injury 
is significant when compared to either control CSF obtained from the lumbar subarachnoid 
space or control CSF from the lateral ventricles. Thus the magnitude of the decrease in 
apoE concentration observed when brain injury CSF is compared to lumbar CSF represents 
an underestimate of the true decrease that would be observed when compared to the less 
often available ventricular control CSF. It has been demonstrated that continuous CSF 
drainage does not significantly reduce the concentration of apoE in non-brain injured 
controls over time. Thus, the loss of apoE from brain injury CSF is unlikely to be a 
consequence of brain apoE exhaustion due to external drainage. The high concentration of 
apoE in control ventricular CSF obtained via ventricular catheters suggests that there is no 
significant decrease in apoE due to sampling via this route. Furthermore, there was no 
significant difference in the apoE concentration before or after passage through a 
ventricular catheter in-vitro. The conditions for collection and storage are particularly 
important for hydrophobic polypeptides such as Ap, which have a tendency to aggregate 
and adsorb onto surfaces. Thus the CSF collection tubes utilised in this study were of the 
polypropylene type as recommended by Hesse et al. (Andreasen et al. 2001; Hesse et al. 
2000) Brain injury and control CSF samples were processed and stored in an identical 
manner, and underwent only one freeze-thaw cycle prior to simultaneous batch analysis. 
Analysis was performed within three months of freezing in the majority of cases, though 
serum or plasma apoE is reported to be stable when stored at -20 degrees centigrade for as 
long as three years. (Alsayed et al. 1990; Blum et al. 1980; Koffigan et al. 1987; Kottke 
et al. 1991; Phillips et al. 1983; Schiele et al. 2000b) The stability of apoE in the CSF 
samples used for this study is supported by the finding that the frozen CSF standard curve 
and QCs did not change significantly over the six-month period of apoE ELISA evaluation
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and sample analysis. The consistent finding that CSF apoE is decreased in SAH CSF 
obtained from patients in the USA and Scotland provides supporting evidence that the 
differences in brain injury CSF and control CSF are not due to systematic differences in 
sample processing between the two units. The apoE concentration of CSF supernatant 
before and after centrifugation was not significantly different suggesting that the apoE was 
not lost from the supernatant in the initial centrifugation step. All samples once thawed 
were vortexed prior to sample dilution. The rapid freezing after sampling and addition of a 
protease inhibitor to all the CSF samples decreased the chance that apoE was lost due to 
increased proteolysis in brain injury CSF. Poly acrylamide gel electrophoresis of control 
and brain injury CSF did not identify apoE antibody immunoreactive fragments suggestive 
of apoE proteolysis.
The possibility" that the decrease in CSF apoE is attributable to dilution is unlikely for the 
following reasons. First, in the acute phase after TBI, ventricular volume is often decreased 
such that CSF spaces including the basal cisterns, third and lateral ventricles may become 
completely obliterated. This observation often results in difficulty cannulating the 
ventricle, and is associated with raised intracranial pressure and unfavourable outcome. 
(Teasdale et al. 1984) Second, a substantial increase in CSF volume would be required to 
produce the scale of decrease in CSF apoE observed after TBI, which would not be 
tolerated within the fixed confines of the skull. Third, the brain tissue water content has 
been estimated to increase by less than ten percent after TBI. (Marmarou et al. 2000) 
Fourth, from the analysis of lipoprotein particles a significant decrease in LpE was 
observed, but not in LpAI, which would be expected if the effect was due to dilution alone. 
This strongly supports the concept that the observed decrease in apoE after TBI is specific 
to apoE. It is possible that dilution accounts for some of the decrease in CSF apoE 
observed after SAH, as acute hydrocephalus is not an uncommon finding, (van Gijn J. and 
Rinkel, 2001) However, there is still a substantial decrease in the relative amount of LpE to 
LpAI supporting the concept that apoE is selectively lost from the CSF after SAH as well.
Reduced production of apoE, by astrocytes, oligodendrocytes and microglial cells, in 
response to brain injury could potentially contribute to the decreased concentration 
observed in CSF after acute brain injury. However, failure of apoE production would not 
explain the decrease observed after SAH, where plasma apoE is likely to be released into 
the CSF. In vitro, pro-inflammatory cytokines, which are prevalent after acute brain injury, 
are reported to result in reduced astrocyte culture medium apoE concentration. (Baskin et 
al. 1997; Starck etal. 2000)
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Soon after acute brain injury, the concentration of albumin (and total protein) increase 
substantially indicating substantial opening of the blood brain barrier. The effect is 
relatively transient given that the CSF concentration of albumin (and total protein) 
decreases progressively over subsequent days. During this time period, the ratio of apoE to 
albumin (or total protein) is disproportionately decreased suggesting that apoE is 
selectively depleted from the CSF. One would speculate that the brain has substantial 
capacity to clear apoE given that the concentration of apoE in plasma (which is released 
into the subarachnoid space or neuropil, at the time of brain injury, or haemorrhage) is an 
order of magnitude higher than in CSF. (Carlsson et al. 1991) Analysis of paired plasma 
and CSF samples has not been undertaken in this preliminary study. The possibility that 
apoE released into the CSF after injury is rapidly cleared to the plasma compartment 
requires further investigation.
An alternative explanation for the findings that apoE and Ap are depleted in brain injury 
CSF is possible, for which there is indirect supporting evidence from studies of other forms 
of human brain injury, and experimental brain injury. It is hypothesised that selective 
retention and active uptake of apoE, and Ap, takes place within the neuropil and 
subarachnoid space as part of the response of the brain to injury, and this results in 
diminished concentrations in the CSF. Such a concept would not be novel as there are 
several neurological disorders for which such a mechanism has been proposed to explain 
the observation that Ap or apoE concentration are decreased in the CSF and increased in 
the brain parenchyma. For example, patients with AD have decreased concentration of Ap 
in the CSF compared to controls, whilst the concentration of Ap in the brain parenchyma is 
increased. (Andreasen et al. 1999; Andreasen et al. 2001; Fagan et al. 2000; Kuo et al. 
1996; Mehta et al. 2000; Motter et al. 1995; Nitsch et al. 1995; Shoji et al. 1998; 
Tamaoka et al. 1997) Similarly, increased apoE immunoreactivity has been observed in 
AD brain, and the concentration of apoE is reported to decrease in the CSF of patients with 
AD. (Blennow et al. 1994; Hesse et al. 2000; Landen et al. 1996; Skoog et al. 1997) 
However, decreased apoE concentration in the CSF of patients with AD has not been 
consistently reported with some studies reporting increased concentrations. (Blain et al. 
1997; Fukuyama et al. 2000; Lindh et al. 1997; Merched et al. 1997) Indeed in this study 
there was no significant difference between the concentration of apoE in the CSF of the 
control group and that of eighty-two patients investigated for dementia, although the 
number of patients in this group who will meet the criteria for definite AD is unknown at 
this time. In the present study, the concentration of apoE in the CSF of patients with 
definite MS was decreased, which is consistent with the observations of others. (Gaillard et
al. 1996; Rifai et al. 1987) These findings in CSF of MS patients are corroborated by the 
observation that apoE immunoreactivity is increased in macrophages and astrocytes 
located in regions of demyelinating MS brain. (Carlin et al. 2000) There is evidence from 
experimental brain injury studies, and human post mortem studies, that apoE is upregulated 
in the brain after injury, and participates in a co-ordinated response to acute brain injury. 
Neurons, which do not normally demonstrate immunopositivity to apoE, develop 
immunoreactivity after experimental transient global ischaemia, and acute subdural 
haematoma. In the subdural model intense immunoreactivity to apoE localises to the 
neuronal population adjacent to the haematoma. Possible explanations for this observation 
include the transport of apoE from the haematoma to injured neurons beneath the 
haematoma, increased de-novo synthesis of apoE by the injured neuron, or increased 
uptake of apoE released by other cells in the neuropil in response to injury. In the transient 
ischaemia model, intense apoE immunoreactivity is initially observed in astrocytes, which 
is later followed by apoE immunoreactivity in the population of neurons that are 
selectively vulnerable to ischaemia. (Horsburgh et al. 1997; Horsburgh et al. 2000b; 
Horsburgh and Nicoll, 1996) Although these temporal and cell type dependent changes 
suggest that apoE is involved in a co-ordinated response of the brain to injury, the actual 
role that apoE plays is not known. APOE knockout mice have delayed tissue clearance 
after cerebral infarction, macrophage related apoE expression being observed at the centre 
of infarcts in wild-type mice. (Kitagawa et al. 2001) There is evidence from experimental 
brain injury that apoE has a role as an anti-oxidant, or may be functioning as a lipid and 
cholesterol transporter recycling debris to injured cells. (Horsburgh et al. 2000a; Kitagawa 
et al. 2002; White et al. 2001a) These findings in experimental brain injury corroborate 
findings in human brain injury given the observation that apoE immunoreactivity is 
increased among patients who die after TBI, global ischaemia, and Herpes encephalitis. 
(Horsburgh et al. 1999a; Nicoll et al. 2001) Importantly, APOE dependent endocytic 
pathway alterations have been observed in the human hippocampus after fatal global 
ischaemia. (McColl et al. 2003) Thus there is a body of evidence to support the concept 
that brain apoE is up-regulated in response to injury. However, these studies do not explain 
the concept that apoE is decreased in the CSF after SAH where it is likely that substantial 
quantities of apoE are released into the subarachnoid space at the time of haemorrhage. 
There have been no systematic studies in post-mortem specimens from patients who die 
after SAH examining the distribution of apoE, or Ap within the brain. The possibility that 
apoE is depleted due to binding with debris released after cell injury and haemolysis, and 
that this is a non-specific process facilitating debris disposal without recycling or 
functional significance has not been excluded.
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In addition to a role in CNS cholesterol trafficking, apoE appears to promote the formation 
of extracellular fibrillary amyloid. Amyloid beta (especially Ap 1.42) is hydrophobic and 
binding interactions between apoE and Ap have been reported in-vitro. (LaDu et al. 1994; 
LaDu et al. 1995; Munson et al. 2000; Pillot et al. 1999) Studies using APOE and APP 
transgenic mice support the concept that apoE is pro-amyloidogenic. (Bales et al. 1999; 
Bales et al. 1997; Holtzman et al. 2000a) The finding from this study that after acute brain 
injury Ap and apoE concentration decrease in the CSF may be explained by the formation 
of insoluble apoE-Ap aggregates. These aggregates may precipitate in vivo or be rapidly 
cleared to the plasma compartment. Studies of post-mortem tissue from patients who die 
after TBI identify apoE in association with aggregates of Ap in the neuropil consistent with 
this hypothesis. (Bales et al. 1997; Clinton et al. 1991; Gentleman et al. 1997; Graham et 
al. 1996; Graham et al. 1999; Horsburgh et al. 2000) Raby et al report an increase in Ap 
concentration in the CSF of TBI patients. (Emmerling et al. 2000; Raby et al. 1998) CSF 
samples were analysed from six TBI patients (average age thirty-five years) and twenty- 
four post mortem controls (average age seventy eight years) raising concerns about sample 
size and control selection. The authors compare mean values from one hundred and five 
TBI samples raising the additional concern that the statistical significance reported is 
confounded by repeated measures. They report that the concentration of Ap is significantly 
elevated compared to controls after TBI. However, Franz et al report findings in TBI CSF 
concordant with the present study. In 29 patients with severe head trauma, the 
concentration of Api-42 was significantly lower than that of controls, and low levels were 
associated with more severe outcome. (Franz et al. 2003) There are no published series 
reporting alterations in CSF Ap after SAH, though they are reported to be unchanged after 
ischaemic stroke. (Hesse et al. 2000)
The decrease in apoE and Ap observed in this study occurs within days of injury, and 
returns to normal approximately one week after injury. Due to the absence of CSF samples 
very soon (i.e. within hours) after injury it has not been possible to investigate the 
possibility that apoE is initially increased. Furthermore, the requirement to restrict external 
ventricular drainage to the minimum clinically indicated time period limits the analysis of 
CSF for longer than one week after TBI and two weeks after SAH. The absence of 
correlation between the trough in apoE, and Api.42, concentration and the time elapsed 
from injury to the time of maximal change suggests that these proteins are rapidly depleted 
from the CSF. One may speculate that the greater hydrophobicity of AP1.42 would result in 
the rapid formation of insoluble aggregates. From the weak correlation between the time 
taken to reach trough Ap 1.40 and the magnitude of the reduction we may speculate that Ap
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1.40 is depleted in a time dependent process after TBI. The ratio of APmo to AP1.42 did not 
change significantly after injury suggesting that the decrease in these peptides is not 
fragment length specific.
Analysis of the time course for the change in apoE and Ap concentration enabled 
determination of the lowest value attained after injury and its relationship to injury severity 
and clinical outcome. There was significant correlation between injury severity and Ap4o 
after TBI and apoE after SAH. Although no deductions regarding causality may be 
inferred, we may hypothesise that more severe injury results in increased clearance of apoE 
and Ap from the CSF. Alternatively, some other factor that is influenced by injury severity 
also influences the concentration of these proteins, or low CSF concentration results in 
more severe injury. There was significant correlation between clinical outcome and the 
lowest CSF concentrations of apoE and Ap after SAH. Thus we may hypothesis that the 
degree of the decrease in apoE and Ap concentration observed in the CSF soon after SAH 
determines some of the variation in clinical outcome three months later. Again, other 
confounding variables may account for the association. From the time course data, it is 
apparent that CSF apoE is significantly diminished by a lesser degree and for shorter time 
period after SAH then TBI. This may be due to the greater amount of plasma derived apoE 
released into the subarachnoid space after SAH compared to TBI. According to the GCS 
score, the TBI patients were more severely injured than the SAH patients. Thus, it is 
possible that the TBI patients have lower CSF apoE due to greater retention within the 
brain, or greater clearance to the plasma, or some other factor. In addition, hydrocephalus 
due to CSF outflow obstruction is more common after SAH then TBI, which may result in 
less rapid clearance of apoE from the CSF.
The observation that outcome after SAH was less favourable in patients with low CSF Ap 
is intriguing suggesting that Ap peptides may be important after SAH. Importantly apoE 
isoform dependent properties have been identified for Ap peptides and these may be 
important after SAH. Firstly, vasoactive properties have been identified for Ap peptides 
and promotion of endothelin-1 mediated vasospasm by Ap appears to be apoE isoform 
dependent. (Paris et al. 1998) Secondly ischaemic susceptibility of transgenic APP mice 
appears to be dependent on apoE isoform, possibly by modulation of the inflammatory 
response induced by middle cerebral artery occlusion. (Koistinaho et al. 2002) 
Furthermore, Ap appears to diffuse freely within neural tissue raising the possibility that 
Ap cleared via the cerebral vasculature may become deposited within smooth muscle, as in 
Cerebral Amyloid Angiopathy, resulting in intimal narrowing and alterations in cerebral
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blood flow. (McCarron et al. 1999; Meyer-Luehmann et al. 2003) Lastly, Ap peptide 
induce free radical mediated oxidative stress and neuronal vulnerability appears to be 
APOE dependent. (Butterfield et al. 2002)
In addition to the decreased concentration apoE, and Ap, in the CSF after acute brain 
injury, the time course for release of S100B, and Tau was investigated. These proteins 
were chosen as they are selectively expressed in astrocytes and neurons respectively, and 
are emerging as marker proteins for the processes of astrocytosis and axonal disintegration 
that occur after brain injury. Furthermore ELISA assays developed for use in CSF were 
readily available. There are few reports relating to the concentration of Tau in CSF from 
patients with TBI. (Zemlan et al. 2002; Zemlan et al. 1999) Zemlan developed an ELISA 
for cleaved Tau using monoclonal antibody generated by differential CSF hybridoma 
screening using CSF from TBI and control patients. CSF Tau was elevated one thousand 
fold in the fifteen TBI patients. Affinity purification identified a cleaved form of Tau in the 
TBI CSF, which consisted of the interior portion of the protein, containing the 
microtubule-binding domain. Although the mechanism and type of TBI (e.g. from the CAT 
scan) is not specified, the authors conclude that CSF Tau measurement may be useful for 
the quantification of axonal injury and disintegration. The concentration of Tau in the CSF 
of the patients investigated in this study increased by the same order of magnitude as in 
Zemlans' study. Importantly, the Tau assay kit used in this study is commercially available 
enabling other groups to add to this series. Total Tau has been reported to increase 
substantially after stroke, but there appears to be no increase in phospho-Tau, which is the 
predominant form, observed to increase in AD. (Blennow et al. 1995; Hesse et al. 2001; 
Sjogren et al. 2001) The assay used in this study assays total Tau concentration preventing 
estimation of the proportion of phospho-Tau released after acute axonal injury. Increased 
Tau immunoreactivity has been observed in the brains of patients with a history of mild 
chronic repetitive head trauma, being predominantly localised to perivascular regions. 
(Geddes et al. 1999) CSF Tau was significantly higher in SAH compared to TBI, and time 
from injury to maximal CSF Tau concentration was significantly longer. Although this 
may partly be explained by the longer period of ventricular drainage, it is also possible that 
after SAH there is greater microtubule disintegration and a more sustained release 
compared to TBI. This finding is surprising given that the TBI patient group was more 
severely injured according to the admission GCS, and unfavourable outcome was less 
prevalent. The detection antibody used in the ELISA kit is specific for CNS Tau, therefore, 
the high concentrations observed in SAH CSF are unlikely to result from cross reactivity 
with epitopes present in plasma. One explanation might be that injury severity, and
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outcome, after TBI may not be due to the quantity of axonal loss, but the anatomical 
distribution of axonal loss. Alternatively, axonal loss may be greater after TBI compared to 
SAH, but recovery greater after SAH. Thus one might speculate that the less profound and 
shorter decrease in apoE observed after SAH facilitates the survival (and reconnection) of 
injured axons not destined to undergo complete disintegration.
As discussed in the introduction, S100B has emerged as a non-specific marker protein, 
which is elevated in the CSF of patients with a range of neurological disorders. It is not 
known if the high S100B observed in the CSF after acute human brain injury is due to an 
active response of the brain to injury, or a passive process whereby brain injury disrupts 
astrocytic (and oligodendrocyte) integrity releasing cell constituents into the extracellular 
space. The pattern of release in this study is similar to that reported by others, with 
maximum CSF S100B concentration occurring within two days of injury, followed by 
sustained levels for up to two weeks after SAH. (Persson et al. 1987) In-vitro S100B has 
concentration dependent paracrine effects that are trophic to developing or injured neurons 
at nanomolar concentrations, but at micromolar concentrations result in glial activation, 
upregulation of nitric oxide synthase (NOS), and apoptosis. (Delphin et al. 1999; Hu et al. 
1997; Ikura and Yap, 2000) Several intracellular functions have been attributed to S100B 
including the regulation of cytoskeletal dynamics through disassembly of tubulin 
filaments, and inhibition of protein kinase phosphorylation. (Sorci et al. 1998) The role 
that S100B plays in acute brain injury is not yet established. The high concentration of 
S100B observed in the CSF after acute brain injury is in the micromolar range and 
precedes the release of Tau into the CSF. One may speculate that S100B released after 
brain injury acts as a signal for apoptotic cell death resulting in the disintegration of 
microtubules manifest by the release of Tau into the CSF. There was significant correlation 
between peak S100B concentration and clinical outcome after SAH and TBI, but not injury 
severity. One may speculate that high S100B concentration results in worse outcome, or 
merely reflect more severe damage, which itself results in a more severe outcome. The 
peak Tau concentration correlated significantly with both injury severity and clinical 
outcome after SAH. Thus, in the case of Tau, it seems likely that the increase in CSF Tau 
reflects the severity of the injury and this reflects in the poorer outcome for the patient.
4.2.2 The analysis of lipoprotein particles in control, TBI, and SAH CSF
Size exclusion chromatography is now regarded as the optimal method for isolating Lps 
from the CSF, and in agreement with others, the current study identified a solitary peak of 
CSF Lps. (Guyton et al. 1998; LaDu et al. 2000; Montine et al. 1998; Montine et al.
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1997) The CSF Lps contrast plasma Lps in several ways. First, due to the absence of apoB 
in the CNS, there are no apoB containing LDL Lps. Second, the triglyceride content of 
CSF is substantially less than that of plasma such that there is no detectable VLDL in CSF. 
Third, a unique CSF Lp of a size in the upper HDL and lower LDL range is present in 
CSF. These Lps are referred to as HDLj and are rarely seen in human plasma. The larger 
CSF Lps (HDLj) are mainly apoE containing particles. The CSF LpEs are the "end-stage" 
cholesterol particle ready for receptor mediated endocytosis. ApoAI resides on the smaller 
Lps where it promotes the esterification of cholesterol through it's activation of LCAT. 
Thus the LpAs are in the process of expanding to form LpEs, the final cholesterol transport 
package. The concept that CSF lipoprotein particles remodel after injury is supported by 
the finding that there was no significant difference between the ratio of FC to TC in control 
and brain injury CSF and the FC to TC ratio was constant across the lipoprotein profile 
range.
After TBI, LpE virtually disappears from the CSF. In contrast to LpE, LpA did not 
decrease significantly after TBI, but the apoAI localised to a smaller population of Lps 
than those present in control CSF. Smaller sized apoAI particles are the preferred 
substrates for the formation of cholesterol ester by lecithin cholesterol acyltransferase 
(LCAT), which facilitates efficient reverse cholesterol transport. The majority of the 
increased lipoprotein cholesterol and phospholipid is associated with very small particles, 
the characteristics of which are still to be determined. We speculate that after TBI, CSF 
LpE is markedly decreased due to increased clearance via lipoprotein receptors of the 
ependymal layer lining the ventricular space, the astrocytes adjacent to the arachnoid 
space, the neurons in the adjacent cortex and the pial cells of the arachnoid itself. In 
support of this concept, APOE dependent endocytic pathway alterations have been 
identified in human hippocampus after global ischaemia. (McColl et al. 2003) There is 
evidence for cholesterol and phospholipid recycling within the peripheral and CNS after 
experimental injury, and apoE is believed to participate in this process along with other 
lipoproteins. (Poirier, 1994; White et al. 2001a) The finding that CSF LpE is diminished 
after TBI might also be explained by the formation of insoluble aggregates with the Pmo 
and ApM2 peptides. In-vitro binding between LpE and the Ap peptides could be 
investigated using affinity chromatography to determine whether LpE is absorbed onto a 
column surface to which Ap peptide has been immobilised. Whilst APOE genotype does 
not appear to influence the lipid composition of LpE, there is evidence to support 
differential binding between CSF lipoproteins comprising different apoE isoforms. (Fagan 
et al. 2000; Rebeck et al. 1998) Alternatively LpE cleared to the plasma compartment is 
likely to be rapidly remodelled to LDL via peripheral CETP, and cleared via the liver.
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Figure 26 Schematic illustration of cholesterol recycling after acute brain injury
Lipid released from neurons undergoing necrotic or programmed cell death release 
cholesterol and other lipids. The debris combines with apoE and rafts o f lipid and apoE 
remodel through the action of lecithin cholesteryl ester transferase to form high density 
lipoprotein (HDL) particles. Initially the particles are rich in apoAI as it promotes the 
activity o f LCAT. Once the particle has maximally accumulated cholesterol ester, apoAI 
disengages, and the apoE rich particles form. The apoE rich particle may be taken up via 
receptor mediated endocytosis by cells expressing receptors such as rab4, rabantin-5, and 
the LDL family o f receptors. The cholesterol ester may then be eliminated from the CNS 
via the 24S-hydroxycholesterol pathway for excretion via the liver, or be utilised for repair 
within the CNS.
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After SAH the CSF Lp profile is more complex due to the presence of plasma Lps released 
into the subarachnoid space at the time of haemorrhage. There is almost one order of 
magnitude more cholesterol in the CSF after SAH compared to controls. After SAH, when 
plasma Lps are released into the subarachnoid space, one would expect both LpE and LpA 
to increase in the CSF as their concentration in plasma is an order of magnitude higher than 
in the CSF. It is surprising that while the concentration of LpA in the CSF after SAH 
increases compared to control CSF, the concentration of LpE in SAH CSF is lower than 
that observed in controls. Thus as with TBI, apoE containing Lps are cleared from the CSF 
compartment after SAH. In addition, as observed from the elution profile of TBI CSF, 
SAH CSF also has small (estimated from elution profile to be < 7 nm) apoAI-containing 
lipoprotein particles. We speculate that these small lipoprotein particles will be discoidal in 
shape and are formed when rafts of phospholipid and free cholesterol are sheared from 
neuronal membranes after neuronal cell death. (LaDu et al. 1998) Thus the excess lipid 
released into the neuropil after cell death may combine with apoAI and through reverse 
cholesterol transport involving apoE is delivered to neurons involved in synaptogenesis 
and sprouting. (LaDu et al. 2000)
4.2.3 Limitations of the study
There are a number of limitations to this study. First, due to limited availability of CSF in 
brain injured patients, the study population is small, selective, and derived from more than 
one centre. Small sample size limits the power to relate differences in marker protein 
concentration to differences in injury type, injury severity, APOE genotype and clinical 
outcome. The patient sample in this study is restricted to patients for whom there is a 
clinical indication for ventriculostomy. After TBI, intraventricular pressure monitoring 
tends to be performed in patients at the severe end of the clinical spectrum, and these 
patients tend to have poorer outcome. The small sample size coupled to the positively 
skewed nature of the severity of injury prevents analysis comparing more than two 
variables by multiple regression. Thus, it is not possible to correct for factors known to 
influence outcome after brain injury, such as age, temperature, hypoxia, hypotension, 
pupillary response to light and the presence of hemiparesis, brain stem reflexes and the 
lesions identified on CT scanning. Furthermore, selection bias limits the generalisability of 
the findings to patients with less severe injury who do not undergo ventriculostomy. The 
SAH group, though also too small for multiple regression analysis, did include less 
severely injured patients and consequently the clinical outcome was less positively skewed. 
Significant correlations were identified in the SAH patients between CSF parameters and
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both injury severity and clinical outcome. Injury severity, assessed using the Glasgow 
Coma Score, after SAH or TBI did not correlate with clinical outcome in this study.
Second, assaying the concentration of a substance in the ventricular or lumbar CSF of 
healthy normal controls is not ethical, due to the invasiveness of the procedure, and the 
associated risks. Thus the control group was selected from patients with suspected shunt 
dysfunction, hydrocephalus, or a suspected neurological disorder for whom there was a 
clinical indication for CSF analysis. The control patients did not have acute brain injury, 
had normal conscious level and ICP, and the CSF indices were within the normal range. A 
substantial number of control CSF (less than five cells per cubic millilitre) samples were 
analysed and these were categorised according to the indication for CSF analysis and 
biochemical indices. From the analysis of these subgroups it was possible to estimate the 
influence of category type upon the concentration of apoE in the control CSF. Patients with 
a diagnosis of definite MS were found to have significantly lower CSF apoE concentration 
compared to the other subgroups. However, there was no significant difference between 
the apoE concentration of the other subgroups. On the basis of this finding, patients with 
suspected or definite MS were not used as controls. Although there was significant 
correlation between the concentration of albumin in the CSF of the control group and age, 
there was no significant correlation between CSF apoE and age. The association between 
the ratio of apoE to albumin in the CSF of the control group and age just failed to reach 
statistical significance. Control CSF for the determination of control values for Tau and Ap 
were selected from the population of control CSF specimens such that they matched the 
age distribution of the brain injured patients, and had albumin and total protein 
concentration within the ninety-fifth centile of the larger control population. The values for 
the various protein concentrations determined in the control group of this study compared 
reasonable favourably to those reported by others given the variations that exist between 
groups with regard to control selection, methodology, and random variation. In the present 
study the apoE concentration of control CSF was 12.5 ±5.5 mg/L. This is higher than that 
reported by Carlson (7.5 ± 3.2), Pirttilla (5.6 ± 1.7), Blennow (5.1 ± 2.7), Hesse (4.5 ± 2.7), 
Skoog (3.8 ± 1.7), Song (4.1 ± 1.7) and Merched (0.8 ± 0.3). (Blennow et al. 1994; 
Carlsson et al. 1991; Hesse et al. 2000; Merched et al. 1997; Pirttila et al. 2000; Skoog et 
al. 1997; Song et al. 1997) Importantly, in the present comparative study brain injury and 
control CSF was assayed simultaneously. Thus it is the relative, and not absolute, apoE 
concentration that are important to this study. The validity of the CSF controls is 
underpinned by the normality in terms of total protein concentration and low albumin 
(absence of plasma contamination). Furthermore, the concentration of astrocytic and
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neuronal markers, S100B and Tau respectively, were similar in the controls used in the 
present study when compared to values in the published literature. The concentration of 
S100B in control CSF was 0.39 pg/L, almost identical to that reported in controls by Green 
et al (0.4). (Green et al. 1997) The concentration of Tau in control CSF was 190 pg/ml 
which compares favourably to that reported by Green et al (198 pg/ml) and Vandermeeren 
(120 pg/ml). (Green et al. 1999; Vandermeeren et al. 1993) In relation to the Ap peptides 
assayed, published values for the concentration of Api.40 and Api-42 in "normal" CSF are 
approximately 10 ng/ml and 1 ng/ml respectively. (Andreasen et al. 1999; Kanai et al. 
1998; Mehta et al. 2000; Motter et al. 1995; Shoji et al. 1998) Again though the absolute 
values obtained from the controls in the present study are less than these published values, 
the relative difference between control and brain injury CSF is striking.
In addition, a critical limitation arising from the analysis of CSF stems from the 
uncertainty as to how closely the composition of ventricular or subarachnoid CSF reflects 
that of the extracellular space. Studies in human brain injury comparing ventricular CSF 
and extracellular fluid (ECF) concentrations (determined using microdialysis catheters) of 
metabolites, amino acids, and proteins are at an early stage. Ventricular CSF most likely 
reflects global release via the CSF, and excludes molecules transported via perivascular 
and other channels. There is evidence in the literature that Ap diffuses relatively freely 
through neural tissue, and may be deposited in periarterial interstitial fluid drainage 
pathways in AD. (Meyer-Luehmann et al. 2003; Preston et al. 2003; Weller et al. 2000; 
Weller et al. 1998) A preliminary microdialysis study identified substantially higher 
concentrations of S100B in the ECF of brain injured patients compared to ventricular CSF 
suggesting very high local ECF concentration or some other factor (personal 
communication). With respect to apoE, ECF concentrations may be relatively low due to 
receptor mediated uptake and an intracellular location. Thus the present study at best 
presents indirect in-vivo evidence and should be interpreted accordingly.
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Figure 27 ApoE- amyloid aggregate hypothesis
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The function o f APP is unknown, but under normal physiological conditions APP is 
cleaved by secretase enzymes to form hydrophobic peptide fragments (Ap). Ap diffuses 
within neural tissue and is conveyed by bulk flow to the CSF of the ventricular system (the 
CSF sump) or via perivascular channels to blood vessel walls. In Cerebral Amyloid 
Angiopathy (CAA) Ap accumulates in vessel walls for unknown reasons. In AD Ap 
colocalises with apoE in amyloid plaque. Ap mo is the predominant form in those with AD 
in possession of the APOs4 allele. Amyloid aggregates appear to be neurotoxic resulting in 
dystrophic neurites and activation of the inflammatory response. As AD develop and 
advances, the concentration of Ap in the CSF diminishes as Ap accumulates in the cortex 
as Ap aggregate. This process is promoted by apoE with possession o f the APOe4 allele 
having the greatest amyloid promoting effect.
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4.3 Future investigations and potential clinical relevance
Although these data demonstrate alterations occurring in the CSF of patients with acute 
brain injury, the extrapolation that these finding reflect the response of the brain to injury 
may not be justified. This is at best indirect evidence to support a role for these proteins in 
the response of the brain to injury. Key areas that require further investigation are as 
follows. First, the possibility that apoE, and Ap, are depleted from the CSF due to 
increased clearance to the plasma compartment requires investigation. Peripheral insults 
such as acute myocardial infarction are associated with alterations in plasma lipoprotein 
and lipid profiles, which may persist for months after the initial insult. (Ryder et al. 1984) 
Marked alterations in lipoprotein particles have been observed in the plasma of patients 
undergoing a systemic inflammatory response to bacterial infection. Total plasma HDL 
decreases in these patients due to the decrease in plasma apoA HDL; plasma apoE HDL 
actually increases. (Barlage et al. 2001) After ischaemic stroke (where APOE appears not 
to influence outcome) the investigators of the Northern Manhattan Stroke Study reported 
that lipoproteins remained stable during the acute phase. (Kargman et al. 1998) Such 
studies have not been undertaken after TBI and SAH. Under normal circumstances the 
plasma to CSF ratio for apoE is approximately ten to one, resulting in a steep gradient 
across the intact blood brain barrier. In order for apoE and LpE to decrease in the CSF due 
to increased transfer to the plasma compartment there would have to be a substantial 
decrease in plasma apoE to reverse this gradient even under conditions of impaired blood 
brain barrier integrity.
A relatively simple approach would be to administer labelled apoE into the CSF before 
experimental brain injury and determine the distribution of the labelled apoE thereafter. 
Cannulating the ventricles or cistema magna of rodents subjected to experimental brain 
injury presents significant challenges due to scale, but has been performed in rodents as 
small as mice enabling studies to be conducted on transgenic mice. When apoE was 
infused into the lateral ventricle of APOE knockout mice, however, apoE was not detected 
by immunocytochemistry. (Horsburgh et al. 2000a) Labelled apoE could also be 
introduced to the plasma compartment prior to experimental brain injury, and the 
anatomical distribution determined after injury and in controls. The attraction of 
experimental brain injury is the ability to control for, and limit, variation in biological 
factors, and the type or size of injury to a degree that is often not possible in human 
studies. Furthermore, histological and biochemical examination of the brain tissue is 
feasible, and the administration of agents is often acceptable. The disadvantage of
169
experimental brain injury is that findings from experiments performed in the controlled 
environment of the laboratory on different species may be of limited relevance to humans.
Second, the hypothesis that apoE and Ap decrease in the CSF as a result of increased 
retention and uptake by the brain could be explored further in humans by a variety of 
means. For example comparison could be made between the concentration of apoE in the 
CSF, brain tissue, and plasma during surgery after brain injury. For example, CSF is often 
drained from the subarachnoid space for the purpose of brain relaxation during aneurysm 
surgery, and brain tissue may be resected for the purposes of access to the aneurysm neck 
(e.g. gyrus rectus). These patients would have been fasted for general anaesthetic reducing 
the concerns relating to gastric ulceration. CSF is less often accessible at the time of 
surgery after TBI due to raised intracranial pressure, but it might be feasible to determine 
the concentration of apoE in contused brain resected after trauma. Controls are a problem 
in this type of study, though relatively normal brain may be resected during the course of 
epilepsy surgery. Alternatively, in vivo measurement of the tissue concentration of smaller 
proteins and peptides could be attempted using microdialysis but would require the 
development of dialysis membranes with high recovery of the protein. Methods for 
imaging these proteins in-vivo may be on the very distant horizon. (Bacskai et al. 2001; 
Fox and Rossor, 2000) In addition, CSF and brain tissue could be obtained from autopsy 
cases and comparisons made between patients who die after acute brain injury and those 
dying from other causes, provided consent can be obtained for tissue retention for the 
purpose of medical research. Studies of this nature may be confounded by changes that 
occur post mortem particularly in cases where there is a time delay between death and 
autopsy during which time brain liquefaction occurs. Further immunocytochemical studies 
could be performed on archive brain injury tissue to supplement previous studies with 
focus upon the distribution of apoE, and CNS lipoprotein receptor immunoreactivity after 
SAH. A limited study undertaking semi-quantitative apoE determination in archival head 
injury material found no increase in apoE levels compared to controls. (Horsburgh et al. 
2000)
The end-point of clinical research is improved outcome for patients. The question as to 
whether novel treatment strategies targeting brain apoE, Ap, or cholesterol, have the 
potential to improve patient outcome after acute brain injury requires definitive evidence to 
support their involvement in the response of the brain to injury. This study provides some 
novel preliminary evidence supporting a role for these molecules in the response of the 
brain to injury, but large scale systematic studies would be required, in addition to the post 
mortem and experimental brain injury studies outlined above, to establish such a role.
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Placebo controlled randomised trials of neuroprotective agents have proved expensive and 
of no demonstrable benefit to brain injury patients. (Maas et al. 1999) The challenges that 
beset the neuroprotection studies apply equally to large-scale observational studies. One 
particular criticism of the neuroprotection trials was the failure of the investigators to 
monitor the physiological effect to which the agent was targeted, focussing mainly on 
clinical outcome as the treatment outcome measure. In addition, it had not been established 
that a process, which may be demonstrable in experimental brain injury, actually occurred 
in the various types of human brain injury, nor at what time point the process was 
occurring. In future studies there is likely to be increased use of physiological and 
biochemical monitoring to determine treatment effects. This may include intracranial 
pressure monitoring and trend analysis, brain oximetry and cerebral blood flow studies, 
and biochemical monitoring using microdialysis and or positron emission tomography or 
magnetic resonance spectroscopy. In addition there is the potential that proteins relevant to 
acute brain injury could be serially monitored in CSF, microdialysis dialysate, plasma, and 
urine. These could potentially help classify and quantify the response of the brain to injury 
in terms of secondary processes such as cytoskeletal disruption, astrocytosis, neuronal 
apoptosis or necrosis, microglial activation and the inflammatory response. The less 
invasive the means of monitoring such proteins (e.g. plasma and urine versus CSF or 
microdialysis) the less is the associated risk, and the wider the acceptability. However, 
biochemical monitoring of plasma (and CSF) reflect global changes in the response of the 
brain to injury, obscuring valuable information relating to focal injury, which is an 
important component to brain injury. Microdialysis does give biochemical information 
about focal events, but there may be uncertainty relating the position of the microdialysis 
membrane to the intended area of monitoring. Currently available dialysis membranes have 
acceptable recovery of molecules with a molecular weight below 12KDa. Plasma 
monitoring has a number of other disadvantages. First, there is a time delay during transit 
of the protein from the brain to the plasma via the CSF and cerebral venous sinuses, 
making the correlation of plasma concentration with acute cerebral events such as raised 
intracranial pressure or ischaemic insults problematic. Second, dilution and metabolism in 
the peripheral compartment, coupled to the possibility of shared epitopes between the CNS 
protein and peripheral proteins, requires the assay to have high sensitivity and specificity. 
The substantial advantage of plasma monitoring is that monitoring can continue over a 
much broader time window than is acceptable for the invasive methods. Furthermore, 
plasma monitoring of protein release after brain injury may enable monitoring of patients 
who are not severely injured, in whom invasive measures are inappropriate. Patients with 
so-called mild and moderate head injury are often managed with less therapeutic
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intervention than those with severe head injury. However, it has recently been recognised 
that these so-called mild and moderate head injuries constitute the substantial majority of 
community based disability after head injury. (Thornhill et al. 2000) This raises the 
question as to whether this patient group should be more aggressively targeted for 
pharmacological intervention. Whilst imaging techniques such as MRI may facilitate the 
non-invasive stratification and monitoring of structural alterations after mild and moderate 
head injury, there are limitations due to availability and injury classification. Stratification 
of injury severity and monitoring of secondary processes after injury may be feasible by 
assaying brain derived proteins released into the plasma compartment after injury. There 
are a number of published series reporting increased plasma S100B after acute brain injury, 
but no large scale studies and no studies reporting increased plasma Tau. (Anderson et al. 
2001; Biberthaler et al. 2001; Herrmann et al. 2001; Petzold et al. 2002; Raabe et al. 
1999a; Raabe et al. 1999b) Furthermore, there are no published series reporting alterations 
in Ap, apoE, or cholesterol after acute brain injury. Thus whilst CSF studies such as this 
provide insight into the response of the brain to injury they are of limited utility with 
regard to large scale observational studies.
There are several key questions relating to the finding that apoE, and Ap, is decreased in 
the CSF in response to injury, the answers to which may be clinically relevant:
• If the apoE is decreased in the CSF because it is retained and taken up by the brain 
after injury, is the apoE beneficial or harmful?
• If the apoE is decreased in the CSF because it is lost to the plasma compartment, is this 
effect beneficial or harmful?
• Would treatment strategies targeting the depletion of apoE from the CSF improve 
clinical outcome after acute brain injury?
Whilst there is evidence that apoE has cholesterol and lipid recycling functions, and
antioxidant activity, there is also evidence that apoE promotes amyloid formation. The
relative importance that these postulated functions have upon outcome must be determined
before undertaking studies targeting CNS apoE after brain injury. Evidence from
experimental brain injury using APOE transgenic mice, which exhibit impaired neuronal
plasticity after injury, identify increased apoE immunoreactivity in association with
clearance of lipid and cholesterol from the site of injury. The observed effect is not
dependent of APOE genotype and therefore does not explain the observed difference in
recovery observed in TBI and SAH patients of different APOE genotype. (White et al.
2001a; White et al. 2001b) The failure to determine differences in functional recovery
after experimental injury in many studies limits estimation of the relevance of changes
observed histologically. Although intraventricular infusion of apoE appears to decrease
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oxidative stress in experimental brain injury, the failure to determine such an effect on 
functional recovery, limits interpretation of such findings in terms of potential clinical 
benefit. There are a number of preliminary studies that could be performed in vitro. First, 
the toxicity of lipoprotein particles, isolated from the CSF as described in this study, to 
serum free human cell cultures of neurons and glial cells could be determined. Importantly 
effects upon Ap and cholesterol metabolism should be assessed. Second, the effect of 
insults such as hypoxia, added Ap, or cholesterol to such cultures could be evaluated. 
Third, the effect of cholesterol lowering or apoE modifying agents could be assessed upon 
these cultures under different conditions. ApoE labelled with a fluorescent marker could be 
added to the culture medium to monitor apoE trafficking in response to injury.
The studies with APP and APOE transgenic mice support the concept that apoE is 
amyloidogenic and that APOE s4 is more so than APOE s3. These findings, coupled to the 
finding of increased amyloid deposition in the brains of patients who die after TBI, provide 
compelling evidence to support an isoform dependent interaction that is important after 
TBI. However, studies with APP transgenic mice suggest that amyloid deposits may be 
cleared after experimental brain injury. (Bales et al. 1997; Nakagawa et al. 1999; 
Nakagawa et al. 2000) Furthermore, studies of long-term survivors of TBI, who die for 
other reasons, do not identify increased numbers of Ap deposits in TBI patients compared 
to controls. (Macfarlane et al. 1999) Although these studies suggest that Ap deposition 
after TBI may be reversible, they do not provide evidence that Ap deposition results in 
worse outcome after TBI. The data identifying increased prevalence of Ap deposits in the 
brains of APOE e4 patients who die after TBI could be interpreted as suggesting that 
patients who have the APOE e4 allele have more deposits and are more likely to die after 
TBI. (Roses and Saunders, 1995) The clinical relevance of Ap deposition and clearance 
after TBI stems from the recent finding that Ap deposits are cleared from APP transgenic 
mice immunised with Ap. (Dodart et al. 2002a; Games et al. 2000) Importantly, in these 
studies, evidence of improved function in immunised animals was presented. Clinical trials 
assessing Ap immunotherapy in AD have currently been halted due to adverse effects 
underlining the requirement to understand more about human apoE and Ap biology. 
(Schenk et al. 2000) Intriguingly, a recent case report identified post-mortem findings in 
the brain of an AD patient who died after Ap immunization (AN-1792) similar to those 
observed in the transgenic mice studies. (Nicoll et al. 2003)
This study suggests that cholesterol containing LpE is selectively depleted from brain 
injury CSF. Relatively little is known about brain cholesterol flux in the normal human
brain, and even less in relation to chronic and acute brain injury. One may speculate that 
the LpE is decreased in the CSF due to increased uptake by the brain. Thus cholesterol and 
other debris released from injured cells undergoing necrotic or apoptotic death may be 
recycled to viable cells with an ongoing cholesterol demand. It is also possible that 
excessive cholesterol release after injury is potentially toxic, and the response of the brain 
to this biochemical hazard is to clear the excessive cholesterol to the plasma compartment 
for metabolism in the liver and clearance via the gastro-intestinal tract. In the CNS 
cholesterol is converted to 24S-hydroxycholesterol for excretion via the liver. There are 
reports that 24S-hydroxycholesterol is increased in the plasma of patients with AD, and it 
is speculated that this reflects increased cholesterol turnover due to increased 
neurodegeneration in the brains of AD patients. It is also reported that this effect is greatest 
in AD patients who posses the APOE e4 allele. (Lutjohann et al. 2000; Papassotiropoulos 
et al. 2000) Intriguingly, patients who are brain dead and patients with advanced AD have 
decreased plasma concentration of 24S-hydroxycholesterol. (Bretillon et al. 2000) The 
increased interest in cholesterol and AD stems from the key role that apoE plays in 
cholesterol homeostasis and the recent finding that patients treated with Statins have a 
decreased prevalence of AD. (Jick et al. 2000; Wolozin et al. 2000) If it can be shown that 
cholesterol is an important determinant of outcome after acute brain injury, and high brain 
cholesterol levels adversely affect outcome then treatment of acute brain injury patients 
with Statins that decrease brain cholesterol levels may improve outcome. The effect of 
Statins could be monitored centrally via microdialysis or via the CSF as in this study or in 
the plasma via 24S-hydroxycholesterol, which would be expected to decrease. The 
attraction of such a study in patients with acute brain injury is that Statins have well 
characterised safety profiles, and are administered parentally. Cholesterol has also been 
implicated in Ap deposit formation through in-vitro evidence supporting the concept that 
the cholesterol status of the cell membrane lipid bi-layer is an important determinant for 
the activity of the APP cleavage enzyme a-secretase. (Bodovitz and Klein, 1996) 
Furthermore, in vitro evidence suggests that cholesterol depletion due to Statins results in 
decreased amyloid deposition in hippocampal neurons. (Simons et al. 1998) Prior to any 
consideration of the use of cholesterol lowering agents in the context of acute brain injury, 
the relationship between brain or plasma cholesterol status and outcome must be 
established. After ischaemic stroke, low cholesterol appears to be associated with worse 
recovery, and low plasma cholesterol is a risk factor for haemorrhagic stroke. (Dyker et al. 
1997; Iso et al. 1989; Leppala et al. 1999; Vauthey et al. 2000) Thus after acute brain 
injury it may be more beneficial to supplement the brains' depleted cholesterol-apoE (LpE) 
status by the infusion of HDL.
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5 Conclusions
After traumatic brain injury and subarachnoid haemorrhage there is a profound decrease in 
the concentration of apolipoprotein E in the cerebrospinal fluid compared to that found in 
controls. The decrease in the apolipoprotein E concentration is paralleled by a decrease in 
the apolipoprotein E class of lipoprotein particles in the cerebrospinal fluid. The decrease 
in apolipoprotein E is paralleled by a decrease in the concentration of amyloid-beta. The 
decrease in apolipoprotein E and amyloid-beta correlate with the severity of injury and 
clinical outcome. The concentration of marker proteins for astrocytes and neurons are 
increased in the cerebrospinal fluid after traumatic brain injury, and these correlate with the 
severity of injury and clinical outcome.
These findings provide new indirect evidence to support the concept that apolipoprotein E 
plays a role in the response of the brain to injury. These findings are consistent with those 
from other studies suggesting that apolipoprotein E participates in a co-ordinated response 
to clear or recycle debris that results from brain injury. In addition, the finding that both 
apolipoprotein E and amyloid-beta decrease in the cerebrospinal fluid after injury is 
consistent with the concept that apolipoprotein E and amyloid-beta form insoluble 
aggregates in-vivo. From the finding that the concentration of apolipoprotein E in the 
cerebrospinal fluid of patients with subarachnoid haemorrhage is lower in those with more 
severe clinical outcome, one may hypothesise that increased clearance adversely affects 
recovery. This effect is not detected at later time points suggesting that low concentrations 
of apolipoprotein E in the cerebrospinal fluid are critical soon after injury.
This study takes the first steps to find in-vivo evidence to support a role for apolipoprotein 
E in the response of the brain to injury. From this study emerge a number of avenues for 
future investigation using post-mortem material, experimental brain injury, and further 
clinical studies. The justification for the further investigation of the relationship between 
apolipoprotein E, amyloid-beta deposition, and cholesterol homeostasis after acute brain 
injury, is the recent identification of novel treatment and prevention strategies for chronic 
neurodegenerative disorders. Thus amyloid-beta immunization or cholesterol lowering 
agents may have a role after acute neuronal injury. In addition, if low cerebrospinal fluid 
apolipoprotein E results in worse outcome, this begs the question as to whether 
apolipoprotein E supplementation by administration to the plasma or cerebral ventricle 
would improve outcome?
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6 Appendix
6.1 Summary of issues to address when obtaining consent
6.1.1.1 For all samples
• The sample will be treated as a gift
• The donor has no right to a share of any profits that might arise from research using the 
sample.
• Who will be responsible for custody of the sample (host institution/funding body).
• What personal information will be used in the research.
• The arrangements for protecting the donor’s confidentiality.
• If the research might reveal any information of immediate clinical relevance, this will
be fed back.
• Arrangements for feeding back or obtaining access to individual research results, if 
any, and for informing participants of the outcome of the research.
• Consent to access medical records, if required.
• Specific consent for any genetic tests, if required.
6.1.1.2 If the sample is to be stored for possible secondary use
• The types of studies the sample may be used for and the diseases that may be
investigated
• Possible impact of secondary studies on the interests of donors and their relatives.
• Means of accessing information on secondary studies, if appropriate.
• Secondary studies will have to be approved by an ethics committee.
• Consent to share samples with other uses.
• Consent to commercial use, and an explanation of the potential benefits of commercial 
involvement, if appropriate.
6.2 Patient information sheet and consent form
6.2.1.1 Information sheet for patients and their relatives participating in the apoE 
CSF study
Thank you for considering taking part in this study. Before reading any further, could I 
remind you that you are under no obligation to participate in this study and if you should 
decide to participate you are able to discontinue at any stage.
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6.2.1.2 What is the study about?
We are doing research into a brain protein called apoE. ApoE may be involved in the 
recovery process following brain injury. You may not have had a brain injury but the 
analysis of your fluid is important to us for comparison with those who have had a brain 
injury. Relatively little is known about this protein but it may have a role in recovery after 
brain injury and the type of protein we inherit may influence this process. We hope this 
research will provide useful information that may benefit patients in the future.
6.2.1.3 What does the study involve?
We require your permission to undertake research on a sample of brain fluid (cerebrospinal 
fluid or CSF for short). This fluid would normally be discarded. The tests we would like to 
do involve the study of the apoE protein and the DNA (genetic material) of the gene that 
produces the protein. No extra procedure is involved but we do require your permission to 
keep the fluid and perform the tests. It would also be helpful for us to store the sample for 
future analysis of other proteins and genes that may be related to brain injury.
6.2.1.4 Who will have access to the data?
The information from this investigation will be stored on a computer that is not linked to 
other systems such as the Internet so will only be known to the research team here in 
Glasgow. The results of this study will at a later date be published in medical journals so 
that other doctors and researchers can share this knowledge but it will be presented in such 
a way that patient confidentiality is preserved. If you have any further questions please do 
not hesitate to contact me. If I am not available at that time then please leave a name and 
number so I can call you back. Thank you for your consideration. Andrew Kay BSc MBBS 
FRCS. Wellcome Trust Clinical Research Fellow. University Department of Neurosurgery. 
Tel: 0141 201 2047
6.2.1.5 Consent form for CSF study
I consent to residual cerebrospinal fluid (CSF) being used for analysis of the protein apoE 
including the determination of the APOE gene type.
YES/NO
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I consent to storage of residual CSF and analysis of other proteins and genes that may be 
involved in brain injury.
YES/NO
I understand that I am under no obligation to participate in this study and that I may 
discontinue at any stage.
YES/NO
I have read the patient information sheet and understand that any questions relating to the 
study may be discussed with a member of the research team.
YES/NO
I understand that information arising from this research may at a later date be presented in 
medical journals and that my anonymity and confidentiality is assured.
YES/NO
Name (Please print)
Signature
Date
6.3 ApoE ELISA
In detail, 5 p i of neat rabbit polyclonal anti human apoE antibody (DAKO ref. no. A0077), 
was added to 25ml of 0.02 mol/1 Citrate buffer pH9.6 and mixed. 100 p i of the diluted 
antibody solution was aliquotted to each well of a 96 well ELISA plate (Nunc-immuno 
plate, Maxisorp ref. no. 43945A) and the plate incubated overnight at 4°C. After overnight 
incubation the plate was washed four times with 300 pi phosphate buffered saline (PBS) 
pH 7.3. After four washes the plate was blotted dry. 150 p i of fresh blocking buffer (2% 
Bovine Serum Albumin in PBS pH 7.3) was aliquotted into each well, and the covered 
plate was incubated at 37° C for one hour. The CSF sample/antibody diluent (dilution of 
equal volume of blocking buffer with PBS pH 7.3) was prepared, and CSF samples diluted
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one volume in three hundred. The standard curve (100 pg/1, 50 pg/1, 25 jLXg/1, 12.5 jLxg/1, 6.2 
g/1, 3.1 (J.g/1, apoE) which had previously been prepared as a batch, aliquotted, and stored at 
-80°C, was thawed along with the internal quality controls. After incubated at 37° C for 
one hour the ELISA plate was washed four times with 300 pi of wash buffer (PBS pH 
7.3/Tween 20) and blotted dry. The standard curve and diluted CSF samples were then 
added in duplicates of 100 pi to the ELISA plate. The plate was covered and incubated for 
one hour at 37° C. The goat anti human apoE antibody (CHEMICON ref. no. AB497) was 
diluted in assay diluent by adding 12.5 pi of the goat anti human apoE antibody to 25ml of 
assay diluent. After incubation of the standards and samples, the ELISA plate was washed 
four times as previously described. The diluted goat anti human apoE antibody was added 
to each well (100 pi) and the plate was covered for incubation at 37° C for one hour. The 
rabbit anti goat peroxidase (HRP) conjugate was prepared by adding 5 p i of rabbit anti 
goat IgG HRP conjugate to 25ml of assay diluent. After incubation at 37° C for one hour, 
the plate was washed as previously described. The diluted HRP conjugated (100 p i) 
antibody was aliquoted into each well, and the plate covered for incubation at 37° C for 
one hour. The HRP substrate was prepared and kept in the dark at room temperature until 
required. After incubation at 37° C for one hour, the plate was washed. In addition to the 
usual four washes with PBS/tween the plate was washed two times with 300 pi of PBS 
pH7.3, and blotted dry. 14 pi of 30% H2O2 was added to the 20ml of substrate solution 
and mixed. 100 p i of this solution was aliquotted into each well and incubated at room 
temperature for 15 minutes. The colour reaction was stopped by adding 50 pi of 1M 
hydrochloric acid to each well. The absorbance was determined at 492nm and 405 nm 
using a plate reader. The concentration of apoE was determined for each sample relative to 
the standard curve by plotting the standards and fitting a polynomial regression line, from 
which sample values mathematically derived. The internal quality control assayed on each 
plate comprised a CSF pooled from 100 patients CSF samples, and plasma pooled from 
100 plasma samples. These were prepared, frozen, and stored at the same time as the 
standard curve.
6.3.1.1 Reagents required for one plate (usually do 2 or more)
96 well Nunc Maxisorp plate 
1 g BSA, fraction V (SIGMA, ref. A 7030)
1 g Glycine (Merck, ref. 104201)
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1 ml Tween 20 (Sigma, ref. P I379)
1 compound ci-phenylenediamine (Sigma, ref. P8412)
10 ul H202 30 % (Merck, ref 107298)
1 gN a2C 03 (Merck, ref. 106392)
1 g NaHC03 (Merck, ref. 106329)
25 g Na2HP04, 2 H20  (Merck, ref. 106580)
20 g NaCl (Prolab, ref. 27810295)
3 g KH2P 04 (Merck, ref. 104873)
5 ml H2S04 (Merck, ref. 100731)
0.5 g Citric acid (Merck, ref 818707)
5 ul Rabbit polyclonal antibody anti human apoE (DAKO, ref A0077)
5 ul Goat polyclonal antibody anti human apoE (CHEMICON, ref. AB 497)
5 ul Rabbit polyclonal antibody anti goat IgG conjugated with peroxidase (DAKO, ref. 
P0449)
A variety of standards are available e.g. Human recombinant apolipoprotein E3 or E4 or 
E2 from PANVERA, CHEMICON, or DADE BEHRING.
6.3.1.2 Stock Solutions
(Volumes calculated for a 96 well plate)
• R1 Sodium Carbonate 0.20mol/l -store for 1 month at +4°C
Na2C 03 0.53 g 
H20  25 ml
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• R2 Sodium Hydrogen Carbonate 0.2 mol/1- store fori month at +4°C 
NaHC03 0.42 g
H20
• R3 Carbonate Buffer 16 mmol/l-Bicarbonate 34 mmol/1 pH 9.6- Store 1 week at +4° C 
Sodium anhydride solution 0.2 M (Rl) 2 ml
Sodium hydrogen carbonate 0.2 M (R2) 4.25 ml 
H20  16 ml
If pH>9.6, add R2 until pH=9.6 
If pH<9.6,add Rl until pH=9.6 
Make up to total volume of 25 ml
• R4 Disodium Phosphate 10/15 mol/1, NaCl 1.54 mol/1 
Na2HP04, 2H20  23.76 g
N aC l18 g 
H20  200 ml
Warm to 40°C to dissolve
Store at room temperature for 1 week
• R5 Potassium Phosphate 1/15 mol/l-Store 1 week at +4°C 
KH2P 04 2.27 g
H20  250 ml
• R6 Citrate Buffer 0.04mmol/l pH 5.8- Store 1 week at +4°C
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Citric acid 0.192 g 
Na2HP04, 2H20  0.538 g 
H20  20 ml
Adjust to pH 5.8 as necessary 
H20  25 ml
• R7 Sulphuric Acid 1 mol/l -store 6 week at room temp 
H2S04 1,47 ml
H20  25 ml
• R8 Coating Polyclonal Rabbit Ab (Abl)- 1/5005, 118 ng/well in carbonate buffer
• R9 Phosphate disodium solution 1/15 mol/l, NaCl 0.154 mol/l 
Phosphate disodium solution 10/15 M NaCl 1.54 M (R4) 100ml 
H20  1000 ml
• R10 PBS buffer 1/15 mol/l, NaCl 0.154 mol/l pH 7.4 
Solution of mono-potassium phosphate 1/15 M (R5) 150 ml 
Solution of disodium phosphate 1/15 M, NaCl 0.154 M (R9) pH 7.4
• Rl 1 BSA with 2% glycine 7.5 g/1 
BSA (Sigma, ref. A7030) lg 
Glycine (Merck, ref. 1.04201) 0.375 g
PBS buffer 1/15 M, NaCl 0.154 M pH7.4 (R10) 50 ml
• R12 Sample/Ab diluent
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Blocking reagent (Rl 1) 35 ml
PBS buffer 1/15 M, NaCl 0.154 M pH 7.4 (RIO) 35 ml
• R13 Wash Solution
PBS 1/15 M, NaCl 0.154 M pH 7.4 (RIO) 500ml 
Tween 20 (Sigma, ref. P I379) 0.5 ml
• R14 goat polyclonal anti human apoE -1/2 000
• R15 HRP anti goat IgG- 1/5000
• R16 Substrate (OPD at 2.8 mg/ml)
Citrate buffer 0.04 mol/l pH 5.8 (R6) 10.5 ml 
H20 2 30% (MERCK, ref. 107298) 7 ul 
a-phenylenediamine, HCL (SIGMA, ref. P8412, 30 mg)
6.3.1.3 Summary of Steps
• Coat
Polyclonal Dako (118 ng/well) 100 pl/well
Seal with sticking paper and incubate for >17 hours at 4°C
Prepare solutions R9R10R11 R12R13
• Wash-PBS
Wash 3 times with PBS 1/15 M pH 7.4 (R10) 300pl/well 
Remove wash buffer
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• Block
Block solution (Rl 1): 150 pl/well
Incubate for 1 hour in a well-humidified room at 37°C
• Prepare dilutions and standard curve 
Dilute samples; thaw standard curve and QCs
• Wash
Wash 3 times with wash solution (R13) 300 pl/well
• Add samples and standard curve 
Aliquot 100 pl/well
• Capture
Seal plate and incubate for 2 hours at 37°C in humidified room
• Incubate with detection antibody 
Prepare R14 (final dilution Ab2 1/2000)
3 washes R13 300 pl/well
Remove wash 
R 14 100 jLxl/well
Incubate plate for 1 hour at 37°C in humidified room
• Incubation with HRP Ab 
Prepare R15 (Ab3 diluted to 1/5 000)
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3 washes (R13) 300 jul/well 
Dry
R15 at 4°C
Incubate plate at 37 °C for 1 hour in humidified room
• Develop colour reaction 
Prepare R16
4 washes (R13) 300 pl/well
2 washes with PBS Buffer (RIO) 300 pl/well 
Dry
Substrate (R16) 100 pl/well 
<30 mins at room temperature
•  Stop reaction
Sulphuric acid 1 mol/l (R7) 100 pl/well or 50 pl/well of 1M HCL 
Read absorbance at 492 nm.
6.4 Albumin rocket electrophoresis
• Electrophoresis buffer 
Barbitone buffer pH =8.6/1 = 0.075
Per litre: Na-Barbitone 13.14g, Barbitone 2.07g, Ca-lactate 0.58g.
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Dissolve the Na-Barbitone in half the final volume of H2O, add Barbitone and mix until 
dissolved. Dissolve the Ca-lactate and make up to final volume. Preserve by adding lml/L 
of 5% w/v thymol in isopropanol (anti-bacterial).
• Stain
2g Comassie Brilliant Blue G250 dissolved in 1L of Methanol (350): glacial acetic acid 
(100): water (550) by volume. Ethanol may substitute methanol.
• Destain
Methanol (350): glacial acetic acid (100): water by volume. Ethanol may substitute 
methanol.
• Gel
50mL electrophoresis buffer, 1.5g polyethylene glycol 6000 (PEG6000), 0.5g ME agarose. 
Dissolve in boiling water. Gel dimensions 190mm x 159mm x 1.5mm thick gel (47mL).
• Antibody
Poly- goat anti-human albumin (Inctar, Lot No. 918743)
Cool gel to 65 0 C before adding antibody 
Concentration = 200 pi in 50 ml 
CSF neat 5pl/well
• Electrophoresis
Power 150V/25mA. Run overnight, but can be run in 3 hours.
• Assay
Remove gel and press under filter paper x 15-30 minutes. Wash in normal saline x 15-30 
minutes. Repress and dry. Stain for 15 minutes.
• Destain
• Dry with hairdryer
Enlarge with photocopier x 200
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Measure with ruler for calibration curve.
Albumin standard = 50mg/mL dilute down4 0 / 3 0 / 2 0 / 1 0 / 5
6.5 Sequential preparation of VLDL, IDL, LDL, HDL2 and HDL3 by 
ultracentrifugation
6.5.1.1 IDL 1.019 g/ml (Containing VLDL).
4 ml Plasma + 0.32 ml d = 1.182g/ml mix and overlay with 1.68 ml of 1.019g/ml. 
Centrifuge at 35,000 r.p.m. overnight in 50.4 rotor. Remove and discard the top 2ml.
6.5.1.2 LDL 1.063 g/ml
To remaining 4 ml add 1.47 ml d = 1.182 mix and overlay with 0.53 ml d = 1.063g/ml. 
Centrifuge at 35,000 rpm overnight in 50.4 rotor. Remove and keep the LDL in the top 2 
ml if 4 ml of Plasma was spun.
6.5.1.3 HDL2 1.125 g/ml.
To the remaining 4 ml add 1.3 ml d = 1.3104 g/ml + 0.7 ml of d = 1.125 g/ml. Centrifuge at 
35,000-rpm for 48hr in 50.4 rotor. Remove and keep the top 1 ml. (Discard next 2ml).
6.5.1.4 HDL3 1.21 g/ml.
To remaining 3 ml add 3ml of d = 1.3104 mix. Centrifuge at 35,000-rpm for 48hr in 50.4 rotor. 
Remove and keep the top 1ml.
6.6 Brain tissue preparation
Unfixed post-mortem brain tissue was obtained from control subjects courtesy of Dr Axel 
Petzold and the MS Society Tissue Bank at the Institute of Neurology, Queen's Square. 
The mean post-mortem interval was 26.9 (1-40) hours. Snap-frozen blocks of control tissue 
(0.5-1 g wet weight) were cut and re-suspended at 1:5 g/mL in Tris-HCL buffer (100 mM 
Tris, pH 8.1 with 1% Triton X-100). Samples were homogenised on ice by sonication, 
triturated 3 times through 19 and 21 gauge needles and spun at 20,000g. In order to 
separate myelin protein, di-iso-propyl (1:5,000) was added. After extensive mixing the 
mixture was spun at 20,000g. The supernatant was covered by a myelin layer. A needle
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was put through the myelin layer and the supernatant drawn up into a 1ml syringe. A 
protease inhibitor cocktail containing AEBSF for inhibition o f trypsin and chymotrypsin; 
aprotinine for inhibition o f trypsin, chymotrypsin, plasmin, trypsinogen, urokinase and 
kallikrein; leupeptin for inhibition of calpain, trypsin, papain and cathepsin B; statin for 
inhibition o f aminopeptidases; pepstatin A for inhibition o f acid proteases and E-64 for 
inhibition o f cysteine proteases was added in a dilution of 1:100 to supernatant. After 
dilution into aliquots o f 1:1000, 1:5,000, 1:10,000, and 1:100,000 the samples were stored 
at -70°C.
6.7 CSF PAGE
Results from 4% PAGE and immunoblotting o f brain injury and control CSF samples.
a = control CSF: [apoE] ELISA = 7.1 mg/L 
b = control CSF: [apoE] EUSA = 31 mg/L 
c = control CSF: [apoE] ELISA = 18 mg/L 
d = TBI CSF: [apoE] EL,SA = 0.5 mg/L 
e = TBI CSF: [apoE] ELISA = 0.2 mg/L 
f  = TBI CSF: [apoE] EUSA = 10.5 mg/L 
g = TBI CSF: [apoE] ELISA = 5.5 mg/L
h and i = white matter homogenate: [apoE]ELISA = 0.5 and 0.4 mg/L respectively
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